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The present PhD project investigated the role of psychophysiological stress-function and 
adversity exposure in auditory verbal hallucinations and the clinical status of voice-hearers. 
Psychosis is associated with several alterations in biological stress systems, including the 
autonomic nervous system (ANS) and the hypothalamic-pituitary-adrenal (HPA) axis, as well as 
subjective stress levels and -reactivity. Exposure to childhood trauma has been particularly 
linked to the emergence of auditory verbal hallucinations in psychosis, as well as a dysregulation 
of stress-psychophysiology. However, it remains unclear whether changes in stress-function and 
-reactivity are related to auditory hallucinations specifically, or only to psychosis more generally. 
Further, auditory verbal hallucinations occur in both clinical and non-clinical populations. Voices 
in healthy and clinical voice-hearers share many characteristics, including phenomenological 
(such as loudness) and neurophysiological correlates of auditory verbal hallucinations. However, 
healthy voice-hearers do not experience distress in response to their voices, and their voices 
contain less negative content. It remains unknown whether psychophysiological stress-function 
may also discriminate clinical and non-clinical voice-hearers, and whether dysregulated stress-
function is associated with the experience of hearing voices, and/or need for care. Evidence 
suggests there is increased childhood trauma exposure in healthy voice-hearers, at similar rates 
to clinical voice-hearers. However, adolescence/adulthood adversity remains largely unexplored 
in healthy voice-hearers, as does exposure to other risk factors including socioeconomic 
adversity and substance use.  A more recent version of the diathesis-stress model, the three hit 
model, has highlighted the role of adversity after childhood in shaping pathological trajectories, 
which may partially explain the difference in distress and need for care in clinical and healthy 
voice-hearers. Lastly, it is not known whether, and to what degree, voice content contributes to 
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psychophysiological dysregulation in clinical voice-hearers. To address these issues, the present 
project investigated three key research questions: 
1. Does adolescent/adulthood adversity exposure differ between healthy voice-
hearers and clinical voice-hearers, and is the differential adversity exposure 
associated with increased stress-sensitivity? 
2. Does the content of voices exacerbate stress-reactivity? 
3. Does psychophysiological stress-function in clinical voice-hearers differ from those 
of healthy voice-hearers and healthy controls without voices? 
Methods 
Three individual studies are reported to assess these research questions: 
1. A cross-sectional study of clinical and healthy voice-hearers was carried out to assess 
the role of familial risk and adversity exposure in childhood, and adolescence/adulthood 
in the context of the three hit model. Further, the association of adversity exposure with 
perceived stress was examined.  
2. A cross-sectional design with a healthy non-voice hearing sample was carried out using 
simulated auditory hallucinations with negative and neutral content to assess their 
impact on psychophysiological stress-reactivity during psychosocial stress exposure. The 
potential buffering effects of mindful appraisals of voices on psychophysiological stress-
reactivity were also assessed.  
3. A cross-sectional study of clinical and healthy voice-hearers, as well as a healthy control 
group with no voices, was carried out comparing the three groups on diurnal HPA and 
ANS activity, HPA response to pharmacologically induced negative feedback, and HPA 
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and ANS responses, as well as subjective reactivity, to a psychophysiological stress 
paradigm.  
Results 
The cross-sectional study on adversity exposure showed that, unexpectedly, victimisation and 
discrimination experiences were similar in clinical and healthy voice-hearers in both childhood 
and adolescence/adulthood. However, the two groups differed on familial psychosis risk, 
adolescence/adulthood socioeconomic status, and substance use, with the clinical group 
reporting greater rates of adversity exposure. These variables were further predictive of 
perceived stress, after controlling for group. The analogue voice study demonstrated that 
negative voices exacerbated subjective, but not physiological, stress-reactivity, compared to 
neutral voices and ambient sounds. Having a mindful stance towards the voices during the task 
was associated with lessened stress-reactivity. Finally, as predicted, clinical voice-hearers 
showed several indices of aberrant psychophysiological stress-function of the HPA axis, 
compared to both healthy voice-hearers and controls without voices, although not always in the 
predicted direction. Contrary to our predictions, there were no differences between groups on 
parameters of the ANS. However, there was some evidence to suggest stress-function in healthy 
voice-hearers also diverges from non-voice-hearing controls on some HPA parameters, including 
reduced cortisol levels during stress exposure, slower speed of cortisol recovery from the 
stressor, and lower HPA negative feedback capacity.  
Conclusion 
The present thesis found evidence to suggest that specific types of adversity exposure and 
stress-function are related to the need for care of clinical voice-hearers and may be involved in 
pathological outcomes of voice-hearing. Differential adversity exposure, and its relationship to 
5 
 
stress-sensitivity may therefore partially relate to psychopathological trajectories in voice-
hearing. The negative content of voices may further contribute to the maintenance of need for 
care through exacerbated stress-reactivity. Finally, dysregulated psychophysiological stress-
function is present in clinical voice-hearers, and partially discriminates them from healthy voice-
hearers. Overall, the present findings identified specific potential psychophysiological markers 
of risk and resilience in auditory verbal hallucinations and need for care. This thesis provides an 
initial stepping stone for future research developments to explore precise causal and 
mechanistic relationships of adversity exposure, psychophysiological stress-function and need 
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Chapter 1 – Thesis Rationale and Outline 
The primary aim of the present PhD project was to investigate the role of psychophysiological 
stress-function, distress and adversity exposure in voice-hearing, and how it relates to the 
clinical status of voice-hearers. Psychosis frequently presents with distressing auditory verbal 
hallucinations, as well as disruption of physiological and subjective stress-regulation. The 
aetiology of auditory verbal hallucinations (AVHs) in psychosis appears closely linked to stress-
exposure (Bentall, Wickham, Shevlin, and Varese, 2012), and there is emerging evidence that 
psychosis may be causally linked to childhood trauma (Read, van Os, Morrison, and Ross, 2005; 
Varese et al., 2012). Psychosis is further characterised by increased threat perception 
(Underwood, Kumari, and Peters, 2016), subjective stress-reactivity (Reininghaus et al., 2016) 
and aberrant activity of the body’s stress systems (Borges, Gayer-Anderson, and Mondelli, 2013; 
Bradley and Dinan, 2010; Ciufolini, Dazzan, Kempton, Pariante, and Mondelli, 2014; Montaquila, 
Trachik, and Bedwell, 2015). However, the dysregulation of psychophysiological stress-function 
specifically in relation to AVHs remains largely unexplored.  
Although initially classified as a “first-rank” symptom of schizophrenia (Schneider, 1959), AVHs 
have increasingly been recognised in significant proportions of healthy individuals with no need 
for care. Healthy voice-hearers (HVHs) are individuals who experience persistent auditory verbal 
hallucinations, yet without suffering the significant distress this experience may cause in 
psychosis patients (clinical voice-hearers; CVHs), and with no discernable need or desire for 
clinical intervention. Indeed, for some of these individuals, the experience of hearing voices is 
regarded as positive, meaningful and life-enriching (Johns et al., 2014). Not only has this 
“discovery” of HVHs fundamentally questioned the diagnostic value of AVHs, but they may also 
be a study population of crucial value to the understanding and treatment of AVHs in a clinical 
context. To ascertain the similarities and differences between HVHs and CVHs, and the 
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implications for the psychosis continuum, a systematic review of the HVH literature was 
conducted in Chapter 2.  
As identified by the systematic review, several issues in HVHs relating to stress-function have 
not been addressed to date. First, the existing literature strongly suggests that childhood trauma 
in CVHs and HVHs is significantly more prevalent than in HCs (Daalman et al., 2012b; Johns et 
al., 2014). However, the literature on HVHs has not investigated exposure to victimisation in 
adult life, or to other risk factors such as substance misuse or socio-economic disadvantage, 
which may have an impact on the outcome of AVHs. According to the three hit model of stress 
and resilience, genetic predisposition, early life experiences and later-life environment interact 
in the aetiology of stress-related mental disorders (Daskalakis, Bagot, Parker, Vinkers, and de 
Kloet, 2013). To address whether differential adversity exposure at specific developmental 
stages may account for need for care status of voice-hearers, a cross-sectional comparison of 
adversity exposure in a sample of CVHs and HVHs was undertaken in Chapter 4. In this study, 
we compared CVHs and HVHs on measures of familial incidence of mental illness, victimisation 
and discrimination exposure and socioeconomic status up to age 13, and victimisation, 
discrimination, as well as socioeconomic status and substance misuse in adolescence and 
adulthood. Further, we investigated the association of these variables with stress-sensitivity 
(i.e., perceived stress in everyday life) after controlling for clinical status. 
While the systematic literature review of healthy voice-hearers highlighted many similarities in 
the phenomenology of AVHs in CVHs and HVHs (e.g., number of voices or perceived location), it 
also showed that there are differences on other parameters, such as frequency and voice 
content. CVHs mainly hear negative and derogatory voices, and HVHs hear primarily neutral or 
positive voices (Johns et al., 2014). Such differences in voices may partially account for 
differential voice-distress. To assess whether AVHs and their content impact on stress-reactivity, 
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an experimental paradigm was carried out in Chapter 5. Healthy individuals with no AVHs 
underwent a psychosocial stress paradigm whilst being exposed to simulated AVHs with 
different content, to assess the degree to which voice content may drive subjective and 
physiological stress dysregulation. Participants in this study were randomly allocated to either 
negative voices, neutral voices, or non-voice ambient sounds, and their subjective stress 
response as well as HPA- and ANS-response were assessed. The potentially moderating effects 
of mindful appraisals of the simulated voices on stress-reactivity were also examined.  
As reviewed in Chapter 3, dysregulation of the neuroendocrine and nervous stress systems is 
detrimental to physical as well as psychological well-being (Baumeister, Lightman, and Pariante, 
2014; McEwen, 2008), and has been implicated in the aetiology and pathophysiology of 
psychosis (Bradley and Dinan, 2010; Pruessner, Cullen, Aas, and Walker, 2017).  Thus, a potential 
substrate of the clinical divergence of HVHs and CVHs may be found in compromised integrity 
of the body’s systems dedicated to dealing with stress. To address the question of whether 
physiological stress-function is divergent between CVHs and HVHs, a detailed assessment of 
neuroendocrine and autonomic nervous system function was conducted in CVHs, HVHs and 
healthy controls in Chapter 6. In this study, we assessed unstimulated baseline activity of the 
HPA-axis and ANS over the course of one day, measured negative feedback capacity of the HPA-
axis, and assessed subjective, HPA and ANS responses to an acute psychophysiological stressor. 
To our knowledge, it is the first study to investigate stress-function specifically in relation to 
AVHs, and through the addition of a HVH sample allows for differentiation of findings relating to 
AVHs in general, or specifically to AVHs and need for care. The overall conclusions, strengths and 





Chapter 2 – Auditory Verbal Hallucinations and Continuum 
Models of Psychosis: A Systematic Review of the Healthy 
Voice-Hearer Literature 
This chapter was published in Clinical Psychology Review: Baumeister, D., Sedgwick, O., Howes, 
O., and Peters, E. (2017). Auditory verbal hallucinations and continuum models of psychosis: A 
systematic review of the healthy voice-hearer literature. Clinical Psychology Review, 51, 125–
141.  
2.1 Introduction 
There is accumulating evidence that the experience of auditory verbal hallucinations (AVHs) is 
not uncommon in healthy individuals, and is not necessarily an indicator of psychopathology. A 
significant proportion of healthy individuals experience psychosis-like symptoms such as voice-
hearing at some point in their lives; usually AVHs present as transient experiences, for example 
during childhood and adolescence, periods of bereavement or in the form of hypnagogic or 
hypnopompic false auditory perceptions (de Leede-Smith and Barkus, 2013). A recent meta-
analysis estimated a median prevalence of 6% and median incidence of 1.2% of hallucinatory 
experience in the general population (Linscott and van Os, 2012). Notably, Linscott and van Os’ 
(2012) meta-analysis found that 20% of those who report psychotic experiences (including other 
phenomena such as delusional beliefs) go on to experience them persistently, 7.4% in the 
context of a psychotic disorder. These rates may be similar for AVHs specifically, as a recent 
cohort study of 1,912 adolescents found that of the 5% who reported auditory hallucinations at 
baseline, they were still present in 27% two years later (De Loore et al., 2011). The term ’healthy 
voice-hearers’ (HVHs) has been coined to describe individuals who experience persistent 
auditory verbal hallucinations, yet have no need for clinical care and do not suffer the significant 
distress this experience may cause in clinical populations (‘clinical voice-hearers’; CVHs). 
21 
 
However, there remains uncertainty over how the two populations are related. The present 
systematic review aims to address such conceptual difficulties and provide a comprehensive 
overview of the currently available evidence. 
The recent focus on AVHs in the healthy general population has arisen from a wider 
reconceptualisation of psychosis and a shift from diagnostic to symptom-focused approaches. 
Classically, AVHs were defined as first-rank symptoms of schizophrenia (Schneider, 1959), as 
part of discrete, categorical models, i.e. those employed by diagnostic classification systems 
(Table 2.1; Model 1). However, these diagnostic models, although still employed in clinical 
practice, have been criticised for their lack of an empirical evidence-base (Bentall, 2004; Kaymaz 
and van Os, 2010; Linscott and van Os, 2010; van Os, 2009). Transdiagnostic, symptom-focused 
approaches have been proposed both for psychosis (e.g., the transdiagnostic psychosis 
spectrum; Reininghaus and van Os, 2016) as well as wider mental health (e.g., the Research 
Domain Criteria project; Insel et al., 2010). AVHs are present in a range of mental health 
difficulties, including depression and anxiety, post-traumatic stress disorder, emotionally 
unstable personality disorder, and obsessive-compulsive disorder (Johns et al., 2014; 
Upthegrove et al., 2016; van Os and Reininghaus, 2016). Further, the impact and presentation 
of AVHs may differ within individuals in need for care, and there have been proposals to subtype 
AVHs in clinical research and practice (Smailes, Alderson-Day, Fernyhough, McCarthy-Jones, and 
Dodgson, 2015).  
Conceptually, there has also been a marked shift from categorical models towards a continuum 
view of psychotic symptoms and anomalous experiences that extends not just across diagnostic 
categories but also into the (healthy) general population. This has long been proposed by 
researchers such as Claridge (1994) and Bentall (2004), and has gained considerable 
epidemiological support (Linscott and van Os, 2013; Linscott and van Os, 2010; van Os, Linscott, 
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Myin-Germeys, Delespaul, and Krabbendam, 2009). According to the continuum model, HVHs 
are situated on a continuous dimension between CVHs and non-voice-hearing healthy 
individuals (healthy controls; HCs) in terms of their anomalous experiences, but without crossing 
the threshold for need for care. However, different conceptualisations of the continuum model 
exist in the literature (see Table 2.1; models 2 and 3). Claridge (1994; Siever and Claridge, 2002) 
has differentiated between ‘quasi-dimensional’ (Table 2.1; Model 2) and ‘fully dimensional’ 
(Table 2.1; Model 3) models. In the former, the continuum describes disease severity; it is 
assumed that psychotic experiences and distress are part of the same dimensions and that 
psychotic experiences are ultimately indicative of a psychobiological abnormality but simply in 
attenuated form. It is further assumed that only a small proportion of the general population 
has a predisposition for such experiences. In a fully dimensional model, however, the continuum 
of anomalous experiences may be largely independent from the continuum of clinical distress 
or need for care, and makes no prediction regarding the outcome of psychotic experiences. The 
propensity for such experiences is distributed in the general population as part of normal 
individual differences and only in extreme forms necessitates care. Such a conceptualisation is 
more in line with viewing voice-hearers without need for care as being truly “healthy”, rather 
than merely “subclinical”.  
However, these conceptualisations may still be over-simplistic (Kaymaz and van Os, 2010; 
Linscott and van Os, 2010). Linscott and van Os (2010) carried out a systematic review and meta-
analysis of primarily epidemiological data on what they refer to as the ‘extended phenotype 
model’. Their results suggest that there is evidence for continuity of symptoms, based on the 
high incidence and prevalence rates of psychotic experiences in the general population 
compared to the actual rate of clinical psychotic disorders. However, they also found evidence 
for a dichotomous distribution of individuals who have a liability to schizotypal traits from 
individuals who do not. These mixed findings suggest the possibility that the psychosis 
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continuum may encompass two latent, discontinuous subgroups, leading to a hybrid 
conceptualisation of quasi- and fully-dimensional models. Current evidence further suggests 
that psychosis is a complex multifactorial construct, with individual symptoms or characteristics: 
a) lying on individual continua (Russo et al., 2014; van Os, 2009); b) showing differing prevalence 
rates and causal factors (Wigman et al., 2011b; McGrath et al., 2015); c) having differing 
implications for a need for care or clinical risk (Wigman et al., 2011b; Kaymaz et al., 2012); and 
d) demonstrating varying correlational or predictive relationships with other symptoms 
(Wigman et al., 2011a; Bell et al., 2008). Most recently, van Os and Reininghaus (2016) have 
proposed a transdiagnostic psychosis spectrum in which psychotic symptoms in the general 
population are continuous with clinical psychotic disorders, but can nonetheless present 
independently. This conceptualisation encompasses both specific psychosis factors (e.g., 
positive symptoms) as well as nonspecific associations with psychopathology (e.g., affective 
dysregulation), and the combination of these two underlying constructs then becomes critical 
in leading to a need for care. 
In an editorial aiming to stimulate the continuum debate, David (2010) suggests that the 
continuum hypothesis should be taken as the null hypothesis, and the present review examines 
whether there is evidence to refute it in relation to AVHs specifically. The focus on AVHs allows 
investigation of the psychosis continuum in the context of a specific phenomenon of the 
psychosis dimension that presents both across health-pathology and across different types of 
pathology. Assessing whether the available research on HVHs has produced results congruent 
with the current evidence on the psychosis continuum can attest to its relevance and add to its 
validity. Indeed, Johns and colleagues (2014) call on research to investigate the role of the quasi- 
and fully-dimensional continua in AVHs in healthy individuals. In turn, the psychosis continuum 
models provide an important context to determine to what extent HVHs are “healthy” and are 
likely to remain so. For instance, whilst HVHs may present as currently healthy, the 
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transdiagnostic extended phenotype model presented by van Os and Reininghaus (2016) notes 
the temporal continuity of psychotic experiences with clinical disorders, i.e., HVHs may be at 
greater risk of psychotic disorders long-term. Furthermore, examination of the relationships 
between AVHs in healthy populations and other symptom dimensions and characteristics 
relevant psychosis, such as affective difficulties, risk factors, or neurobiological substrates, may 
be valuable for the understanding of AVHs and need for care in clinical populations. 
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Table 2.1 – Model conceptualisations and hypotheses 
Model conceptualisation Model hypotheses 
 
Model 1: Diagnostic discontinuous model 
• HVHs differ from HCs on almost no parameters, indeed HVH should not be 
identifiable as a separate group 
• AVHs in HVHs cannot be explained in such a model, and those experiences 




Model 2: Quasi-dimensional model 
• HVHs form a middle-point between CVHs and HCs on almost all parameters 
• AVH parameters (e.g. frequency) in HVHs are consistently lower than in 
CVHs, i.e. present in an attenuated form 





Model 3:  Fully dimensional model 
• AVHs should occur unrelated to distress in HVHs 
• Parameters not related to AVHs will vary at random, HVHs do not differ from 
HCs in need for care 
• Occurrence of psychotic experiences is not necessarily related to 
distress/need for care 
Note: Vertical shading indicates mental well-being or the absence of need for care, horizontal shading indicates psychological difficulties and need for care, and 











Whilst the reviewed continuum conceptualisations relate to psychosis or schizotypal personality 
traits across the wider population, rather than the specific phenomenon of auditory 
hallucinations, their relevance to AVHs in healthy individuals is inferred here. Similarly, whilst 
still relevant, many studies in the HVH literature were not carried out with the continuum 
hypothesis in mind and are thus integrated into an overarching framework to consider this 
literature. According to the diagnostic model, benign AVHs should be highly dissimilar as an 
experience to those found in CVHs, and HVHs and HCs should be indistinguishable on almost all 
parameters (e.g., risk factor exposure). According to the quasi-dimensional model, HVHs will be 
on a middle-point between CVHs and HCs on almost all parameters, including need for care and 
voice-distress. In such a model, increases in the occurrence of psychotic experiences would be 
associated with increased need for care. Lastly, a fully-dimensional model would predict that 
the occurrence of AVHs is largely unrelated to need for care, and HVHs should not be at greater 
risk of distress than HCs. Other parameters should vary at random. However, according to the 
more recent epidemiological conceptualisation of extended, transdiagnostic phenotypes with 
latent subgroups, the available evidence would be expected to support both quasi- and fully-
dimensional models to a similar degree. Thus, the present review has two main hypotheses: 
firstly, the evidence will be incompatible with the diagnostic model; secondly, the evidence will 
provide support for both quasi- and fully-dimensional models, depending on methodology used 
and sample characteristics of the study. 
Several narrative reviews have been published on AVHs in healthy populations (Badcock and 
Chhabra, 2013; Badcock and Hugdahl, 2012; de Leede-Smith and Barkus, 2013; Johns et al., 
2014; Larøi, 2012). However, these tend to be broader (e.g. inclusive of prodromal populations), 
or more theoretical or narrow in their discussion (e.g. of neurocognitive mechanisms) than the 
focus of the present review. Moreover, by their narrative nature, they are more vulnerable to 
bias than the systematic approach undertaken here. The present systematic review aims to: give 
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a comprehensive overview of the phenomenon of persistent AVHs in healthy adult populations; 
consider the evidence for models of the psychosis continuum in the context of AVHs; and 
identify areas where future research is needed.  
2.2 Methods 
2.2.1 Search Strategy  
A systematic review of the literature was performed using PsycINFO, EMBASE, and Medline for 
the subject headings “auditory hallucination*” and “voice hear*” cross-referenced separately 
with the terms “healthy”, “no need for care” and “non-clinical”. The literature review was 
performed in February 2016. Articles were limited to research in human participants, and 
published in English language. The initial search produced 230 on PsycInfo, 346 on Embase and 
161 on Medline (see Figure 2.1). Additionally, 17 papers were identified through search of 
references in identified papers. One additional paper was identified through personal 
communication with the authors (Jacobsen et al., Under Review). The following criteria were 
used for exclusion and inclusion into the review: 
Exclusion criteria: 
• Only voice-hearers with a clinical diagnosis of a psychotic disorder or other conditions 
associated with AVHs (e.g. PTSD, epilepsy) 
• Only hallucination-proneness assessed (e.g. Launay-Slade Hallucination Scale (LSHS; 
Launay and Slade, 1981)  scores) and no reporting of current AVHs  
• Childhood and adolescent samples 
• General assessment of anomalous experiences only 
• Elicited hallucinatory experiences (e.g. signal detection tasks or through hypnosis) 
• Drug-induced hallucinations 





• Studies with a sample of individuals without clinical diagnoses who report hearing voices 
but no related distress 
• Articles published in English language 
2.2.2 Selection 
After exclusion of duplicates, articles not published in English language, and studies not including 
human participants, 398 article titles and abstracts were scrutinised for inclusion into the 
review. Seventy appropriate articles were identified for full-text analysis, of which 36 met 
criteria for inclusion. Full-text analysis and data extraction were carried out independently by 
two authors, and any inconsistencies were discussed until consensus was reached.  Notably, 
several of the identified studies (from the Dutch (Utrecht) group, marked in Table 2.2) included 
the same or overlapping samples, however often with slightly different numbers of participants 
and different main outcome measures. Ineligible articles (n = 34) were excluded for the following 
reasons: only hallucination proneness/anomalous experiences measured (n = 17); only elicited 
hallucinations measured (n = 10); adolescent sample (n = 3); only assessment of non-wakeful 
hallucinations (n = 1); hallucinations in epilepsy sample (n = 1); no stratification for need for care 
(n = 2) (see Figure 2.1).  Studies where samples were selected purely on the basis of proneness 
to hallucinations (e.g., using a total score on the LSHS) were excluded as such measures may 
include a) non-AVH hallucinations and b) transient experiences. However, studies that used 
individual AVH-specific LSHS items (e.g., “In the past I have had the experience of hearing a voice 
and then found no one was there”) as part of their inclusion criteria were included (see Table 
2.2), if they satisfied the criterion of ‘reporting of current AVHs’. 
Study characteristics are presented in Table 2.2. The results presented below are organised with 
a focus on specific characteristics that have emerged from the literature, rather than by their 
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congruence with the explanatory models evaluated here, which is returned to in the discussion. 
The structure of the results is aimed at aiding the reader interested in discrete aspects of HVH 
research, and improving reading experience and accessibility. Results are presented by the 
following characteristics: voice phenomenology, their impact and appraisal, mood disturbances, 
impairment and functioning, related psychotic phenomena, cognitive functioning, 
neuroimaging, trauma exposure and familial risk. 
Figure 2.1 – PRISMA diagram of search strategy 
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Table 2.2 – Systematic overview of included studies 
Study Sample Group characteristics AVH Selection Mean Age % Female Measures 




CVHs were recruited from 
mental health services, 
HVHs were recruited from 
spiritualist sources. 
Psychiatric status in HVHs 
was not formally assessed 
and meeting criteria for a 
psychiatric diagnosis was 
not amongst the exclusion 
criteria. Anyone with an 
organic condition that 






Presence of AVHs was 
assessed via PSYRATS 
but was not a formal 






-Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale 
- Beliefs About Voices Questionnaire - 
Revised 
- Post-Traumatic Diagnostic Scale 
- Impact of Events Scale 
- Beck Anxiety Inventory 








Clinical status was 
assigned by stratifying for 




responded to having 
"heard voices that no 
one else can hear". 
48.01 66.01 - Hearing Voices Questionnaire 










n/a - Stroop Color-Word Task  
- WAIS-III  
- Childhood Trauma Questionnaire 
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Study Sample Group characteristics AVH Selection Mean Age % Female Measures 
4. Cottam et 
al., 2011 
15 C-CVH  
14 NR-
CVH  
20 C-HVH  
HVH-Cs were recruited 
from churches. They were 
not formally assessed for 
psychiatric status. CVHs 
were recruited from 
mental health services. 
Participants were 
included if they 
endorsed the LSHS 
item "In the past I 
have had the 
experience of hearing 
a voice and then 










- Launay-Slade Hallucination Scale 
- Topography of Voices Rating Scale 
- Affective Experiences Questionnaire 
- Cognitive Assessment of Auditory 
Hallucinations (supplemented with 










HVHs were excluded if 
they met criteria for a 
DSM-IV diagnosis other 
than depressive or anxiety 
disorders in complete 
remission. Individuals 
were screened for illegal 
substance use via urine 
samples, and alcohol or 
drug abuse in the last 3 
months led to exclusion. 
HVHs were recruited 
online; CVHs were 
recruited from mental 
health services. CVHs 
consisted of patients with 
schizophrenia, 
schizoaffective disorder 
and psychosis not 
otherwise specified. 
Participants were 
initially screened with 
LSHS items 
concerning having 
heard a person's 
voice when no-one 
was there and having 
been troubled by 
voices in their head. 
Voices had to be 
distinct from 
thoughts and have a 
perceptual quality, 
minimum frequency 
for AVHs in HVHs was 
once per month and 
minimum duration 






- Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale 
- Structured Clinical Interview for DSM-IV II - 
Personality Disorders 










As in Daalman et al 
2011a. All participants 
had an IQ of 80 or above. 
As Daalman et al., 
2011a, except 
minimum frequency 
of AVH was once 
every 3 months for at 





- Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale 
- Stroop Color-Word Task 
- Wechsler Adulthood Intelligence Scale III 
subtasks (backward digit span-task, forward 
digit span-task, vocabulary test, similarities 
test) 
- California Verbal Learning Test 
- Complex Figure of Rey-Osterrieth 
- Controlled Oral Word Association Test 
- Semantic Fluency Test 
- National Adult Reading Test  
- Raven's Advanced Progressive Matrices 
- Structured Clinical Interview for DSM-IV II - 
Personality Disorders 



















- Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale 
- Launay-Slade Hallucination Scale 
- Semantic Expectation Task 
- Structured Clinical Interview for DSM-IV II - 
Personality Disorders 
















- Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale 
- Childhood Trauma Questionnaire 
- Structured Clinical Interview for DSM-IV II - 
Personality Disorders 








As Daalman et al., 2011a As Daalman et al., 
2011a, except 
minimum frequency 
of AVH was once 








- Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale 
- Cognitive Biases Questionnaire for 
Psychosis 
- Structured Clinical Interview for DSM-IV II - 
Personality Disorders 










As Daalman et al., 2011a; 
5-year follow-up (thus 
healthy status may not 
apply) 
As Daalman et al., 
2011a 
n/a n/a - Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale 
- Comprehensive Assessment of Symptoms 
and History 
11. Davies et 
al., 2001 
18 CVH 
17 C-HVH  





reported being born-again 
Christians or members of 
evangelical Christian 
churches, and reported 
no previous treatment for 
mental illness. No 
evangelical Christians 
were in the CVH group. All 




hearer groups if they 
endorsed the LSHS 
item "In the past I 
have had the 
experience of hearing 
a voice and then 








- Launay-Slade Hallucination Scale 
- Affective Experiences Questionnaire 
- Perceptions of Voices Questionnaire 
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Study Sample Group characteristics AVH Selection Mean Age % Female Measures 






As Daalman et al., 2011a 
CVH group reported AVH 
at least once an hour. 








- Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale (items for 
frequency, emotional valence, distress and 
control) 
- Positive and Negative Syndrome Scale 
- Global Assessment of Functioning Scale 
- Schizotypal Personality Questionnaire (HVH 
& HC only) 
- Diffusion Tensor Imaging 
- Magnetisation Transfer Imaging 
- Comprehensive Assessment of Symptoms 
and History 















- Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale 
- Positive and Negative Syndrome Scale 
- Global Assessment of Functioning Scale 
- BOLD fMRI during paced verbal fluency 
task 
- Structured Clinical Interview for DSM-IV II - 
Personality Disorders 
- Comprehensive Assessment of Symptoms 
and History 
- Schizotypal Personality Questionnaire 
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- Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale  
- Positive and Negative Syndrome Scale 
- Global Assessment of Functioning Scale 
- Schizotypal Personality Questionnaire 
- BOLD fMRI during AVHs (indicated by 
balloon squeezes) 
- Structured Clinical Interview for DSM-IV II - 
Personality Disorders 













- Global Assessment of Functioning Scale 
- Schizotypal Personality Questionnaire 
- BOLD fMRI during resting-state 
- Structured Clinical Interview for DSM-IV II - 
Personality Disorders 











was assessed on the 
prevalence of 
psychotic symptoms 
using the PSYRATS 
- - - Hospital Anxiety and Depression Scale 
- Psychotic Symptoms Rating Scale 
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Study Sample Group characteristics AVH Selection Mean Age % Female Measures 





HVHs were recruited from 
spiritualist sources and 
opportunity sampling, 
CVHs were recruited from 
mental health services, 
HCs were recruited via 
opportunity sampling. 
None of the HVHs or HCs 
had a psychiatric 
diagnosis or were 
receiving treatment.  
Presence of AVHs was 







- Positive and Negative Syndrome Scale 
- Psychotic Symptoms Rating Scale Auditory 
Hallucinations Subscale 
- Meta-Cognitive Questionnaire (Short 
Version) 




HVHs were included if 
they had no previous 
psychiatric history. CVHs 
were recruited from 
mental health services, 
HVH were recruited via 
opportunity sampling and 
voice-hearer groups. 
CVHs had to have 
persistent AVHs over 
the last 6 months, 





- Semi-structured interview covering 
characteristics of voices, history of voices, 
triggers, interpretations of voices, coping 
strategies and traumatic life events 
- Dissociative Experience Scale 




Study Sample Group characteristics AVH Selection Mean Age % Female Measures 










- Peters Delusion Inventory 
- Psychotic Symptoms Rating Scale 
- Schizotypal Personality Questionnaire 
- Global Assessment of Functioning Scale 
- [18F]-DOPA Positron Emission Tomography 
- Structured Clinical Interview for DSM-IV II - 
Personality Disorders 








CVHs were recruited from 
two UK sites; HVHs were 
recruited as part of the 
wider UNIQUE study (see 
Peters et al., 2016). 
Voice-hearers 
reported at least 
occasional voices on 









- Autobiographical Memory Task 
- Appraisals of Anomalous Experiences 
interview 







Study Sample Group characteristics AVH Selection Mean Age % Female Measures 






cohort; 8000 contacted of 
whom 2533 responded 
with questionnaire data 
Two LSHS items were 
used:  “In the past I 
have had the 
experience of hearing 
a person’s voice and 
then found that there 
was no-one there” 
and “I often hear a 
voice speaking my 
thoughts aloud”. 
Those who answered 
yes to both items 
were asked additional 








- Launay-Slade Hallucination Scale 
- Hospital Anxiety and Depression Scale 
- Additional questions regarding stressful life 












were excluded, so were 




either hearing voices 
when no one is 
around, or hearing 








- Psychotic Symptoms Rating Scale 
- fMRI 
- Consonant-vowel Dichotic Listening Task 
- Hughson-Westlake Audiometric Test 
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HVH individuals were only 
included if they had not 
sought psychiatric help 
for their voices, or heard 
voices when under the 
influence of substances. 
Individuals were 
included if they 
reported currently 
hearing voices or 






- Hospital Anxiety and Depression Scale 
- Beliefs about Voices Questionnaire – 
Revised 
- Topography of Voices Rating Scale (3 items 
only) 




None of the HVHs were in 
contact with psychiatric 
services. Formal screening 
for psychiatric symptoms 
was not possible. Most 
HVHs were occasional 
cannabis users. CVHs 
were schizophrenia 
patients recruited from 
mental health services. 
HVHs reported 






- Structured Interviews 




Participants had no 
history of psychiatric or 
neurological illness and 
were recruited via 
opportunity sampling. 
Recruitment occurred 
via self-reports, AVHs 






- Positive and Negative Syndrome Scale 
- Beliefs about Voices Questionnaire 















Of the CVHs and CNVHs, 
45 had schizophrenia, 60 
had OCD. Individuals were 
classified as HCs and HVHs 
if they denied the 
presence of any 
psychiatric illness and 
contact with any mental 
health services. 
AVHs were assessed 
as having heard 








- Yale-Brown Obsessive Compulsive Scale 
- Community Assessment of Psychic 
Experiences 
- Interview assessment 
- Launay-Slade Hallucination Scale 





Study recruited healthy 
individuals with psychotic 
experiences (PEs), who 
were assessed as having 
no need for care and no 
previous diagnosis for a 
psychotic disorder. 
Voice-hearing was 
assessed using the 




hearing was carried 










- Scale for the Assessment of Positive 
Symptoms 

























- Structured Clinical Interview for DSM-IV II - 
personality disorders 
- Comprehensive Assessment of Symptoms 
and History 













- Comprehensive Assessment of Symptoms 
and History 
- Psychotic Symptoms Rating Scale - 
Auditory Hallucinations 
- Launay-Slade Hallucination Scale 
- Global Assessment of Functioning Scale 
- Structured Clinical Interview for DSM-IV II - 
personality disorders 
- Schizotypal Personality Questionnaire 
- Peters Delusion Inventory 
- Revised NEO Personality Inventory 
- Childhood Trauma Questionnaire 
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- Comprehensive Assessment of Symptoms 
and History 
- Launay-Slade Hallucination Scale 
- Structured Clinical Interview for DSM-IV II - 
personality disorders 
- Schizotypal Personality Questionnaire 
- Peters Delusion Inventory 
- Thought and Language Index 
- Thematic Apperception Test 
- Global Assessment of Functioning Scale 





excluded if they heard 
voices due to an organic 
illness or substance 
misuse. CVHs were 
recruited from mental 
health services. HVHs 
were excluded if they 
currently had contact with 
mental health services in 
relation to voice-hearing. 
Individuals heard 






- Psychotic Symptoms Rating Scale  
- Voice and You Questionnaire 
- Beliefs about Voices Questionnaire - 
Revised 
- Beck-Depression Inventory - II 
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Study Sample Group characteristics AVH Selection Mean Age % Female Measures 
32. Taylor and 
Murray, 
2012 
6 HVH Participants were 
included if they reported 
no frequent distress and 
reported no contact with 
mental health services in 






hearing the voices of 
spirits was taken as a 
proxy for AVHs. 













- Comprehensive Assessment of Symptoms 
and History 
- Structured Clinical Interview for DSM-IV II - 
personality disorders 
- Schizotypal Personality Questionnaire 
- Peters Delusion Inventory 
















- Comprehensive Assessment of Symptoms 
and History 
- Structured Clinical Interview for DSM-IV II - 
personality disorders 
- Positive and Negative Syndrome Scale 
- Schizotypal Personality Questionnaire 




Study Sample Group characteristics AVH Selection Mean Age % Female Measures 




Recruitment sources not 
clear 
HVHs were individuals 
with no current or 
past mental health 







- Psychotic Symptoms Rating Scale  
- Cognitive Assessment of Voices Interview 
- Modified Goals Task 





anyone hearing voices 
was free to participate. 
Some subgroup analyses 
were carried out in 
relation to whether 
individuals had received 
mental health care. 
Participants were 





65.4 - Self-reported qualitative questionnaire 
comprising 13 items 
Note: CVH – Clinical Voice Hearer; HVH – Healthy Voice Hearers; HC – Healthy Control; Gen Pop – General Population Sample; BPD – Borderline Personality 
Disorder; SZ – Schizophrenia; CNVH – Clinical participants who do not hear voices; C – Christian; NR – Non-religious; PE – Healthy individuals with psychotic 
experiences; CPE – Clinical individuals with psychotic experiences; n/a – not available; * - indicates that studies belong to the same Dutch cohort; 1 – no 







Out of the 36 studies reviewed, 17 were drawn from the Dutch (Utrecht) sample of HVHs, 
comparing them to HCs and/or CVHs. These studies employed the same selection and screening 
criteria, which were amongst the most stringent (see Table 2.2). Although these studies 
generally had different main outcomes, some of the basic data such as voice phenomenology 
were assessed in samples recruited from the same cohort, albeit with slightly different 
participant numbers in each. Therefore, separate publications may report the same finding, 
confounding any cumulative strength of evidence by the shared participants across studies.  
Nevertheless, these studies had different clinical and/or healthy control samples, and did not 
always report the same results on the same measure. Therefore, they are still reported as 
individual findings, but with an indication (*) that they belong to one cohort (see Table 2.2 & 
Table 2.3). 
Sample sizes differed considerably depending on methodology employed across all 36 studies. 
As would be expected, studies relying largely on questionnaire-based data had larger sample 
sizes than studies using neuroimaging or qualitative assessments. Although a priori matching 
across samples for at least one variable occurred in a sizeable minority of studies, primarily 
handedness, gender and/or age, several studies reported that samples did not match on 
education. Moreover, it should be noted that both CVH and HVH within and between individual 
studies are likely to show considerable degrees of heterogeneity, both due to differences in 




Twenty-seven of the reviewed studies reported on the phenomenology of voices in some 
capacity, 14 of which were from the same cohort. Phenomenological similarities and differences 
in AVH are presented in Table 2.3, and summarised below, in a subset of 17 studies that 
compared the major phenomenological characteristics of AVHs in HVHs and CVHs. Finally, 
Daalman et al. (2016*) report that AVHs in non-clinical samples show a high level of persistence, 
with continued experience of AVHs in 86.4% of their sample at 5-year follow-up. 
50 
 
Table 2.3 – Voice phenomenology findings 








3. Andrew et al., 
2008 
↓ ↓ ↓ = - - ↓ ↑ - 
4. Cottam et al., 
2011 
- ↓ ↓ - - - - - - 
5. Daalman et 
al., 2011a* 
↓ ↓ = = ↑ external ↓ 3rd 
person 
↓ ↑ - 
6. Daalman et 
al., 2011b* 
↓ ↓ = = ↑ external - ↓ ↑ - 
7. Daalman et 
al., 2012a* 
↓ ↓ = - ↑ external - ↓ ↑ - 
8. Daalman et 
al., 2012b* 
↓ ↓ = = ↑ external - ↓ ↑ ↓ 
9. Davies et al., 
2001 
- ↓ - - - - - - - 
10. de Weijer et 
al., 2013* 
- ↓ - - - - ↓ ↑ - 
11. Diederen et 
al., 2010* 
↓ ↓ = = ↑ external ↓ ↓ ↑ - 




↓ = = = = ↓ ↑ - 
13. Hill et al., 
2012* 
= = = = = = ↓ = ↓ 
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14. Honig et al., 
1998 
↓ ↓ - = - ↓ 3rd 
person 
↓ ↑ ↓ 
15. Krakvik et al., 
2015 
- ↓ - - - - ↓ - ↓ 
16. Leudar et al., 
1997 
- - - ↑ inside 
head 
- - ↓ - - 
17. Moritz and 
Laroi, 2008† 
- - ↑ - - - - = ↓ 
18. Slotema et al., 
2012* 
↓ ↓ = = ↑ external - ↓ ↑ ↓ 
19. Sommer et al., 
2010b* 
- ↓ - - - - - - - 
20. Sorrell et al., 
2010  
 
- - - - - - ↓ - - 
Note: ↑ indicates greater in HVHs than CVHs, ↓ indicates lower in HVHs than CVHs, = indicates similar in HVHs and CVHs, - indicates no results available; 
* indicates that studies belong to the same Dutch cohort; † when comparing HVHs to CVHs with a diagnosis of schizophrenia (as opposed to OCD). 
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 Age of Onset 
Five out of six publications comparing age of AVH onset reported an earlier age in HVHs than 
CVHs (Daalman et al., 2011a*; De Weijer et al., 2013*; Honig et al., 1998; Sorrell, Hayward, and 
Meddings, 2010), with age of onset in HVHs typically occurring between late childhood and early 
adolescence (Daalman et al., 2011a*; Linden et al., 2011; Sommer et al., 2010a*; van Lutterveld 
et al., 2010). However, Kråkvik et al. (2015) did not find a significant difference in age of onset 
between CVHs and HVHs. 
 Frequency and duration of voices 
Fourteen out of 15 studies reported a lesser frequency of voice-hearing in HVHs, with only one 
study failing to find a significant difference. Similarly, eight out of ten studies reported a lesser 
duration of hallucinatory episodes in HVHs, although two found no difference between HVHs 
and CVHs.  
 Perceptual Qualities 
Eleven studies compared the loudness of voices between HVHs and CVHs, with 8 finding no 
significant difference, two reporting quieter voices and one reporting louder voices in HVHs. 
Similarly, in 10 studies all but one reported that the perceived location of voices did not differ 
between HVHs and CVHs, with only one reporting that HVHs were more likely to perceive them 
as located inside the head (Leudar, Thomas, McNally, and Glinski, 1997). There is some evidence 
that HVHs perceive their voices with less clarity than CVHs (Cottam et al., 2011; Lawrence, Jones, 
and Cooper, 2010), but similar rates report their voices as indistinguishable from real voices 
(Moritz and Larøi, 2008).  
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 Voice identities 
Three out of four studies reported that HVH heard fewer different voices, particularly those 
commenting in the 3rd person. The majority of HVHs appear to hear one voice, although a 
sizeable minority hear multiple voices, with more than 10 in 5.4% of HVHs (Lawrence et al., 
2010). According to Sommer et al. (2010a*) 18% of HVHs reported commenting voices, and 11% 
heard voices speaking with each other; similarly, Peters et al. (2016) reported fewer 
commenting or conversing voices in HVHs compared with CVHs.  Leudar and colleagues (1997) 
reported that both CVHs and HVHs are addressed by voices directly, and voices commonly sound 
like individuals known to the voice-hearers; whilst voices in the clinical group are more 
frequently those of public figures or supernatural characters, HVHs are more likely to identify 
voices as similar to themselves or family members (Leudar et al., 1997).  However, Kråkvik et al. 
(2015) found no differences in the voice identities reported by CVHs and HVHs. Further, Sorrell 
et al. (2010) reported that gender and identity of AVHs does not appear to differ between 
groups. Religious groups more frequently identified their voices to be religious entities, however 
HVHs more often heard “God” and rarely “the Devil”, whilst CVHs more often heard “the Devil” 
but rarely “God” (Cottam et al., 2011).  
 Content 
Of the 14 studies comparing HVHs and CVHs, all reported lower levels of negative voice content 
and emotional valence in HVHs. Indeed, in one sample 71% of HVHs had never experienced 
negative voice content (Sommer et al., 2010a*).  Similarly, voices in religious HVHs mostly have 
mixed or neutral content, whereas religious CVHs mostly hear mixed and negative content 
(Cottam et al., 2011). However, Beavan and Read (2010) found that, in a sample of CVHs and 
HVHs that were not formally stratified by clinical status, no participants had experienced positive 
voice content only. In a small qualitative study, Leudar et al. (1997) found that directive voices 
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in CVHs frequently issued commands to carry out specific actions or violent acts, but in HVHs 
they more commonly “gave advice” on a particular course of action or mundane activities. HVHs 
heard significantly fewer negative evaluative comments about themselves, including their own 
thoughts (Honig et al., 1998), but heard significantly more comments evaluating others. This was 
also reported in the larger sample of Kråkvik et al. (2015), where HVHs were less likely to hear 
voices commenting on them. Whilst there was no difference in commanding voices, CVHs were 
more compliant with and swayed by commands. Interestingly, Varese et al. (2015) identified 
personal goals (e.g., being a confident person) as a substrate of voice content: in the majority of 
both CVHs and HVHs, personal goals of participants matched the content of the voices they 
experienced. 
2.3.3 Voice Impact and Appraisal 
 Distress and Control  
As would be expected, out of the 23 studies investigating distress all reported that voice-hearing 
in HVHs was associated with little to no voice-related distress, and/or that voice distress was 
significantly higher in CVHs. Comparing HVHs and CVHs, 10 studies found that HVHs reported 
greater control over voices, with only two studies finding the same level of control in HVHs and 
CVHs. Indeed, one study reported that healthy status was significantly predicted by high control 
over voices, low frequency of voices, age of onset before age 16, and predominantly positive 
voice content (Daalman et al., 2011a*). Need for control and low perceived control were also 
found to predict voice-distress by Hill et al. (2012), while Beavan and Read (2010) reported that 
negative emotional responses were predicted by negative voice content, more voices talking or 
arguing with each other, commenting on the individual, talking for longer periods, and taking 
over thoughts of the individual (Beavan and Read, 2010), as well as disturbing contact with 
others (Kråkvik et al, 2015). CVHs are significantly more afraid of voices than HVHs, and see 
voices as troublesome and disturbing daily life (Honig et al., 1998). Interestingly however, one 
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study indicated that despite negative elicited emotions being more likely to be reported by the 
CVH group, there was no significant difference in positive emotions elicited by AVHs in CVHs and 
HVHs (Kråkvik et al., 2015). Nonetheless, more than 90% of HVHs report no disturbance to their 
life by AVHs (Sommer et al., 2010a*), and all six studies comparing the disruptive impact of 
voices between HVHs and CVHs reported less disruption in HVHs.  
 Beliefs about Voices 
Out of the eight studies comparing beliefs of origin between HVHs and CVHs, six found that HVHs 
were more likely to attribute the voices to external origins, whereas two found no significant 
difference between the groups. All of the six studies assessing beliefs about voices indicate that 
HVHs have significantly less negative beliefs about voices, which is associated with more positive 
voice impact. Hill et al. (2012) reported that CVHs scored higher than HVHs on negative beliefs 
about worry and need for control of voices. Voice-related distress was significantly associated 
with negative beliefs about uncontrollability and danger of voices. Lawrence et al. (2010) found 
that, compared to scores from a previously published sample of CVHs, HVHs had significantly 
lower beliefs of malevolence, omnipotence and resistance towards voices, but higher scores of 
benevolence and engagement with voices. Levels of distress correlated with malevolence, 
omnipotence and resistance. Higher frequency was associated with higher levels of depression, 
anxiety, malevolence, omnipotence and resistance. Andrew et al. (2008) found that CVHs were 
more likely to appraise their voices as malevolent, which was predictive of depressive 
symptoms, and were more likely to use resistant coping strategies. Similarly, Kråkvik et al. (2015) 
found that CHVs were more likely to try to actively ignore voices, including command 
hallucinations (Leudar et al., 1997), and to try to understand them or argue with them, whilst a 
greater proportion of HVHs than CVHs were likely to do nothing in response to AVHs. Further, 
CVHs who begged voices to keep silent reported increased AVH intensity (Kråkvik et al., 2015). 
In turn, Peters et al. (2016) reported that HVHs were more likely to be accepting of their voices, 
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and adopt a mindful response style compared with CVHs. Qualitative data suggest that in HVHs, 
the initial reaction is marked by resistance, which is associated with increased intrusiveness, but 
eventually engagement (i.e. understanding and acceptance of experience) mitigates distress 
(Taylor and Murray, 2012). Sorrell et al. (2010) reported that HVHs related to their voices with 
less distance. Voice dominance, intrusiveness and hearer distance were significantly correlated 
with distress. However, when controlling for beliefs of malevolence and omnipotence, the 
association of distress and relating variables lost significance. Recently, Daalman et al. (2016*) 
provided evidence that attitudes towards AVHs can be susceptible to fluctuations, with beliefs 
about voices changing in 15.7% of HVHs at a 5-year follow-up. 
 Spiritual Frameworks 
All four studies reporting on spiritual or religious frameworks showed that these are more 
frequently employed by HVHs, with generally positive perceived impact. Daalman et al. (2011a*) 
reported that HVHs more frequently endorsed unspecific external or spiritual explanations, 
whereas CVHs more frequently explained voices to be other (living) people, god, demons/devil 
or implanted devices. In their comparison of religious HVHs to religious and non-religious CVHs, 
Cottam et al. (2011) found that religious HVHs more often experienced AVHs as a positive but 
never a negative power, whereas most clinical participants (both religious and non-religious) 
appraised them as a negative power. Similar findings were reported by Davies et al. (2001), with 
religious HVHs having significantly more positive perceptions of voices than non-religious HVHs 
and CVHs, respectively. In a qualitative study of HVHs recruited as psychic mediums, initial voice 
distress was mitigated by engagement with voices and integration into a spiritual framework 
(Taylor and Murray, 2012).  
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2.3.4 Mood Disturbances 
Three studies formally assessed mood disturbances in HVHs, comparing them to CVHs but not 
to HCs, with all three finding higher rates of emotional difficulties in the CVHs. Andrew et al. 
(2008) reported greater rates of depression and anxiety in CVHs compared with HVHs. Similarly, 
Sorrell et al. (2010) reported significantly greater depression scores in CVHs than HVHs. 
Lawrence et al. (2010) found that scores for anxiety and depression were significantly lower in 
HVHs than for 71 CVHs in an external study sample. However, a number of studies (see Table 
2.2) stipulated an absence of diagnosable affective disturbances as part of their inclusion criteria 
for HVHs. Nevertheless, Sommer et al. (2010a*) additionally reported on previous single or 
recurrent depressive episodes in full remission, and found that HVHs and HCs did not differ in 
their prevalence. The only study that compared depressive and anxiety symptoms in CVHs, HVHs 
and HCs reported significant group differences between all groups (Kråkvik et al., 2015) with 
CVHs having the highest scores and HCs having the lowest scores. Indeed, the HVHs in this 
sample were also significantly more likely than HCs (but less likely than CVHs) to have consulted 
a professional or received treatment for mental health problems unrelated to voice-hearing. 
Woods et al. (2015)’s survey data showed that in voice-hearers who had not previously received 
a psychiatric diagnosis their voices were less likely to be associated with fear or depression. Most 
recently, Daalman et al. (2016*) provided 5-year follow-up data on the mental health of their 
sample of HVHs as well as HCs. Eighty-one individuals with AVHs and 49 HCs were included, 
representing 78.6% and 81.7%, respectively, of the original participants. Five individuals with 
AVHs had transitioned to psychosis yet none of the HCs had developed psychosis. This difference 
was only at trend-level, and disappeared when individuals with previous depressive episodes 
who were in remission at baseline were excluded. However, they also found that 39.5% of their 
previously healthy voice-hearers had developed the need for mental healthcare, significantly 
more than the 12.2% of the healthy control group, even after exclusion of individuals with 
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depression in remission at baseline. Regression analyses revealed that this need for mental 
healthcare was predicted by total distress of AVHs and depression in remission, but not global 
functioning, schizotypy, familial psychosis, childhood trauma, or AVH frequency, control, 
emotional valence or age of onset.  
2.3.5 Impairment and Functioning 
Seven of the identified studies, all of which stem from the same Dutch cohort, reported on the 
potential impairment of HVHs, suggesting some impairments in global functioning that may be 
lesser than those of CVHs, yet greater than in HCs. Sommer et al. (2010a*) found that global 
functioning was significantly lower in HVHs than HCs, and was predicted by genetic loading (i.e. 
prevalence of familial psychiatric disorder). This was corroborated by Diederen et al.  (2010*) 
and van Lutterveld et al. (2014*), who found that CVHs, HVHs and HCs all differed significantly 
from each other in their global functioning, with CVHs scoring the worst, and HVHs scoring better 
than CVHs yet worse than HCs. Additionally, Diederen et al. (2010*) reported that CVHs showed 
reduced global functioning compared to HVHs. Howes et al. (2013*) and Diederen et al. (2013*) 
reported that HVHs showed no impairment in global functioning, but did not compare the 
results of HVHs to HCs. De Weijer et al. (2013*) reported global functioning scores as part of 
their demographic variables, showing lower scores in functioning of HVH compared to HCs, but 
did not report on the statistical significance of this difference. Based on the reported data, we 
conducted a two-tailed t-test assuming unequal variances for a more conservative estimate, 
showing that this difference was significant (p = 0.005, t = 2.95).  
2.3.6 Related Psychotic Phenomena 
Six studies investigated other psychotic experiences in HVHs. Sommer et al. (2010b*) 
investigated thought disorder in CVHs, HVHs and HCs using a thought and language index and a 
thematic apperception test. Impoverishment of language was almost exclusively present in 
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CVHs. Disorganisation scores were significantly lower in HCs than HVHs and CVHs, but HVHs 
were significantly less disorganised than CVHs. Additionally, Sommer et al. (2010a*) reported 
that there was greater preoccupation with, and conviction of, delusional ideation in HVHs than 
HCs. Hill et al. (2012) found that CVHs scored higher than HVHs on positive symptoms, negative 
symptoms and symptoms of general psychopathology. HVHs did not differ significantly from HCs 
on negative symptoms and general psychopathology, but scored higher on positive symptoms, 
which lost significance when the hallucination item was excluded. Sommer et al. (2010a*) 
reported greater schizotypy scores in HVHs compared to HCs, with significant elevations on all 
subscales including non-positive dimensions. Interestingly, schizotypy scores, alongside genetic 
family loading and number of years of education, predicted global functioning. Higher schizotypy 
was also observed amongst HVHs compared to HCs in another study (van Lutterveld et al. 
2014*), however schizotypy scores in one HVH group were similar to published general 
population estimates (Howes et al., 2013*). Further, the majority of HVHs experience other 
hallucinatory experiences, most commonly in visual, olfactory and tactile sensory domains 
(Sommer et al., 2010a*; Peters et al., 2016). 
2.3.7 Cognitive Biases  
Two studies investigated the presence of cognitive biases in HVHs. Daalman et al. (2012b*) 
compared CVHs, HVHs and HCs on cognitive biases for psychosis, including jumping to 
conclusions (reaching conclusions with limited information), intentionalising (suspecting ill 
intent in the actions of others), catastrophizing (endorsing the worst possible outcome of a 
situation), dichotomous thinking (appraising situations in extremes rather than gradients of 
good and bad) and emotional reasoning (emotion-driven reasoning, such that appraisals are 
based on internal emotional states). HCs had significantly lower cognitive biases scores than 
both HVHs and CVHs, and HVHs had lower scores than CVHs. However, there were different 
patterns depending on which type of bias/vignette content was examined: HCs and HVHs scored 
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significantly lower than CVHs on intentionalising, catastrophising, dichotomous thinking and 
jumping to conclusions subscores, and did not differ from each other; while both AVH groups 
scored significantly higher on the emotional reasoning subscale compared to HCs and did not 
differ from each other.  CVHs scored significantly higher on vignettes with threatening themes 
than both HCs and HVHs, who did not differ from each other. In contrast, both CVHs and HVHs 
scored significantly higher on vignettes with themes relating to anomalous perceptions 
compared with HCs, and did not differ from each other. Emotional (voice-distress and emotional 
valence) as well as cognitive (beliefs about origin, control and disruption) interpretations of 
AVHs were significant predictors of cognitive bias scores. Similarly, Jacobsen et al. (Under 
Review) found evidence for a more overgeneral autobiographical memory bias in CVHs 
compared to HVHs and HCs. Moreover, voice-specific autobiographical memory was more 
overgeneral in CVHs than in HVHs. 
2.3.8 Cognitive Functioning 
A total of five studies, all but one stemming from the Dutch cohort, investigated cognitive 
functioning in HVHs, suggesting few significant differences compared to HCs. HVHs show more 
errors in top down semantic expectation when compared to HCs (Daalman et al., 2012a*). 
Moreover, auditory acuity appears somewhat lower in HVHs than HCs (Kompus et al., 2013). 
Similarly, some cognitive functions, mainly in the verbal domain, have been demonstrated to be 
significantly lower in HVHs compared to HCs (Daalman et al., 2011b*). Notably however, 
cognitive functions of HVHs were still within normal ranges. Interestingly, follow-up analysis by 
Begemann and colleagues (2015*) suggested that differential verbal inhibition in HVHs vs HCs, 
as measured by the Stroop paradigm (but no other cognitive measures), is fully explained by 
childhood trauma. A paced verbal fluency task has shown to be equivalent between HVHs, CVHs 
and HCs (Diederen et al., 2010*). Further, there were no differences observed at the behavioural 
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level between HVHs and HCs on a test of effortful attention, as assessed via the oddball 
paradigm (van Lutterveld et al., 2010*).  
2.3.9 Neuroimaging 
A total of 9 studies used neuroimaging to investigate HVHs, with methodologies ranging from 
electroencephalography (EEG), functional magnetic resonance imaging (fMRI), structural MRI, 
diffusion tensor imaging (DTI) as well as positron emission tomography (PET) (Table 2.4; De 
Weijer et al., 2013*; Diederen et al., 2013*; Diederen et al., 2010*; Diederen et al., 2012*; 
Howes et al., 2013*; Kompus et al., 2013; Linden et al., 2011; van Lutterveld et al., 2010*, 
2014*). Howes and colleagues (2013*) used PET imaging with [18F]-DOPA to investigate 
dopamine (DA) synthesis capacity in HVHs and HCs. No significant differences were found in 
whole striatal DA synthesis capacity or associative, limbic and sensorimotor functional 
subdivisions. Thus, the dopaminergic dysregulation observed in psychosis (Howes et al., 2012) 
appears not to be present in HVHs. Similarly, in a verbal fluency paradigm (Diederen et al., 
2010*), HVHs and HCs did not differ significantly on language lateralisation. CVHs showed 
greater activation in the right precentral gyrus and left insula than both HVHs and HCs. CVHs 
also showed greater activation in the right superior parietal lobule than HCs, who did not differ 
significantly from HVHs.  
However, some neurobiological indices appear more similar in HVHs and CVHs. For instance, 
BOLD contrast fMRI during AVHs was not able to distinguish HVHs and CVHs (Diederen et al., 
2012*). Furthermore, Diederen et al. (2013*) reported that during resting-state, HVHs exhibit 
aberrant connectivity of frontal, superior temporal and parahippocampal areas compared to 
HCs. Although no CVH sample was included, the authors point towards similar findings in clinical 
populations, and hypothesise that such alterations underlie the failure of inner speech to be 
attributed as self-generated. De Weijer et al. (2013*) used DTI and magnetisation transfer 
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imaging to compare integrity of white matter tracts in CVHs, HVHs and HCs. For the left arcuate 
fasiculus, both CVHs and HVHs had higher magnetisation transfer ratios than HCs, further 
suggesting some alterations in white matter connectivity, whilst only CVHs had higher 
magnetisation transfer ratios in the right arcuate fasiculus compared to HCs but not HVHs, who 
did not differ significantly from each other. Fractional anisotropy was significantly lower in left 
arcuate fasiculus, right cortico-spinal tract and bilateral uncinate fasiculi for CVHs only, 
suggesting altered connectivity and white matter abnormalities to be largely specific to CVHs. 
Van Lutterveld and colleagues (2014*) conducted a structural MRI study, comparing CVHs, HVHs 
and HCs. There were significant group differences in left paracentral lobule, left pars orbitalis, 
right fusiform gyrus and right inferior temporal gyrus, with CVH lowest, HVH intermediate and 
HCs showing highest cortical thickness. Right insula thickness was decreased in both CVHs and 
HVHs compared to controls. In another study however, EEG measures of the oddball paradigm 
showed activation patterns consistent with increased effortful attention in HVHs, a finding 
diametrically opposed of that typically observed in psychosis patients (van Lutterveld et al., 
2010*). The authors hypothesise that the oddball paradigm is therefore not associated with 
AVHs per se. Indeed, most of the studies found no association between the neuroimaging 
indices and assessed AVH parameters (e.g. frequency or emotional valence). This was the case 
for cortical thickness (van Lutterveld et al., 2014*), striatal dopamine synthesis (Howes et al., 
2013*), lateralisation indices (Diederen et al., 2013*) as well as fractional anisotropy and 
magnetisation transfer ratios (de Weijer et al., 2013*). Thus, with several of these measures it 
appears likely that the investigated parameter is not AVH-related, but population-specific.  
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Table 2.4 – Results of neuroimaging studies 
Study Paradigm                 Tested association 
  HVH compared to CVH HVH compared to  HC CVH compared to  HC 







↑ Fractional anisotropy in left arcuate 
fasiculus, right cortico-spinal tract and 
bilateral uncinate fasiculi 
↑ Magnetisation transfer ratio in left 
arcuate fasiculus  
↑ Magnetisation transfer ratio 
in left arcuate fasiculus 
↑ Magnetisation transfer ratio 
in right arcuate fasiculus 
↑ Radial diffusivity in the right 
arcuate fasicilus 
 
Diederen et al., 
2010* 
BOLD fMRI during 
verbal fluency task 
↑ Lateralisation 






↑ Activation in right precentral 
gyrus, left insula, and right 
superior parietal lobule 
 
Diederen et al., 
2012* 
BOLD fMRI during 
AVHs 
 =  Activation in a priori hypothesised 
regions, comprising bilaterial inferior 
frontal gyri, insula, superior and middle 
temporal gyri, supramarginal gyrus, 
precentral and post-central gyri, 
cerebellum, hippocampus and 
parahippocampal gyrus, as well as across 
all grey matter voxels 






Study Paradigm                 Tested association 
  HVH compared to CVH HVH compared to  HC CVH compared to  HC 
Diederen et al., 
2013* 
BOLD fMRI during 
resting-state 
n/a ↓ Connectivity of left superior temporal 
gyrus with right and left superior temporal 
regions 
↑ Connectivity of left parahippocampal 
gyrus with left inferior frontal region 
= Connectivity of right superior temporal 
and bilateral inferior frontal regions 
No negative correlation of right inferior 
frontal gyrus activity with left 
temporoparietal region in HVHs 
n/a 





n/a = Whole striatal dopamine synthesis 
capacity as well as in associative, limbic and 
sensorimotor functional subdivisions 
n/a 





n/a ↓ Primary auditory cortex activation in 
response to stimulation 
n/a 
Linden et al., 2011 BOLD fMRI during 
AVHs (vs imagined 
voices in HCs) 
n/a ↑ Activation in bilateral inferior parietal 
lobules, left middle frontal gyrus, posterior 
cingulate cortex, left Heschl's gyrus and 
bilateral calcarine sulci 
↑ Time of onset of activity in 
supplementary motor area, followed by 





Study Paradigm                 Tested association 
  HVH compared to CVH HVH compared to  HC CVH compared to  HC 
van Lutterveld et 
al., 2010* 
EEG during oddball 
paradigm 
n/a ↑ P300 amplitudes, processing negativity 
amplitudes 
= P300 latency, processing negativity 
latency, mismatch negativity amplitude 
and latency  
n/a 
van Lutterveld et 
al., 2014* 
MRI ↑ Cortical thickness in left paracentral 
lobule, left pars orbitalis, right fusiform 
gyrus and right inferior temporal gyrus 
↓ Cortical thickness in left paracentral 
lobule, left pars orbitalis, right fusiform 
gyrus and right inferior temporal gyrus 
↓ Right insula thickness 
↓ Cortical thickness in left 
paracentral lobule, left pars 
orbitalis, right fusiform gyrus 
and right inferior temporal gyrus 
↓ Right insula thickness 




2.3.10 Trauma Exposure 
All of the five studies that assessed trauma in HVHs reported increased rates of trauma exposure 
similar to those in CVHs. Honig et al. (1998) first found evidence of elevated trauma rates in 
HVHs: whilst childhood trauma rates were significantly higher in CVHs than HVHs, only 27% of 
HVHs had no history of childhood abuse. Unlike Honig et al., but in a much larger sample, 
Daalman et al. (2012b*) found that CVHs and HVHs did not differ significantly from each other 
in prevalence of childhood sexual, physical or emotional abuse, or physical or emotional neglect, 
which were all higher than in HCs (Sommer et al., 2010a*). Type of trauma did not predict 
emotional valence or phenomenology of voices. Similarly, Andrew et al. (2008) found no 
significant differences in exposure rates to traumatic childhood or adulthood events between 
CVHs and HVHs, although CVHs had higher rates of childhood sexual abuse. Traumatic events 
were more closely associated with PTSD symptoms in CVHs than HVHs. Trauma predicted beliefs 
of high malevolence, low benevolence and high omnipotence of voices, as well as higher levels 
of anxiety. Kråkvik et al. (2015) found higher rates of lifetime trauma exposure in HVHs 
compared to HCs, but lower than in CVHs. CVHs and HVHs did not differ in their experience of 
bullying, although a trend-level effect was observed suggesting higher rates in CVHs, and both 
groups were significantly higher than HCs. Notably, the age of exposure was not assessed. A 
significantly larger percentage of CVHs had been in dangerous situations or accidents than HVHs, 
who in turn had a larger exposure to such events than HCs. Interestingly, HVHs were significantly 
less likely to identify such stressful life events as related to AVH onset, in contrast to CVHs. 
2.3.11 Familial Risk 
Three of the identified studies reported on the potential familial risk of HVHs. In Linden et al. 
(2011), 2 of 7 HVH participants reported a first-degree relative with psychosis. Similarly, van 
Lutterveld et al. (2014*) reported that HVHs and CVHs had a greater number of first- and second-
degree relatives with a psychotic disorder compared to HCs, and they did not differ between 
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each other. Notably, no group differences in the number of relatives with a manic disorder were 
observed. Conversely, Sommer et al. (2010a*) reported that relatives of HVHs had significantly 
higher prevalence rates of depressive disorders, mania and substance use disorders than HCs, 
with a similar trend for psychosis, suggesting higher rates of mental illness in families of both 
HVHs and CVHs. Further, such apparent genetic loading was predictive of global functioning.  
2.4 Discussion 
This systematic review identified a total of 36 studies investigating HVHs, spanning various study 
designs from small qualitative to large epidemiological studies. The literature includes studies 
investigating voice phenomenology, their impact and appraisal, mood disturbances, impairment 
and functioning, related psychotic phenomena, cognitive functioning, neuroimaging, trauma 
exposure and familial risk. Sampling methodologies vary widely, with HVH sample sizes ranging 
from six to 183, and variable recruitment of HC and/or CVH control samples. The findings need 
to be interpreted in the context of a number of limitations in the existing literature, which are 
elaborated below. Most notably, 17 of the 36 reviewed studies are based on variations of the 
same cohort, which may skew results according to the sampling methodology of those studies, 
and may inflate the consistency of some of the findings.  
2.4.1 Phenomenology and Impact 
Contrary to what would be predicted by diagnostic models, the phenomenology of AVHs is 
overall similar in HVH and CVHs, particularly in form (e.g. loudness or location), but less so in 
content and incidence (i.e., frequency and duration). However, the selection of samples based 
on minimum frequency scores of AVHs may lead to a distortion of the phenomenology of AVHs. 
Wider populations, where AVHs may be distributed with lower frequency, are excluded in most 
studies. Thus, it cannot be ruled out that parameters such as AVH loudness are actually 
attenuated once frequency decreases. Large epidemiological research focused on AVHs is 
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necessary to describe such patterns more accurately, with study designs such as those employed 
by Woods et al. (2015) and Kråkvik et al. (2015).   
The impact and appraisal of AVHs differ substantially between HVHs and CVHs, as would be 
predicted by a fully-dimensional model where AVHs themselves are insufficient to cause 
distress. Negative beliefs about voices, such as attributed malevolence and omnipotence, were 
often predictive of mood disturbances and negative emotional reactivity, as hypothesised by 
cognitive models of voices (Chadwick and Birchwood, 1994). CVHs consistently report 
diminished control over their voices, with diminished control as well as need for control being 
predictive of voice-distress. Although it is likely that the distress of clinical voice-hearers is driven 
by increased frequencies and negative voice content, a role of ‘top-down processes’ in driving 
phenomenological characteristics cannot be ruled out. For instance, resistant relationships with 
voices, a coping style predominantly employed by CVHs, may partially account for the increased 
frequencies and duration of AVHs in CVHs. HVHs reported that resistance led to initial distress, 
which was mitigated by engagement (i.e. acceptance and understanding) (Taylor and Murray, 
2012). Indeed, HVHs are more likely to have a mindful response style to voices (Peters et al., 
2016). This is reminiscent of the thought suppression literature, where it has been found that 
actively trying to suppress thoughts paradoxically increases their repetitiveness and 
intrusiveness (Wenzlaff and Wegner, 2000). Thus, it should not be ruled out that 
phenomenology of voices is shaped by their interactions with ‘top-down’ processes such as 
appraisals and coping strategies. Similarly, the negative content of voices may be shaped by the 
presence of mood difficulties, distress or low self-esteem in CVHs, as suggested by the evidence 
on mood-congruent AVHs (Larøi et al., 2012). In turn, the well-replicated finding that AVH onset 
occurs significantly earlier in HVHs may explain divergent cognitive appraisals. It could be 
speculated that earlier onset can be protective against negative appraisals such as thinking that 
one is “crazy”, as societal stigmatising implications of AVHs may not be understood at that age. 
However, in the absence of consistent epidemiological and longitudinal evidence, the cross-
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sectional evidence reported in the literature makes it difficult to determine the direction of 
relationships amongst AVHs variables and outcomes.   
2.4.2 Mental Health and Functioning 
Greater rates of depression and anxiety are reported in CVHs compared to HVHs. The relative 
lack of mood disorders in HVHs again does not support a diagnostic or quasi-dimensional 
framework, i.e. persistent AVHs can occur independent of distress and mood disturbances. 
However, these findings need to be viewed in the context of sample selection and stratification 
in most studies, most notably those of the Utrecht cohort (see Table 2.2) which applied very 
strict eligibility criteria (i.e., exclusion of any current psychiatric disorder or substance use). 
Indeed, Kråkvik et al. (2015), using a more open, epidemiological design, did find higher rates of 
mental health problems in HVHs compared to HCs. Daalman et al. (2016*) further showed that 
despite good mental health at baseline, their HVHs were at higher risk of developing a need for 
mental healthcare, most strongly predicted by voice distress and previous mood disturbances. 
Most of the studies investigating global functioning also showed increased levels of impairments 
in HVHs compared with HCs, although these tended to be of subclinical magnitude and situated 
on a continuum between HCs and CVHs. The reviewed studies thus suggest that although HVHs 
mostly do not require care and suffer no distress (a finding in line with the fully-dimensional 
model); there is nonetheless some evidence of an increased risk of need for care from 
epidemiological or longitudinal research (a finding in line with the quasi-dimensional model). 
Similarly, HVHs score higher than HCs, but lower than CVHs, on disorganisation of thought, show 
higher levels of delusional ideation than HCs, and have more implicit cognitive biases than HCs, 
but less than CVHs. Interpreted from a multidimensional standpoint, this may imply that mood 
disorder and distress are only weakly associated with AVHs, which in turn are more consistently 
associated with other positive symptoms and cognitive biases. However, since much of the 
evidence is cross-sectional, it is as of yet impossible to disentangle causal pathways. 
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The strictly dichotomous stratification in the majority of studies means that clinical individuals 
who are in remission, or generally healthy individuals who show occasional, subclinical distress, 
are often excluded in research. Given that the present literature was born out of a 
reconceptualisation of psychosis towards dimensional models, it is paradoxical that the grey 
zone in which transitions to and from care-necessitating disturbances occur remains largely 
unexplored. Differing psychological factors in HVHs and CVHs such as cognitive biases or voice 
appraisals can, and already do, inform cognitive-behavioural interventions. Therefore, cross-
sectional as well as longitudinal research of such transitioning populations, such as that carried 
out in the literature on at-risk populations, may be most relevant to clinical care and should be 
addressed in future research.  
2.4.3 Risk Factors 
HVHs consistently report the presence of well-established latent risk factors for psychosis, i.e. 
genetic loading (Howes and Murray, 2014) and childhood trauma (Varese et al., 2012). Whilst a 
greater degree of risk exposure would be expected for both groups in Models 2&3, it is striking 
that HVHs and CVHs show almost no difference in exposure to these specific risk factors. 
However, whilst familial incidence of psychiatric disturbances is a reasonable indicator of 
genetic risk, heritability estimates of AVHs in CVHs and HVHs, as well as molecular genetic and 
epigenetic investigations, are needed for a more comprehensive understanding. Additionally, a 
strong case is made for the role of childhood trauma, which was consistently elevated in HVHs 
across all studies, a finding in line with the highly predictive impact of childhood trauma in the 
emergence of AVHs demonstrated in other studies (Read, van Os, Morrison, and Ross, 2005; 
Shevlin, Houston, Dorahy, and Adamson, 2008). This high rate of trauma exposure in HVHs may 
also explain the greater risk for distress in HVHs compared to non-voice-hearing members of the 
general population. Future research should address whether trauma exposure underlies the 
association of AVHs and distress in the general population.  
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However, variables such as socioeconomic status or positive social relationships, which may act 
as further risk or protective factors, have remained unexplored in this context despite their 
potential relevance. Indeed, in the context of wider psychotic experiences, Peters et al. (2016) 
showed that non-clinical individuals were less likely to be members of a minority ethnic group, 
come from a working-class background, live in areas with civic disorder, and were more likely to 
be employed, have higher educational achievements, and have meaningful relationships. Future 
research should further investigate adulthood exposure to adversity, stressful life events and 
everyday stress to assess whether CVHs have greater exposure to the “third hit” proposed in 3-
hit models of stress vulnerability (Daskalakis et al., 2013). That is, if HVHs and CVHs largely share 
the first hit, i.e., a genetic susceptibility, and the second hit, i.e., exposure to childhood traumatic 
events, then a third hit, i.e., in the form of adversity exposure in early adulthood, may crucially 
shape the clinical trajectory. The age of exposure to trauma is of great importance for such an 
assessment and has been omitted in all of the identified studies. Of note, it is surprising that the 
role of drug use as a risk factor has not been assessed in the literature, potentially due to 
stringent sampling procedures. However, evidence by Peters et al. (2016) suggests that non-
clinical individuals who report wider psychotic experiences are less likely to use drugs than both 
their clinical counterparts and HCs, a finding that needs replication specifically in the context of 
HVHs. 
2.4.4 Neurobiology 
Several neuro-cognitive and biological variables appear inconclusive regarding the three 
frameworks, at least in some domains. Whilst findings on cortical thickness (van Lutterveld et 
al., 2014*) and white-matter integrity (de Weijer et al., 2013*) are broadly in line with quasi- 
and fully-dimensional models, several of the functional paradigms showed incongruences with 
such models. Notably, language lateralisation does not differ between HVHs and HCs, but differs 
from CVHs (Diederen et al., 2013*, 2010*). EEG-measured response to the auditory oddball 
paradigm in HVHs diverges from HC populations indicating increased effortful attention, 
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directionally opposing the well-replicated finding that psychosis is associated with decreased 
effortful attention (van Lutterveld et al., 2010*). The authors suggest that this primarily indicates 
that AVHs are unrelated to effortful attention, as correlations of reduced P300 amplitudes with 
positive or negative symptoms in schizophrenia patients have not been consistently replicated. 
Notably, this issue translates to several of the investigated variables: it is often difficult to 
disentangle whether a particular finding is a substrate of AVHs, or a byproduct of wider 
symptomatology and population differences. Thus, for many of these findings it is not clear 
whether apparent discontinuity is ultimately one of the phenomenon or the population. 
Interestingly, Howes et al. (2013*) reported no differences in DA synthesis capacity between 
HVHs and HCs. Increased striatal DA synthesis capacity has been a consistent finding in psychosis 
patients (Fusar-Poli and Meyer-Lindenberg, 2013; Howes et al., 2012) and has also been 
reported in at-risk individuals (Howes et al., 2011). According to the DA hypothesis (Howes and 
Kapur, 2009), increased striatal DA signaling leads to aberrant salience attribution to 
unwarranted stimuli and their associations. Whilst this is hypothesised to lead to the formation 
of delusional explanations, it is not established whether DA dysregulation actually underlies 
hallucinatory experiences. The authors (Howes et al., 2013*) conclude that their findings suggest 
that, at least in the case of non-clinical AVHs, this is not likely to be the case. Speculatively, 
dysregulated DA synthesis may act as a moderating factor upon which the formation of 
delusional beliefs secondary to AVHs is contingent, such as threatening appraisals. However, 
when variables directly associated with AVHs are considered, CVHs and HVHs appear highly 
similar; for instance, Diederen et al. (2012*) found no differences between CVHs and HVHs in 
brain activity during acute AVHs, suggesting a shared neurobiological mechanism underlying 




The evidence considered in the present systematic review does not support strictly categorical 
or disease models of psychotic experiences, and is generally inconsistent with a diagnostic 
conceptualisation (Model 1), thus supporting the first hypothesis. Instead, the evidence 
supports fully-dimensional and quasi-dimensional models (Models 2 and 3) to a similar degree, 
and cannot distinguish between them, as predicted by the second hypothesis. Therefore, a 
hybrid conceptualisation is likely to be the most accurate model (Linscott and van Os, 2013; van 
Os and Reininghaus, 2016). Characteristics of individual symptoms (e.g. frequency, loudness or 
content of AVHs) may differ in their continuity between populations, and may feasibly present 
with skewed or bimodal rather than normal distributions. Especially in the case of bimodal 
distribution, the contrast between continuous and categorical is left as a primarily semantic 
issue, as even the most categorical distinctions (e.g. gender) have blurry boundaries (e.g. 
hermaphroditism or non-binary gender identities). Thus, whilst the evidence ultimately suggests 
continuity, it is upon future epidemiological research to tease out the complexities and 
relationships of symptom dimensions. Nonetheless, research on AVHs in healthy populations 




Chapter 3 – Stress-Function and Psychosis 
3.1 Stress-Physiology and Adaptation 
3.1.1 Stress, Stress-Reactivity and Allostasis 
The term “stress” was first employed in life sciences in the 1930s by early stress researchers 
such as Hans Selye (Selye, 1936), borrowing it from the field of physics where stress describes 
the force applied to an object. Although a universal definition of this widely used term remains 
elusive, it is frequently used to describe pressure, exhaustion or tension, be it psychosocial or 
biological, that is exerted on an organism and threatens homeostasis (Goldstein and Kopin, 
2008; Sapolsky, 2002; Ulrich-Lai and Herman, 2009). The resulting stress reaction can be 
conceptualised as an acute and/or chronic psychological and physiological state that aims to 
maintain homeostasis (McEwen, 2000; Sapolsky, 2002). Notably, this threat to homeostasis may 
be actual or merely perceived, and the stress response can be elicited both in reaction to or 
anticipation of a stressor (Sapolsky, 2002). As would be expected from terminology that can be 
applied to both running after a bus and running away from a lion, a definition of such breadth 
and ambiguity may ultimately have limited power. Thus, the magnitude, duration and context 
of the stressor and of the stress response are crucial in shaping impact and outcome. Indeed, 
there is considerable evidence that the magnitude and composition of the stress response varies 
considerably depending on the specific stressor and the type of threat it poses (Goldstein and 
Kopin, 2008; Miller, Chen, and Zhou, 2007).  
Although often portrayed negatively, the stress response evolved as a highly adaptive process 
to increase the likelihood of an organism’s survival when exposed to threat (McEwen, 2000). 
Through adaptive redistribution of physiological and psychological resources towards the 
purpose of short-term expenditure, the likelihood of survival is optimised, albeit at the cost of 
temporarily compromising long-term bodily processes such as digestion. The purpose of this 
shift is perhaps most aptly described by Robert Sapolsky (2004), pointing out that “if there is a 
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tornado bearing down on the house, this isn’t the day to repaint the garage” (p. 11). 
Physiologically, the stress response is marked by activation of two closely related systems, the 
sympathetic component (SNS) of the autonomic nervous system (ANS) and the hypothalamic-
pituitary-adrenal (HPA) axis, both of which release hormones, adrenaline and cortisol 
respectively, from the adrenal glands (Sapolsky, 2002; Ulrich-Lai and Herman, 2009). In 
combination, they mount an effort to uphold homeostasis by optimising resource distribution 
in the body, and inducing the behavioural fight or flight response (Sapolsky, 2002; Ulrich-Lai and 
Herman, 2009).  
Despite this clear evolutionary purpose, the capacity of human beings to engage these stress 
systems has been recognised to be potentially maladaptive in purely psychosocial contexts, 
where increased blood flow and energy delivery to skeletal muscles confers virtually no 
advantage (Sapolsky, 2002). This is the case for both anticipation of and reaction to stressors, 
particularly so if the stressor is ambiguous. Whilst being attacked by a lion will inevitably lead to 
a stress response, the stress response to, for instance, unpleasant social situations, is neither 
inevitable nor helpful (Sapolsky, 2002). Moreover, in the context of chronic employment of 
psychogenic stress responses, adaptations may occur that impair the future ability to identify 
and respond to potential stressors adequately.  
The term allostasis refers to a process whereby the function of systems such as the ANS and HPA 
axis is chronically altered to maintain homeostatic processes (Danese and McEwen, 2012; 
McEwen, 2008). States of chronic hyper- or hypo-activation of these systems have been 
identified in the aetiology and maintenance of several psychological and biomedical pathologies 
(Baumeister et al., 2014; Danese and McEwen, 2012; McEwen, 2008). These maladaptive states 
are typically described as allostatic load, and are associated with altered stress profiles. An 
appropriate stress response requires a marked activation of stress systems, as well as a rapid 
deactivation with cessation of the stressful stimulus. Sluggish or hypervigilant onset or recovery, 
as well as attenuated or augmented peak response, are indicators of excessive allostatic load 
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(McEwen, 2000, 2008). Similarly, basal function of those systems may be augmented or 
attenuated. Maladaptive changes may develop through exposure to chronic or traumatic 
stressors, to which there is particular vulnerability in early developmental stages but which may 
also occur later in life (Danese and McEwen, 2012). Indeed, it has been proposed that 
pathophysiological changes arise through a three hit model: the first hit being genetic 
predisposition or dispositional susceptibility, the second being exposure to stressful experiences 
in childhood, and the last being exposure in later life (Daskalakis et al., 2013).  
3.1.2 The Autonomic Nervous System 
The most immediate physiological stress reaction is mediated by the SNS, which is one of the 
three branches of the ANS. The other two branches are the enteric and the parasympathetic 
nervous system (PNS), which control digestion as well as processes diametrically opposed to 
those of the sympathetic nervous system, respectively (Sapolsky, 2002). SNS activity is induced 
in response to homeostatic disturbances, such as blood loss, pain or inflammation, and several 
structures of the brain stem and spinal cord, including the medulla and preganglionic neurons, 
are activated almost instantaneously (Goldstein and Kopin, 2008; Ulrich-Lai and Herman, 2009). 
The neurotransmitter noradrenaline is released from the locus coeruleus in the CNS as well as 
sympathetic nerves, and the sympatho-adrenal-medullary (SAM) axis is activated, causing 
release of the hormone adrenaline from the adrenal medulla, the inner section of the adrenal 
glands.  
Noradrenaline and adrenaline induce tachycardia, vasoconstriction, bronchodilation, 
hyperventilation and hypertension, in order to optimise blood and oxygen delivery to the brain 
as well as skeletal muscle (Goldstein and Kopin, 2008; Sapolsky, 2002). Moreover, the SNS 
stimulates energy mobilisation through the stimulation of glycogen and fat metabolism to 
increase glucose and free fatty acids in blood (Sapolsky, 2002). They further stimulate activity of 
the inflammatory immune system to pre-empt injury and subsequent infection (Sapolsky, 2002). 
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Finally, high levels of SNS activity can induce the fight-or-flight response, a state marked by 
cognitive and behavioural hypervigilance, increased arousal as well as anxiety and irritability 
(Morilak et al., 2005; Sapolsky, 2002; Ulrich-Lai and Herman, 2009). Interestingly, the 
noradrenergic response has a lower threshold and responds to events such as orthostasis, 
locomotion, mild blood loss and cold exposure, whereas adrenergic responses are only initiated 
in situations that pose a more substantial threat, such as hypoglycaemia, exercise beyond 
anaerobic threshold, asphyxiation and considerable blood loss (Goldstein and Kopin, 2008). 
Thus, some SNS activity also plays a role during situations that do not pose an actual threat to 
homeostasis and its activity does not necessarily constitute a stress response. The SAM only 
becomes active once a global threat is established, and indeed there is some evidence that SAM 
activity may be more closely associated with HPA activity (Goldstein and Kopin, 2008). However, 
both SNS and SAM adrenal responses appear sensitive to psychological distress (Goldstein and 
Kopin, 2008). Following stress exposure, there is also a protracted rise in PNS activity, mediated 
by the nucleus ambiguous and parts of the vagus nerve, to allow the organism to return to 
homeostasis and resume vegetative function. 
3.1.3 The Hypothalamic-Pituitary-Adrenal axis 
The HPA axis is an endocrine system that is active both in the central nervous system as well as 
in the periphery, which, like the SNS, is stimulated by the brainstem in response to homeostatic 
perturbations. Its activity is primarily mediated by secretion of adrenal steroid hormones called 
glucocorticoids, prominently cortisol in humans (McEwen, 2008; Sapolsky, 2002). It is responsive 
to acute stimulation through stress exposure, particularly stressors of a psychological nature 
(Dickerson and Kemeny, 2004), but also follows a diurnal pattern corresponding to periods of 
rest and activity (Spiga, Walker, Terry, and Lightman, 2014), and shows a rapid oscillatory activity 
hypothesised to allow for optimal responsiveness (Lightman and Conway-Campbell, 2010). The 
diurnal slope is described by peak activity in the morning, referred to as the cortisol awakening 
response, and a trough towards the evening (Spiga et al., 2014). Activation of HPA axis follows 
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a cascade from the CNS to the adrenal cortices (Sapolsky, 2002; Ulrich-Lai and Herman, 2009). 
First, the hypothalamus releases several hormones that can cause down-stream activation of 
the pituitary gland, including corticotrophin-releasing hormone (CRH), arginine vasopressin 
(AVP), oxytocin, noradrenaline and adrenaline. Notably, hypothalamic hormone release during 
stress is idiosyncratic based on particular stress signatures, e.g. whether the organism 
experiences hypotension or hypoglycaemia, with different orchestrations of hormones 
triggering the down-stream signalling cascades (Joëls and Baram, 2009; Sapolsky, 2002). These 
hormones, most prominently CRH, stimulate the pituitary gland to secrete adrenocorticotrophic 
hormone (ACTH) into circulation, which causes the release of cortisol from the adrenal cortices 
cranial to the kidneys. Depending on hypothalamic hormone orchestrations, the secretory 
pattern of ACTH is adapted to a particular stressor (Joëls and Baram, 2009; Sapolsky, 2002).  
Following release of cortisol, it is registered throughout the body by its two cognate receptors, 
the glucocorticoid receptor (GR) and the mineralocorticoid receptor (MR). These receptors can 
be found intracellularly within the cytoplasm, but also as membrane receptors.  MRs have an up 
to 10-fold higher affinity for glucocorticoids, and tend to be occupied and activated tonically 
throughout the day (De Kloet, Vreugdenhil, Oitzl, and Joëls, 1998). During peak HPA activity, e.g. 
during an acute exposure to a stressful stimulus, glucocorticoid release rises so that following 
satiation of MRs a higher number of GRs become activated (De Kloet et al., 1998). Once 
activated, cytoplasmic GRs discard chaperone proteins that bind them, such as the heat-shock 
protein FKBP5, form palindromic homodimers and translocate to the nucleus (Savory et al., 
2001; Silverman et al., 2012). They can then engage in direct protein-protein interactions, e.g., 
with transcription factors such as the inflammatory messenger NF-kB, but also with 
glucocorticoid-response elements within the DNA (Zunszain, Anacker, Cattaneo, Carvalho, and 
Pariante, 2011). In the periphery, this leads to inhibition of the immune system, attenuated 
release of growth and reproductive hormones including gonadotropin and thyrotropin, and it 
induces resistance to these hormones as well as insulin in target tissues (Sapolsky, 2002). In the 
paraventricular nucleus of the hypothalamus and the anterior pituitary gland, activation of the 
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GR directly induces negative feedback that inhibits the release of CRF and ACTH (Smith and Vale, 
2006). Further indirect negative feedback is provided through receptors in limbic, thalamic and 
frontal regions, which send inhibitory projections to the hypothalamus (Ulrich-Lai and Herman, 
2009). It is generally assumed that negative feedback within the HPA axis is primarily mediated 
by the GR, although some research has also demonstrated fast feedback inhibition through the 
MR (Atkinson et al., 2008).  
3.1.4 The Orchestration of Stress in the Brain 
The response to and processing of stress in the brain is highly complex, and in consideration of 
this the present discussion should not be considered comprehensive, but as highlighting guiding 
principles. Activity of the two stress systems is initiated by the paraventricular nucleus (PVN) of 
the hypothalamus, which amongst other hormones releases corticotrophin-releasing hormone 
(CRH) to stimulate the HPA axis, as well as the locus coeruleus, the primary source of 
noradrenaline in the brain (Ulrich-Lai and Herman, 2009). Several surrounding regions send 
afferent nerves to the PVN of the hypothalamus, including the amygdala, the hippocampus, the 
medial prefrontal cortex, the locus coeruleus as well as the brain stem. These connections are 
often indirect and relayed through the bed nucleus in the stria terminalis and wider 
hypothalamus (Smith and Vale, 2006; Ulrich-Lai and Herman, 2009). Further, whilst all of these 
regions try to influence PVN activity directly, they also branch towards competing regions to 
inhibit their influence over the PVN (Smith and Vale, 2006; Ulrich-Lai and Herman, 2009). Several 
higher order systems send associational information to these brain areas, including areas related 
to sensory processing, such as olfactory nuclei or the thalamus; arousal, such as the locus 
coeruleus; and memory, such as the entorhinal section of the hippocampus (Smith and Vale, 
2006; Ulrich-Lai and Herman, 2009).  
Much research has focused on the role of the amygdala, a complex structure of nuclei involved 
in autonomic regulation and fear responses. Notably, the central nucleus of the amygdala only 
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shows a response to homeostatic threats, but not to those of a psychogenic nature, whereas 
the medial and basolateral nuclei do (McIntyre, Kent, Hayley, Merali, and Anisman, 1999; 
Rajbhandari, Baldo, and Bakshi, 2015). Although the amygdala has no direct projections to the 
PVN, it can initiate the stress response through y-aminobutyric-acid (GABA) or glutamatergic 
projections to other areas such as the bed nucleus of the stria terminalis or the dorsomedial 
hypothalamus (Ulrich-Lai and Herman, 2009). Animal models have shown substantial 
amygdaloid remodelling in response to chronic stress exposure, with enhanced dendritic 
arborisation in the basolateral amygdala (Vyas, Mitra, Shankaranarayana Rao, and Chattarji, 
2002). Additionally, prefrontal areas differentially alter the stress response, with prelimbic areas 
having inhibitory effects, but infralimbic areas showing stimulatory effects on the stress 
response in the context of psychogenic stressors (Smith and Vale, 2006; Ulrich-Lai and Herman, 
2009). Functionally, this means that beyond the impact of physiological stressors such as 
homeostatic imbalances, pain or inflammation, the stress response is also shaped by top-down 
processes dependent on cognitive appraisal as well as the integration of memory and 
experiential factors. As such, the stress response can arise from psychogenic activation, 
dependent on the competitive activation of key structures in the limbic area. 
3.1.5 Effects of Adversity on Physiological Stress-Function 
An overwhelming conclusion that has emerged from the literature on stress is that exposure to 
chronic, inescapable and/or traumatic stress alters stress-function for the worse. Chronic 
adaptations in activation or attenuation of the stress systems, commonly termed allostatic load 
(Danese and McEwen, 2012; Korte, Koolhaas, Wingfield, and McEwen, 2005; McEwen, 2000), 
are detrimental to physical as well as psychological well-being. Allostatic changes in HPA 
function have been implicated in a number of mental disorders including depressive and anxiety 
disorders, post-traumatic stress disorder, bipolar disorder and psychosis (Baumeister, Lightman, 
et al., 2014) and are detrimental to the integrity of the central nervous system (Herbert et al., 
2006; McEwen, 2000; McEwen and Gianaros, 2011). Similarly, chronic and excessive activation 
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of the SNS is associated with allostatic load, including detrimental changes to cardiovascular 
function such as atherosclerosis (McEwen, 2008). However, although allostasis has been 
associated with a variety of physical and mental disorders, such dysregulation is specific rather 
than diffuse. Allostatic changes differ depending on the clinical status of samples, since different 
psychopathologies have been associated with different, often opposing HPA profiles 
(Baumeister et al., 2014). For example, total diurnal cortisol output appears elevated in 
depression (Pariante and Lightman, 2008), yet diminished in post-traumatic stress disorder 
(Sherin and Nemeroff, 2011). Similarly, negative feedback function within the HPA axis, as 
measured by cortisol response to the GR-agonist dexamethasone, is blunted in depression 
(Anacker, Zunszain, Carvalho, and Pariante, 2011) yet hyper-responsive in PTSD (de Kloet et al., 
2006).  
The experience of early life stress exposure appears to be of crucial importance to such allostatic 
changes, which have received particular attention in HPA axis research. Healthy individuals with 
a history of sexual or physical abuse exhibit attenuated HPA activity in adulthood when exposed 
to psychosocial stress (Carpenter et al., 2007; Carpenter, Shattuck, Tyrka, Geracioti, and Price, 
2011; Voellmin et al., 2015and). Similarly, GR resistance appears to be altered in individuals with 
early life trauma (Heim, Mletzko, Purselle, Musselman, and Nemeroff, 2008), and alterations to 
the cortisol awakening response have also been reported (Lu et al., 2013; Mangold, Wand, 
Javors, and Mintz, 2010). Interestingly, Carpenter et al. (2009) found that when major 
depression patients were matched to healthy controls based on childhood adversity as well as 
on age and gender, dexamethasone-based assessment of GR-function failed to distinguish 
clinical from non-clinical participants, demonstrating the far-reaching effects of childhood 
trauma. A key mechanism for such allostatic changes may be epigenetic programming. 
McGowan et al. (2009) compared GR methylation in hippocampal regions of suicide completers 
with and without a history of childhood abuse. Greater GR methylation was found in those 
individuals who had been subjected to early life stress. Similarly, greater methylation of the 
promoter region of the GR in leukocyte DNA has been found in healthy adults with a history of 
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childhood stressful experiences (Tyrka, Price, Marsit, Walters, and Carpenter, 2012). These 
changes were further found to have functional implications, with an attenuated response to the 
dexamethasone/CRH test. Further, Klengel et al. (2013) found that childhood trauma is 
associated with demethylation of glucocorticoid response element of the gene coding for FKBP5, 
a heat shock protein that inhibits the ability of cortisol to bind to cytosolic GR, thus decreasing 
GR-responsiveness. There is further evidence that childhood trauma impacts on inflammatory 
immunity, a system in close bidirectional interaction with the HPA axis (Baumeister, Akhtar, 
Ciufolini, Pariante, and Mondelli, 2015). Thus, early life stress may induce long-lasting changes 
to functioning of the allostatic systems, even in the context of good mental health in adulthood.  
Idiosyncratic types of stress exposure later in life may also impact differentially on HPA 
signatures. Exposure to episodic stressors in the context of high chronic stress is associated with 
increased cortisol release and lower GR expression, but exposure to episodic stressors in the 
context of low chronic stress appears to lead to decreased cortisol release and increased GR 
expression (Marin, Martin, Blackwell, Stetler, and Miller, 2007). The particular type of threat a 
stressor poses, for instance to physical integrity or to the social self, is also associated with 
idiosyncratic HPA profiles (Miller et al., 2007). Moreover, cognitive appraisal of the stressor is 
crucial in the emergence of the stress response. Anticipatory stress appraisals predict cortisol 
reactivity to psychosocial stress, as well as sluggish cortisol and blood pressure recovery from 
the stressor following its cessation (Juster, Perna, Marin, Sindi, and Lupien, 2012). Additional 
variables related to lifestyle and physical health, such as age (Ferrari et al., 2001), sleep quality 
(Balbo, Leproult, and van Cauter, 2010), substance use (Schumann, 2006) or metabolic health 
(Bose, Oliván, and Laferrère, 2009), may further impact on biological stress-function and lead to 
allostatic changes that then impair an organism’s ability to adequately respond to stress. Many 
physical health parameters related to stress-function are further adversely affected, including 
cardiovascular health, immune-function, metabolic health, growth and tissue repair, sexual 
function, sleep regulation as well as resilience to energetic crises such as stroke (Juster, McEwen, 
and Lupien, 2010; Korte et al., 2005; McEwen, 2008). 
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3.2 Stress-Function in Psychosis 
3.2.1 Stress Exposure and Stress-Reactivity in Psychosis 
The diathesis-stress model (Nuechterlein and Dawson, 1984; Walker and Diforio, 1997) has long 
suggested that the interaction of vulnerability factors with exposure to stressors may precipitate 
onset of psychotic symptoms and disorders, and contribute to their maintenance. A recent 
variant of the diathesis-stress model, the three hit model of stress exposure (Daskalakis et al., 
2013), proposes that any pathology arises through the interplay of 1) genetic, epigenetic or 
prenatal diatheses, 2) early stressful life events and 3) risk exposure later in life. Indeed, there is 
substantial evidence to suggest that psychosis patients experience greater exposure to stressful 
life events. A recent meta-analysis encompassing 18 case-control studies, 10 prospective studies 
and 8 population-based studies, demonstrated a strong association between exposure to 
childhood adversity and psychosis (Varese et al., 2012). Psychosis patients were 2.7 times more 
likely to have experienced childhood adversities than healthy controls, and in population-based 
studies childhood trauma conferred psychosis risk with an odds ratio of 3.0. Childhood sexual 
and physical abuse are highly prevalent in psychosis patients, and there is evidence to suggest 
that such experiences are particularly linked to auditory verbal hallucinations and other positive 
symptoms (Bentall et al., 2012; Hardy et al., 2016; Read et al., 2005; Shevlin, Dorahy, and 
Adamson, 2007). Indeed, the relationship with auditory verbal hallucinations appears 
transdiagnostic, with bipolar disorder patient with childhood trauma exposure experiencing 
significantly higher rates of voice-hearing than their non-exposed counterparts (Hammersley et 
al., 2003). Recent evidence further suggests that childhood trauma increases the likelihood of 
emergence of delusional ideation in the context of hallucinations (Smeets et al., 2015). 
Interestingly, there is evidence from a prospective general population cohort that the effect of 
childhood trauma on the distress associated with psychotic experiences is mediated by emotion 
regulation, although additional analyses revealed that this effect was only significant for 
paranoid ideation, not hallucinations (Lincoln and Jaya, 2016). 
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Frequently, the content of positive symptoms is related to the abuse, and there is evidence for 
a dose-effect relationship between abuse severity and psychosis risk, as well as symptom 
severity (Read et al., 2005). Evidence from populations at high-risk of developing a psychotic 
disorder (i.e., individuals with subclinical psychosis symptoms or a high familial risk), suggests 
higher rates of stressful life events including childhood and adulthood exposure, in such 
individuals (Bechdolf et al., 2010; Tessner, Mittal, and Walker, 2011; Thompson et al., 2009), 
although the evidence is not unequivocal (Phillips, Edwards, McMurray, and Francey, 2012). In 
particular, childhood sexual abuse is associated with an increased risk of transitioning to 
psychosis in such individuals (Bechdolf et al., 2010). Moreover, stressful life events in adulthood 
are associated with risk of relapse in psychosis patients (Bebbington et al., 2004; Hultman, 
Wieselgren, and Ohman, 1997; Malla, Cortese, Shaw, and Ginsberg, 1990). Interestingly, recent 
evidence suggests that the HPA axis is involved in mediating the risk of trauma exposure on 
psychosis, with an interaction effect of FKBP5 polymorphisms and childhood trauma on 
psychotic symptoms and HPA function (Collip et al., 2013a).  
As pointed out by Phillips and colleagues (2007), there is a need to move beyond assessment of 
stressful life experiences when investigating the stress-psychosis relationship, and consider non-
traumatic daily stressors (i.e., ‘hassles’) as well as appraisals of potentially stressful situations. 
Indeed, some studies have reported lower rates of both stressful life events in ultra high-risk 
and recent-onset psychosis patients longitudinally, yet they appraised life events as more 
stressful (Horan et al., 2005; Phillips et al., 2012). Several studies have utilised the Experience 
Sampling Method (ESM), whereby a portable device is used to assess self-reported perceived 
stress at random times throughout the day. Myin-Germeys et al. (2001) used ESM in psychosis 
patients in remission, first-degree relatives and healthy controls to assess the stressful impact 
of events, activities, thoughts and social situations in daily life. Clinical participants were more 
likely to appraise events in daily life and social situations as stressful compared to healthy 
controls and first-degree relatives and healthy controls, respectively. Moreover, clinical 
participants reported significantly more negative affect and less positive affect than the other 
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two groups. Similarly, individuals at high-risk of developing psychosis are more likely to report 
daily stressors as more distressing (Phillips et al., 2012; Tessner et al., 2011).  
Such vulnerability to even minor stressors may contribute to the onset and maintenance of 
psychosis. In a follow-up analysis of their ESM data, Myin-Germeys et al. (2005) reported an 
association between occurrence of stressors in daily life, and the intensity of psychotic 
experiences (PEs) in both the clinical group as well as relatives. Similarly, Collip et al. (2013b) 
used ESM in a general population sample of female twins, and assessed reactivity to daily life 
stress, subclinical PEs and reactivity to these experiences. Greater affective stress-reactivity and 
PE reactivity were associated with greater persistence of PEs over a 14-month period. The same 
group also reported an association of PE persistence with daily stressors in psychosis patients 
and relatives of psychosis patients (Wigman et al., 2013). Additionally, there is evidence in 
healthy individuals to suggest that acute psychosocial stress and anxiety-provoking situations 
increase paranoid ideation (Kesting, Bredenpohl, Klenke, Westermann, and Lincoln, 2013; 
Lincoln, Lange, Burau, Exner, and Moritz, 2010) and exacerbate monocausal reasoning and 
jumping-to-conclusions in psychosis patients with delusions (Moritz, Köther, Hartmann, and 
Lincoln, 2015). Reininghaus et al. (2016) conducted an ESM study in first-episode psychosis 
patients and at-risk individuals, showing that elevated stress-sensitivity to daily events as well 
as increased threat anticipation were associated with greater rates of PEs. Docherty et al. (2009) 
assessed self-reported trait stress-reactivity in psychosis patients and in healthy controls, and 
followed both groups over a 9-month period. Patients reported greater trait reactivity at 
baseline, and stressful life events over the follow-up period predicted psychotic symptoms, with 
an interaction effect between trait reactivity and number of events. There is now a 
comprehensive literature that strongly suggests increased threat perception as a key factor in 
psychosis and need for care, with supporting evidence from self-report, experimental, and 
neuroimaging studies (Reininghaus et al., 2016; Underwood et al., 2016). 
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It is possible that early life stress may confer psychosis risk through increasing sensitivity and 
vulnerability to stress later in life. Indeed, an ESM study in 50 psychosis patients showed that 
history of childhood trauma was associated with greater reactivity to life stress, and that 
childhood trauma and stress-reactivity interacted to predict intensity of psychotic experiences 
(Lardinois, Lataster, Mengelers, van Os, and Myin-Germeys, 2011). Interestingly, evidence from 
a 10-year prospective cohort study showed that early exposure to adversity increased the risk 
of adversity exposure in adolescence, which in cases of recent severe adversity interacted 
additively to increase the risk of psychosis (Lataster, Myin-Germeys, Lieb, Wittchen, and van Os, 
2012). Thus, it appears that early life adversity exposure may lay the foundation for greater 
vulnerability to stressful events in later life, potentially both in terms of increased risk of 
exposure to adverse events in later life as well as greater reactivity to stress in adulthood. In 
turn, this heightened stress-sensitivity may then further drive the occurrence and intensity of 
psychotic symptoms, and the appraisal of innocuous situations and stimuli as threatening.  
3.2.2 Stress and the Aetiology of AVHs 
Whilst a comprehensive discussion of cognitive models of AVHs is beyond the scope of the 
current thesis, it is nonetheless noteworthy that evidence also suggests a close link between 
stress and emergence of AVHs from a cognitive perspective. Current evidence on the cognitive 
aetiology of AVHs posits that they partially arise due to defective monitoring of inner speech, 
which gives rise to the interpretation of inner speech as an externally originating, and may also 
represent failure to inhibit traumatic or stressful memories and information (Allen, Aleman, and 
McGuire, 2007; Jones, 2010). It has further been suggested that such false detections may arise 
as a by-product of perceptual hypervigilance induced and maintained by stressful life events and 
emotional distress (Dodgson and Gordon, 2009). This is in line with research suggesting 
heightened threat perception in psychosis (Reininghaus et al., 2016; Underwood et al., 2016), 
as well as evidence of trauma exposure in psychosis and its direct link to AVHs (Bentall et al., 
2012; Hardy et al., 2016; Shevlin et al., 2007; Varese et al., 2012). Further, experimental evidence 
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shows that psychological stress increases false auditory perceptions in a signal detection task 
where participants are asked to detect speech in white noise, particularly in individuals with 
higher trait anxiety (Hoskin, Hunter, and Woodruff, 2014).  Whilst specific subtypes of AVHs may 
rely on different causal mechanisms (Dodgson and Gordon, 2009; Smailes et al., 2015), early 
stress exposure may shape an on-going sensory sensitivity biased to quickly identify potential 
threats, which then, maintained by emotional distress and hypervigilance, leads to the 
misidentification of internal verbal events as auditory perceptions. 
3.2.3 Physiological Stress-Function in Psychosis 
 The Autonomic Nervous System 
In line with evidence on stress exposure and stress-reactivity, there is now a considerable 
evidence-base to suggest altered physiological stress-function in psychosis, indicative of 
allostatic load. This appears to be the case for both the HPA axis and the ANS, and alterations of 
the stress system have been found both at rest and under acute stress exposure. However, as 
noted by Holtzman et al. (2013), the HPA axis has received more attention, primarily due to the 
relatively less invasive methods available for its measurement. Nonetheless, several alterations 
of the ANS have also been demonstrated. A recent review of the ANS literature in psychosis 
noted that activity of the sympathetic branch of the nervous system appears to operate at 
normal levels in clinical individuals, whereas activity of the parasympathetic branch is 
dampened, establishing an imbalance in ANS activity (Montaquila et al., 2015). The two primary 
measures that have been employed to detect such an imbalance are heart rate variability (HRV) 
and vagal tone (VT). HRV describes slight arrhythmia of cardiac activity, specifically of the R 
component, i.e., the upward deflection, in the QRS curve that describes the heartbeat. Although 
it may be commonly assumed that the QRS curve occurs at regular intervals, there is a complex 
chaotic rhythmicity. Such mathematical patterns are observed in a variety of biological systems, 
and they are thought to increase adaptability, in the case of HRV conferring cardiac ability. If 
there is always slight variation in R intervals, the cardiovascular system optimises its ability to 
88 
 
flexibly adapt to sudden change in demands, such as onset of a stressor. HRV further 
synchronises with respiratory function, a phenomenon called respiratory sinus arrhythmia 
(RSA), in that exhalation is accompanied in a slowing of heart rate, whereas inhalation sees an 
increase. RSA and HRV are used as a proxy to measure vagal tone, and thus PNS activity. 
So far, more than a dozen studies have demonstrated diminished vagal tone, and thus PNS 
dysfunction, in schizophrenia (Montaquila et al., 2015). Further, several studies have provided 
evidence that diminished PNS activity is associated with psychotic symptom severity and illness 
duration (Bär et al., 2005; Okada, Toichi, and Sakihama, 2003; Toichi et al., 1999). Whilst 
decreased HRV has been demonstrated in unmedicated psychosis patients (Bär et al., 2012; 
Mujica-Parodi, Yeragani, and Malaspina, 2005), antipsychotics have been reported to 
exacerbate ANS imbalance (Birkhofer et al., 2013; Huang et al., 2013), although one study also 
found normalisation of PNS activity following six weeks of risperidone treatment (Chang et al., 
2010). There is further evidence to suggest that in response to stress, increases in SNS activity 
of psychosis patients do not differ from those of healthy controls, however recovery of vagal 
tone and ANS balance fail to initiate following cessation of exposure to the stressor (Akar, Kara, 
Latifoğlu, and Bilgiç, 2014; Castro et al., 2008; Ja´uregui, 2011). Accordingly, skin conductance 
response to stress has been shown to be increased in psychosis (Lincoln, Hartmann, Köther, and 
Moritz, 2015; Zahn and Pickar, 2005). It has been proposed that this sluggish stress recovery 
finds its substrate in inadequate PNS activity which leads to SNS dominance in the ANS 
(Montaquila et al., 2015). Thus, the ANS in psychosis patients may be conceptualised as a state 
of constant arousal, stemming from the uneven balance of the SNS and PNS. Indeed, there is 
evidence to suggest that schizophrenia patients also show significantly faster and more shallow 
respiration compared to controls and healthy relatives (Bär et al., 2012). These respiratory 
patterns are associated with severity of positive symptoms (Bär et al., 2012). Bär et al. (2012) 
also carried out a stress-induction in control and healthy relative participants, showing that 
during acute stress respiratory patterns were comparable to those seen in patients. Additionally, 
Clamor and colleagues (2014) reported that that ANS alteration in psychosis, including HRV 
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measures and vagal tone, are not present in first-degree relatives of psychosis patients, or 
individuals with attenuated positive symptoms. However, there have also been reports of 
alterations to HRV in healthy relatives of schizophrenia patients (Bär et al., 2012). 
Salivary α-amylase is a further biomarker that has been increasingly employed in stress research 
to measure ANS activity. It is responsive to psychosocial stress paradigms, with its reactivity 
preceding the slower onset of HPA activity (Nater et al., 2004). Some studies have reported a 
significant correlation of peripheral noradrenaline and α-amylase in response to stress 
(Chatterton, Vogelsong, Lu, Ellman, and Hudgens, 1996; Rohleder, Nater, Wolf, Ehlert, and 
Kirschbaum, 2004), however such findings have not always been replicated (Nater et al., 2006; 
Wetherell et al., 2006). Indeed, salivary glands are under control of both sympathetic and 
parasympathetic nerves (Proctor and Carpenter, 2007), and α-amylase may more accurately 
reflect overall ANS activity. Accordingly, there is some evidence for a negative association of α-
amylase and PNS activity, as measured by changes to HRV and vagal tone (Bosch, de Geus, 
Veerman, Hoogstraten, and Nieuw Amerongen, 2003; Nater et al., 2006). Such evidence is 
consistent with the two studies that have considered α-amylase as a biomarker in schizophrenia. 
Inagaki et al. (2010) measured α-amylase and resting heart rate in 54 schizophrenia patients and 
55 controls, showing that whilst heart rate did not differ, α-amylase levels were significantly 
higher in clinical participants. Moreover, α-amylase levels were significantly correlated with 
symptom severity. Ieda et al. (2014) elaborated on these findings in 25 schizophrenia patients 
and 25 controls. In addition to α-amylase, the study investigated both low frequencies of heart 
rate variability and ratio of low frequency to high frequency, reflecting PNS and SNS activity, 
respectively. Again, patients showed significantly higher levels of α-amylase, which correlated 
with symptom severity. However, the study also showed lower levels of HRV frequencies related 
to PNS activity in patients, yet no changes to SNS activity. Thus, α-amylase levels in psychosis 




 The HPA Axis 
Alterations of several HPA axis measures have been found in psychosis, including baseline 
function, acute stress-reactivity, cortisol awakening response, morning cortisol, and negative 
feedback function. However, the evidence is often marked by mixed results, associations with 
clinical presentation remain unclear and psychotropic treatments may confound findings. 
There is some evidence for higher baseline HPA activity, as indicated by increased cortisol levels 
in psychosis patients compared with controls. A systematic review by Bradley and Dinan (2010) 
reported evidence for increases in basal cortisol levels in schizophrenia patients, most 
consistently so in first-episode and drug-naïve patients. Moreover, a recent study has reported 
higher hair cortisol levels (an indicator of long-term HPA activity) in drug-naïve first episode 
patients (Andrade et al., 2016). In a study comparing 256 high-risk individuals to 141 healthy 
controls, Walker et al. (2013) demonstrated greater cortisol levels in the high-risk group, as well 
as higher cortisol levels in those who transitioned to a psychotic disorder compared with high-
risk individuals who did not transition. Thus, baseline HPA activity appears to be augmented in 
psychosis. However, it remains unclear whether and how increased cortisol release relates to 
clinical characteristics of symptoms, with generally mixed and inconsistent findings across the 
literature (Bradley and Dinan, 2010). Bradley and Dinan (2010) also identified five studies that 
examined CRH levels in the cerebrospinal fluid of patients and controls, as well as another 17 
that measured ACTH, showing overall inconclusive evidence. Thus, whilst cortisol release may 
differ in psychosis, other components of the HPA axis appear unaffected. Moreover, some 
research has proposed that increased HPA activity of psychosis patients may be reflected in 
greater size of the pituitary gland, yet a recent meta-analysis of 10 studies including first episode 
patients, patient with diagnoses of schizophrenia or schizotypal disorders and/or ultra high-risk 
individuals found inconclusive results compared with healthy controls (Nordholm et al., 2013).  
There is some evidence for a blunted cortisol response to acute stress exposure in psychosis, 
although the literature is small and findings have been equivocal. Ciufolini et al. (2014) 
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performed a meta-analysis of three studies measuring the HPA response to acute social stress 
paradigms. Although their findings should be considered cautiously in light of the small number 
of studies included in the analysis, they found a blunted cortisol response in schizophrenia 
patients both in anticipation of and exposure to the stressor. In a systematic review of studies 
measuring subjective, HPA and heart rate responses to psychosocial stress tasks in schizophrenia 
patients, Lange et al. (2016) concluded that whilst subjective responses did not differ 
significantly from controls, heart rate increases were significantly greater in patients. Regarding 
cortisol response, they noted that while some studies showed differences, overall the findings 
on HPA response were somewhat inconclusive. However, Goldman et al. (2007) reported a 
blunted cortisol and ACTH response to the cold pressor paradigm, whereby a stress response is 
triggered through submersion of a limb in ice-cold water, in schizophrenia patients compared to 
controls. Another recent study utilising the cold pressor paradigm, together with a psychosocial 
stress element (being observed and filmed during the cold pressor; Socially Evaluative Cold 
Pressor Test), found a smaller cortisol response in schizophrenia patients compared to controls 
(Rubio et al., 2015). Similarly, Pruessner et al. (2013) found that individuals at high clinical risk 
showed an attenuated HPA response when exposed to a social stress paradigm. Interestingly, a 
recent study by Lincoln and colleagues showed that psychosis patients showed blunted cortisol 
levels in response to both social and noise stress compared to individuals with attenuated 
psychotic symptoms, but not healthy controls (Lincoln, Köther, Hartmann, Kempkensteffen, and 
Moritz, 2015). A further contradictory finding was obtained by Nugent et al. (2015), who 
introduced the option for participants in their schizophrenia sample to stop the experiment’s 
stress task, in order to assess distress intolerance. In that study, the cortisol response was 
augmented in those participants who showed low distress tolerance and prematurely quit the 
task. There is also some evidence that the attenuated stress response may be partially due to 
antipsychotic use. Houtepen et al. (2015) measured cortisol and alpha-amylase responses to the 
TSST in euthymic bipolar disorder patients, unaffected siblings and healthy controls. Patients 
showed a blunted cortisol stress response, yet an increased response of alpha-amylase. 
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Separating patients based on antipsychotic use, the study found that the cortisol response only 
differed from controls in those patients receiving antipsychotic treatment, independent of other 
clinical characteristics.  
A recent meta-analysis further reported on 44 studies comparing morning cortisol levels in 
psychosis samples to healthy controls, showing significantly increased morning cortisol levels in 
clinical individuals (Girshkin, Matheson, Shepherd, and Green, 2014). This effect was less 
pronounced in first-episode samples, yet greater in medication-free and inpatient samples. 
Notably however, several studies have also provided evidence for a blunted cortisol awakening 
response in psychosis patients (Braehler et al., 2005; Mondelli et al., 2010; Monteleone et al., 
2014). As the cortisol awakening response represents somewhat of a natural stress response to 
waking up, this evidence broadly mirrors the evidence obtained on general baseline cortisol 
levels and acute stress-reactivity. That is, the general pattern appears to show a high baseline 
output, with a blunted response to acute demand. It remains unclear whether this pattern is 
due to a ceiling effect of HPA secretion capacity or whether it is due to functional alterations 
(Holtzman et al., 2013).  
Bradley and Dinan (2010) also identified 85 studies that carried out the dexamethasone 
suppression test (DST) in schizophrenia patients. Dexamethasone is not able to pass the blood 
brain barrier, but exerts its negative feedback by binding to GRs in the anterior pituitary gland 
which lies outside the CNS, leading to suppression of ACTH and subsequently cortisol release. 
Thus, the DST allows at least partial assessment of the HPA axis’ negative feedback capacity. In 
Bradley and Dinan’s (2010) calculation, non-suppression occurred in 26.9% of medicated 
patients, and 29.4% of non-medicated patients, suggesting impaired GR-function in both 
medicated and non-medicated patients. An older meta-analysis reported similar findings, with 
non-suppression in 26.4% of patients and 5.0% of healthy controls (Yeragani, 1990). As with 
basal cortisol levels, Bradley and Dinan (2010) report that there were no consistent associations 
with DST results and clinical characteristics or symptoms. However, nine studies cited by Bradley 
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and Dinan (2010) administered the DST upon admission and after treatment, all reporting high 
levels of non-suppression at baseline with large reductions in non-suppression following 
antipsychotic treatment. Thus, GR-function appears impaired in psychosis, which may be driving 
the increased baseline activity as well as blunted reactivity to acute demands. 
However, there is evidence suggesting that alterations of the HPA axis in psychosis do not 
present uniformly, but rather depend on individual prior stress exposure. Phassouliotis et al. 
(2013) conducted a low-dose DST (0.25mg) in first episode patients, finding lower basal morning 
cortisol and hyper-suppression in response to the DST in patients compared with controls. The 
authors suggest that this may be related to greater levels of childhood trauma found in the 
patient group, and indeed this pattern is similar to the HPA function reported in post-traumatic 
stress disorder (Baumeister et al., 2014). Mondelli et al. (2010) found that the number of 
stressful life events experienced in their first-episode psychosis sample was negatively 
correlated with basal cortisol levels, whereas healthy controls showed a positive correlation. 
Similarly, Braehler et al. (2005) reported lower basal cortisol levels in patients with childhood 
trauma experience compared to patients with no exposure. Thus, idiosyncratic patterns of HPA 
activity may vary depending on variables associated with prior stress exposure rather than being 
associated with clinical diagnoses. 
Finally, whilst the neural diathesis-stress model of schizophrenia proposes that the HPA axis 
mediates the relationship between stress and psychotic symptoms (Pruessner, Cullen, Aas, and 
Walker, 2017; Walker, Mittal, and Tessner, 2008; Walker and Diforio, 1997), little evidence 
suggests associations of aberrant HPA activity and specific psychotic symptoms or their severity 
(Pruessner et al., 2017). This may be due to a) a non-specific effect of HPA-axis dysregulation in 
psychosis, or b) the inability of cross-sectional research designs to find such effects due to 
confounding effects of medication, diagnostic criteria and limited symptom severity ranges in 
psychosis research studies (Pruessner et al., 2017). Indeed, despite the recommendation to 
move away from diagnostic classification systems towards symptom-oriented research (Insel et 
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al., 2010), the present review failed to identify any studies that selected psychosis samples based 
on a specific symptom, e.g., AVHs. Given that psychosis is a multifactorial construct, where 
individual symptom dimensions may be associated with specific neurophysiological substrates 
(e.g., striatal dopamine dysregulation and delusional ideation; Howes et al., 2013; Howes and 
Kapur, 2009; Howes et al., 2012), HPA-axis function may be associated with specific symptoms 
too. In light of the evidence reviewed above, such an association may be particularly likely for 
the AVH dimension.  
3.3 Conclusions and Implications for Voice-Hearer Research 
There is considerable evidence to suggest that psychosis is closely linked with altered stress-
exposure, -reactivity and -physiology. Childhood trauma elevates psychosis risk and sensitises 
to stressful events in later life, with greater subjective stress-reactivity in psychosis patients. 
Moreover, both major branches of the physiological stress system appear altered in psychosis 
patients, suggesting that subjective changes in stress-function are accompanied by allostatic 
load. In several but not all studies, such changes were found to be associated with positive 
symptoms and symptom severity. None of the studies identified here investigated stress-
function specific to voice-hearers. However, the strong link between childhood trauma and 
AVHs, as well as childhood trauma and dysregulated stress-function, suggests that AVHs in 
psychosis may be associated with alterations of the HPA and ANS systems. Thus, it is warranted 
to investigate the particular role that subjective and physiological stress-function may play in 




Chapter 4 – Need for Care, Adversity Exposure and Perceived 
Stress in Clinical and Healthy Voice-Hearers 
This chapter utilised an existing dataset collected as part of a wider study (the UNIQUE study, 
Peters et al, 2016). The doctoral candidate’s contribution to the present chapter is the 
conceptualisation of the research question, identification, selection and scoring of relevant 
variables and participant sub-samples in the dataset, all statistical analyses, and interpretation 
of findings to address the research question. 
4.1 Introduction 
As reviewed in Chapter 3, early life adversity, such as childhood, sexual and physical abuse, has 
been linked to psychosis as a potential risk factor (Read, van Os, Morrison, and Ross, 2005; 
Varese et al., 2012), with some evidence for a dose-dependent relationship between exposure 
and psychosis risk (Read et al., 2005; Varese et al., 2012). Diathesis-stress models propose that 
vulnerability factors, such as genetic predisposition, interact with exposure to stressors in the 
origin and maintenance of psychotic symptoms and disorders (Nuechterlein and Dawson, 1984; 
Walker and Diforio, 1997). Systematic reviews have identified several alterations of 
physiological stress-function in psychosis, including increased autonomous nervous system 
activity (Montaquila et al., 2015), and dysregulation of the hypothalamic-pituitary-adrenal (HPA) 
axis (Bradley and Dinan, 2010). Similarly, experience sampling methods have demonstrated that 
psychosis patients are more likely to appraise daily stressors as more stressful than first-degree 
relatives and healthy controls (Myin-Germeys et al., 2001), and history of childhood trauma in 
psychosis is associated with greater reactivity to life stress (Lardinois et al., 2011). Evidence 
further points to an gene-environment interaction between HPA-related risk alleles and 
adversity exposure in the emergence of psychosis risk (Collip et al., 2013a; Cristóbal-Narváez et 
al., 2016).  
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In recent work on diathesis-stress models, the potential difference between early stressful life 
events and risk exposure later in life is highlighted, suggesting that the emergence of psychosis 
depends on the combination of three ‘hits’: genetic vulnerability, adverse childhood experiences 
and subsequent adolescent/adult experiences (Daskalakis et al., 2013). There is robust evidence 
for the diathesis-stress conceptualisation in psychosis populations (Collip et al., 2013a; Howes, 
McCutcheon, Owen, and Murray, 2016; Varese et al., 2012), and increasingly this relationship is 
being investigated along the psychosis continuum (Chapter 2; Binbay et al., 2012; Peters et al., 
2016). As reviewed in Chapter 2 of this thesis, a novel line of research has identified and 
investigated the phenomenon of psychotic experiences in otherwise healthy populations (Johns 
et al., 2014; Peters et al., 2016). Auditory verbal hallucinations, once stipulated as a hallmark 
symptom of psychotic disorders such as schizophrenia (Schneider and Kurt, 1959), have an 
estimated prevalence of 5-6% in the general population (Linscott and van Os, 2013; McGrath et 
al., 2015). Approximately 12% of these individuals may hear voices persistently (De Loore et al., 
2011; Linscott and van Os, 2013). Although they have a higher risk of developing a psychotic 
disorder, nevertheless the majority suffer no distress or impairment as a result of their voices 
(Chapter 2; Johns et al., 2014).  Research comparing clinical (CVH) and healthy voices-hearers 
(HVH) has identified a number of specific similarities and differences (Chapter 2; Johns et al., 
2014). The two groups do not differ on several phenomenological characteristics, such as 
loudness, perceived location or number of voices. However, voice content is more negative in 
CVHs, frequency is higher, and beliefs about voices are more negative (see Chapter 2). On other 
parameters, such as functioning or cognitive biases for psychosis, HVHs show some deficits 
relative to healthy controls without voices (HCs), although these remain subclinical and are 
significantly lower than CVHs (see Chapter 2). Notably, the dopamine dysregulation seen in 
psychosis is absent in HVHs, as demonstrated in a positron-emission tomography study 
investigating dopamine synthesis capacity (Howes et al., 2013).  
Early life adversity, particularly sexual abuse, is associated with the emergence of auditory 
verbal hallucinations (AVHs) in psychosis (Bentall et al., 2012; Hardy et al., 2016; Shevlin et al., 
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2007). Given the strong evidence for diathesis-stress models in psychosis and AVHs specifically, 
several studies have investigated childhood trauma as well as familial risk in HVHs (the first two 
“hits” of the three hit model). Data from the biggest cross-sectional study of CVHs (n = 100) and 
HVHs (n = 127) to date suggest that childhood sexual, physical and emotional abuse, and physical 
and emotional neglect, do not differ in voice-hearing groups, and are consistently more 
prevalent than in healthy controls (HCs; n = 124) (Daalman et al., 2012b; Sommer et al., 2010a). 
However, other (albeit smaller) studies have reported slightly higher rates in CVHs than in HVHs, 
although childhood trauma rates are still considerably higher than in HCs (Honig et al., 1998). 
One study in particular found no overall differences in trauma exposure, but higher rates of 
childhood sexual abuse in CVHs (Andrew et al., 2008). The only study considering lifetime 
exposure (i.e., combined childhood and adulthood) reports higher rates in HVHs than in HCs, 
but lower rates than in CVHs (Kråkvik et al., 2015). Similarly, rates of psychotic disorders in first- 
and second-degree relatives do not differ between CVHs and HVHs, but are higher than in HCs 
(van Lutterveld et al., 2014). HVHs also report significantly higher rates of familial depressive 
disorders, mania and substance misuse than HCs (Sommer et al., 2010a). Together, these 
findings suggest that diathesis-stress models are also relevant for the emergence of AVHs across 
the psychosis continuum, but raise the important question as to why need for clinical care and 
the impact of voices differ despite seemingly similar risk factor exposure.  
One potential explanation is that the time-period for exposure to trauma as a risk factor for 
psychosis extends beyond childhood trauma. In the three-hit model, the timing of adversity 
exposure, and, specifically, adversity exposure in adolescence/adulthood (i.e., the third “hit”) is 
of crucial importance to developmental trajectories (Daskalakis et al., 2013). Furthermore, 
factors other than exposure to victimisation, such as cannabis and substance abuse, which are 
strongly implicated in psychosis (Large, Sharma, Compton, Slade, and Nielssen, 2011; Marconi, 
Di Forti, Lewis, Murray, and Vassos, 2016), adversely impact on stress physiology (Huizink, 
Ferdinand, Ormel, and Verhulst, 2006), and may also act as adversity exposure in the third “hit” 
(Daskalakis et al., 2013). Such factors have not been investigated in HVHs. The biological stress 
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literature further suggests that the conceptualisation of childhood as anything before 18 years 
of age may conflate distinct periods in stress-function (Casey, 2013; Daskalakis et al., 2013; 
Stroud et al., 2009), and a more detailed analysis of adversity exposure is needed.  
More chronic stressors, such as socioeconomic deprivation or discrimination in childhood and 
adulthood, have been identified as risk factors in psychosis (Kristensen, Gravseth, and Bjerkedal, 
2010; Oh, Cogburn, Anglin, Lukens, and DeVylder, 2016; Saleem et al., 2014; Veling et al., 2007; 
Werner, Malaspina, and Rabinowitz, 2007), but have also not been investigated in HVHs. Yet the 
physiological impact of episodic stressors is contingent on the context of chronic stress, with an 
interaction of episodic and high chronic stress being associated with HPA alterations typical for 
psychosis (Marin et al., 2007). The psychological literature further suggests that repeated 
adversity exposure and social defeat (Birchwood, Meaden, Trower, Gilbert, and Plaistow, 2000; 
Selten, van der Ven, Rutten, and Cantor-Graae, 2013) are crucial in forming cognitive schema of 
low social-rank, including in relation to voices (Paulik, 2012), and are associated with the 
development of paranoid ideation (Valmaggia et al., 2015). Given the impact of early adversity 
exposure on severity of disturbances in psychosis (Read, 1998; Read et al., 2005) and the 
evidence that adversity exposure contributes to increased stress-reactivity in psychosis 
(Lardinois et al., 2011), the question is raised as to whether and which adversity exposure 
predicts need for care and stress-reactivity in voice-hearers. Indeed, it is unclear whether need 
for care arises through repeated exposure to the same types of adversity, or through exposure 
to different adversity types at different time points. 
The present study set out to investigate whether CVHs and HVHs differ in their exposure to the 
three ‘hits’. In line with the stress literature, childhood hits were defined as those occurring at 
or before age 13 and adolescent/adult hits as those occurring from age 13 (Stroud et al., 2009). 
The hits were defined as: 
I. Hit 1: familial risk (comprising family history of psychosis, and family history of 
mood, anxiety and substance use disorders) 
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II. Hit 2: childhood adversity exposure (comprising childhood sexual trauma, non-
sexual trauma, discrimination and childhood socio-economic status (SES))  
III. Hit 3: adolescence and adulthood adversity exposure (comprising 
adolescent/adult sexual trauma, non-sexual trauma, discrimination, adult SES, 
and cannabis and other substance abuse) 
Based on the available evidence, it was hypothesised that CVHs would not differ from HVHs in 
their exposure to Hits 1 and 2, but would significantly differ in their exposure to Hit 3, as 
presented in Figure 4.1. 
To investigate whether adversity exposure contributes to stress-reactivity and -sensitivity, the 
association of adversity exposure with perceived stress within each hit was also investigated. In 
line with the first hypothesis where Hit 3 differentiates CVHs and HVHs, it was hypothesised that 
exposure in Hit 3 would be significantly associated with perceived stress.  
Figure 4.1 – Proposed risk/adversity-exposure for CVHs and HVHs at each hit 
 










































The sample comprised 57 CVHs and 45 HVHs. Sample characteristics are presented in Table 4.1. 
Both groups were recruited from south London and north Wales, as part of the wider Unusual 
Experiences Inquiry (UNIQUE) study (Peters et al., 2016), and were selected if they had current 
AVHs, as indicated by a score of ≥2 on the Scale for the Assessment of Positive Symptoms (SAPS; 
Andreasen, 1984) AVH item. Clinical participants were recruited from inpatient and outpatient 
services in the same regions of south London and north Wales (the South London and Maudsley 
NHS Foundation Trust (SLaM) and the Betsi Cadwaldr University Health Board (BCUHB) 
respectively). Non-clinical participants were recruited through specialist sources, such as 
spiritual organisations, in the community (described in Peters et al. (2016) in more detail).  
For clinical participants to be included, they had to have: a) a diagnosis of a psychosis spectrum 
disorder (ICD-10 F20-39 diagnoses). For non-clinical participants, they had to present with: a) 
absence of psychosis diagnosis or treatment; b) presence of psychotic experiences for at least 
five years (to avoid recruitment of prodromal individuals); c) no voice-related distress, as 
indicated by a score of <2 (‘unmet need’) on the Camberwell Assessment of Need (Phelan et al., 
1995) ‘psychological distress’ item. Both groups had to: a) be above 18 years old; b) have 
sufficient command of the English language; c) have no history of neurological disease, brain 
injury or epilepsy, and d) have no primary substance dependence. 
4.2.2 Measures 
 Victimisation Experiences Schedule 
The Victimisation Experiences Schedule (VES) was developed as part of the UNIQUE study 
(Peters et al., 2016). The measure was used to assess frequency, duration and subjective impact 
of 14 victimisation items grouped into three categories (presented in Table 4.1). Sexual 
victimisation was assessed on three items (e.g., unwanted sexual intercourse), non-sexual 
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victimisation was recorded on six items (e.g., physical abuse), and discrimination was assessed 
on five items (e.g., being treated unfairly by the police). For each item, up to three potentially 
discrete events were recorded. Further information was recorded for each event on: age at 
exposure; frequency of exposure (scored 0-4; ranging from “Never” to “Very Frequently (weekly 
+)”); duration of exposure (scored 0-4; ranging from “Never” to “More than one year”); and 
impact at the time of exposure (phrased as “How much did this event/experience affect you at 
the time?”, scored 0-4; ranging from “Not at all” to “Totally”). Total possible ranges of scores for 
each frequency, duration and impact were 0-36 for sexual victimisation, 0-72 for non-sexual 
victimisation and 0-60 for discrimination. Total overall scores are presented in Table 4.2. 
To create an indicator of severity, a composite score for each victimisation category was 
calculated, adding frequency, duration, and impact scores. Any event occurring age 13 and 
below represented the first hit (Childhood sexual victimisation; Childhood non-sexual 
victimisation; Childhood discrimination), and events occurring above age 13 represented the 
second hit (Adulthood sexual victimisation; Adulthood non-sexual victimisation; Adulthood 
discrimination).  
Table 4.1 – VES subscales 
Victimisation Type Victimisation event 
Sexual victimisation Upsetting sexual experience 
 Unwanted sexual intercourse 
 Unwanted sexual contact due to physical force or threat of force 
Non-sexual victimisation Bullying 
 Psychological abuse 
 Physical abuse 
 Parental neglect 
 Treat of assault 
 Actual assault 
Discrimination Unfair treatment at work 
 Unfair treatment by the police 
 Unfair treatment by the court system 
 Unfair treatment by neighbours and/or family 




A Principal Component Analysis was carried out to determine whether the VES scales based on 
frequency, duration and impact represented a latent factor indicative of a general severity of 
victimisation exposure. The Kaiser-Meyer-Olkin measure verified sampling adequacy of all scales 
and Bartlett’s test of sphericity indicated sufficiently large correlations of all scales (see Table 
4.2). All scales had an eigenvalue over the Kaiser’s criterion of 1. Since no item had a coefficient 
below 0.5, all items were included, with the lowest factor loading being 0.92. Cronbach’s α 
indicated good or excellent reliability for all items (lowest was 0.87).  
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Table 4.2 – Validity and reliability analyses for VES scales (frequency + duration + impact scores)  
Scale KMO Bartlett’s test Eigenvalue Explained 
Variance 
Lowest Factor  
Loading 
Cronbach’s α  Score 
Range 
Childhood sexual victimisation .77 χ2 (3) = 411.1, p < 0.001 2.84 94.6% .96 .96 0-108 
Childhood non-sexual victimisation .74 χ2 (3) = 519.3, p < 0.001 2.88 96.0% .97 .98 0-216 
Childhood discrimination .74 χ2 (3) = 498.2, p < 0.001 2.86 95.2% .96 .97 0-180 
Adulthood sexual victimisation .72 χ2 (3) = 399.7, p < 0.001 2.75 91.5% .92 .96 0-216 
Adulthood non-sexual victimisation .74 χ2 (3) = 410.4, p < 0.001 2.80 93.2% .94 .87 0-432 
Adulthood discrimination .77 χ2 (3) = 393.4,p < 0.001 2.83 94.2% .96 .96 0-360 
104 
 
 Scale for the Assessment of Positive Symptoms 
The SAPS (Andreasen, 1984) is a 35 item scale, comprising four subscales: hallucinations, 
delusions, bizarre behaviour and thought disorder. Each item is scored from 0-5 for severity and 
frequency (“none” to “severe”), leading to a total range of scores from 0-175. Cronbach’s α in 
the present study indicated good reliability (0.84).  
 Appraisal of Anomalous Experiences Interview 
The Appraisal of Anomalous Experiences Interview (AANEX; Brett et al., 2007)) is a semi-
structured interview used to measure psychotic experiences in clinical and non-clinical samples. 
Seventeen anomalous experiences, including AVHs, are rated for lifetime and current (last 
month) presence on a 3-point scale (1=not present; 2=unclear; 3=present). Whilst the measure 
also assesses context, appraisal and cognitive responses associated with anomalous experiences 
(AANEX-CAR), only items assessing presence of experiences (AANEX-Inventory) were utilised in 
the present study. 
 Demographic Assessment 
A demographic assessment was carried out to obtain information on: age, gender, ethnicity, 
years in education, occupation of head of house in childhood, past drug use, current 
medications, family history of psychosis, family history of other mental health diagnoses 
(including depression, anxiety, obsessive-compulsive disorder, bipolar disorder and substance 
use disorders), diagnosis, number of admissions and inpatient status. Years in education were 
used as a proxy for adulthood SES, as these are not confounded by disorder-related disability 
and unemployment (Kristensen et al., 2010). Occupation of head of house in childhood was used 
as a proxy for childhood SES (as in Peters et al. (2016)). Past drug use was recorded separately 
for cannabis use and use of other substance (excluding alcohol and tobacco), using frequency 
on a range from 0-5 (“never” to “daily”).  
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 Perceived Stress Scale 
The Perceived Stress Scale (PSS) 10-item version (Cohen and Williamson, 1988; Roberti, 
Harrington, and Storch, 2006) was used to measure levels of perceived stress in the last month. 
Each item (e.g., “How often have you felt nervous or stressed?”) was scored on a 5-point Likert 
scale ranging from “never” to “very often”), with a potential score range of 0-40 and higher 
scores representing higher levels of perceived stress. Cronbach’s α in the present study 
indicated excellent reliability (0.91). 
4.2.3 Procedure  
Ethical approval was granted by the NRES Committee London Westminster (reference 
12/LO/0766) and the SLaM/Institute of Psychiatry (reference R&D2012/047) and CBUHB 
(reference Jackson/LO/0766) R&D Offices. 
Following screening by research workers (either via phone or face to face), participants signed 
the informed consent form and were assessed on all questionnaire measures, in addition to 
other experimental procedures not reported here (see Peters et al. (2016) for more detail). 
Participants were debriefed and compensated for their time, and were offered a follow-up 
phone call to ensure they suffered no distress due to participation.  
4.2.4 Statistical Analysis 
Frequentist statistical analyses were carried out using SPSS for Windows (IBM Corp., 2015), and 
JASP (JASP Team, 2016) was used for Bayesian analysis to express likelihood of data supporting 
the hypotheses. Bayesian statistics, a statistical method based on estimation of probabilities, 
were carried out to provide an additional metric to evaluate findings with greater confidence. 
For the first hypothesis, separate analyses were carried out for each adversity variable 
(dependent variables); group (i.e., CVH vs HVH) was the independent variable. Chi-square 
analyses were carried out for binary dependent variables, non-parametric Mann-Whitney U for 
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non-normally distributed continuous variables, and independent t-tests for normally distributed 
variables. False Discovery Rate correction for multiple testing was applied to analyses within 
each hit, and FDR-adjusted p-values are reported throughout (Benjamini and Hochberg, 1995). 
For the second hypothesis, the association of adversity variables with PSS scores was assessed 
using three multiple regression models, separating adversity variables by hit, entering group in 
the first step to control for clinical status, and using bootstrapping (n = 1000) for more 
conservative and accurate estimation (Tabachnik and Fidell, 1989). P-values below the 0.05 
threshold were accepted as statistically significant. Bayes factors of 3 and above were 
interpreted as sufficient evidence for the alternative hypothesis over the null hypothesis, and 
Bayes factors of 1/3 and below as sufficient evidence for the null hypothesis (Kass and Raftery, 
1995). Calculated effect sizes were converted to Cohen’s d to allow for comparison across 
effects. Effect size conversions were carried out using formulas commonly used in meta-
analyses and research synthesis (Borenstein, Hedges, Higgins, and Rothstein, 2009; Cooper, 
Hedges, and Valentine, 2009; Fritz, Morris, and Richler, 2012; Lipsey, Wilson, and Lipsey, 2001; 
Morris and DeShon, 2002). 
4.3 Results 
4.3.1 Sample Characteristics 
Results from analyses of sample characteristics are presented in Table 4.3. CVHs and HVHs did 
not differ on age, but there were significant differences in gender, ethnicity, and employment. 
CVHs were more likely to be male and unemployed, and less likely to be of white ethnicity. The 
two groups also differed in SAPS total score, SAPS AVHs (single item), and perceived stress, with 
CVHs showing higher scores across all measures. However, groups showed no differences on 






Table 4.3 – Sample characteristics (Mean ± SD unless specified otherwise) 
 Clinical Voice-
Hearers 
(n = 57) 
Healthy Voice-
Hearers 
(n = 45) 
Statistics 
Age 41.7 ± 12.5 45.4 ± 12.5 t (100) = 1.5, p = 0.76,  
d = 0.30, BF10 = 0.5 
Gender (% Female) 38.6% 73.3% χ2 = 12.2, p < 0.001*,  
d = 0.7, BF10 =70.2 
Ethnicity (% White) 66.7% 91.1% χ2 = 8.6, p = 0.003*,  
d = 0.6, BF10 = 7.5 
Employment (% 
Unemployed) 
82.5% 37.8% χ2 = 21.5, p < 0.001*,  























Hospital Admissions 4.13 ± 3.4   
Care Status (% Inpatient) 32.7%   
SAPS Total Score 31.8 ± 15.3 15.6 ± 7.4 U = 404.0, Z = -5.8, p < 
.001*,  
d = 1.45, BF10 = 2.3 x 106 
SAPS AVH Score 4.2 ± 1.1 2.7 ± 0.9 U = 447.0, Z = -5.9, p < 
.001*,  
d = 1.34, BF10 = 9.4 x 107 
AANEX Total Lifetime 36.5 ± 5.1 35.4 ± 5.2 t (99) = 1.0, p = 0.3,  
d = 0.20, BF10 = 0.3 
AANEX Total Current 31.1 ± 6.1 30.4 ± 5.1 t (98) = 0.7, p = 0.5,  
d = 0.14, BF10 = 0.3 
Perceived Stress Score 21.7 ± 7.4 13.4 ± 8.0 t (93) = 5.2, p < 0.001*,  
d = 1.04, BF10 = 12,248.2 
Note: * = significant p-value; NOS = Not Otherwise Specified; BF10 = Bayes Factor (strength of 




4.3.2 Main Effects of Hit Exposure 
Results are presented in Table 4.4. For Hit 1, chi-square showed that a significantly greater 
percentage of CVHs than HVHs reported a family history of psychosis, but no difference was 
found for family history of other disorders.  
For Hit 2, all variables were non-normally distributed. Mann-Whitney U showed no significant 
differences on severity scores for childhood sexual victimisation, childhood non-sexual 
victimisation, and childhood discrimination. The chi-square test showed there was no significant 
difference in childhood socio-economic status.  
For Hit 3, all variables were non-normally distributed. Mann-Whitney U tests showed significant 
differences for years in education, with CVHs reporting fewer years than HVHs, and for cannabis 
and other substance use, with a greater percentage of CVHs than HVHs reporting exposure to 
both variables. No significant differences were found for severity scores on sexual victimisation, 
non-sexual victimisation, and discrimination. However, HVHs showed trends to greater 
exposure to sexual (p=0.07) and non-sexual victimisation (p=0.07) in adolescence and 
adulthood, although this was not corroborated by Bayesian analyses.  
Of note, the percentage of individuals reporting victimisation in both childhood and 
adolescence/adulthood was high in both groups (range 15.8% to 37.8% for sexual, and 66.7% to 
82.2% for non-sexual, victimisation), with slightly higher percentages in the non-clinical group 
for all categories.  
Sensitivity analyses using G*Power for Windows (Faul, Erdfelder, Lang, and Buchner, 2007) 
indicated that the present analyses were powered to detect group difference effect sizes of 
Cohen’s d = 0.58, at β = 0.8. 
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Table 4.4 – Results summary (unless specified otherwise reported as: Percentage (%) exposed, Mean ± SD  for % exposed) 
 Hit Variables Clinical Voice-Hearers Healthy Voice-Hearers Statistical Results 
Hit 1 Family History Psychosis (%) 25.5% 2.3% χ2 = 9.5, p = 0.004*, d = 0.64, BF10 = 18 
 Family History Others (%)  15.8% 20.0% χ2 = 0.3, p = 0.61, d = 0.11, BF10 = 0.2 
Hit 2 Sexual Victimisation 15.8%, 12.1 ± 7.1 24.4%, 12.9 ± 8.3 U = 974, Z = -1.1, p = 0.54, d = 0.42, BF10 = 0.3 
 Non-Sexual Victimisation 68.4%, 23.4 ± 17.1 82.2%, 28.0 ± 17.0 U = 1169.0, Z = -2.1, p = 0.16, d = 0.15, BF10 = 1.1 
 Discrimination 8.8%, 14.4 ± 10.5 6.7%, 6.7 ± 1.9 U = 1249.5, Z = -0.5, p = 0.63, d = 0.05, BF10 = 0.3 


















χ2 = 5.1, p = 0.61, d = 0.46, BF10 = 0.1 
Hit 3 Sexual Victimisation 21.0%, 7.7 ± 3.4 37.8%, 10.7 ± 8.5 U = 1060.0, Z = -1.9, p = 0.07, d = 0.30, BF10 = 1.8 
 Non-Sexual Victimisation 66.7%, 16.4 ± 12.1 82.2%, 19.5 ± 14.5 U = 988.5, Z = -2.0, p = 0.07, d = 0.40, BF10 = 1.0 
 Discrimination 63.2%, 18.8 ± 10.9 60%, 19.6 ± 12.9 U = 1235.0, Z = -0.3, p = 0.74, d = 0.06, BF10 = 0.2 
 Years in Education (M±SD) 14.5 ± 4.8 17.3 ± 4.4 U = 753.0, Z = -3.6, p = .003*, d = 0.76, BF10 = 9.7 
 Cannabis Use 50.9%, 3.1 ± 1.2 26.7%, 2.5 ± 1.4 U = 930.5, Z = -2.7, p = 0.01*, d = 0.48, BF10 = 7.0 
 Other Substance Use 36.8%, 2.2 ± 1.3 8.9%, 1.5 ± 1.0 U = 910.5, Z = -3.3, p = 0.003*, d = 0.51, BF10 = 21.9 
Note: * = significant p-value (FDR-adjusted); BF10 > 3 supports alternative hypothesis; BF10 < 1/3 supports null hypothesis 
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4.3.3 Relationship between Adversity and Stress 
Multiple regression results are presented in Table 4.5. Group was significantly associated with 
perceived stress in the first step of the multiple regression models. Multiple linear regressions 
showed that the two variables in the first hit were associated with perceived stress, explaining 
6.8% of the variance after controlling for group. Family history of psychosis, but not family 
history of other disorders, was related to perceived stress, with individuals with a psychosis 
family history reporting higher stress. Bayesian analysis confirmed this model as the winning 
model (marked BFM in Table 4.5). 
For the second hit, multiple linear regressions also showed that adversity was significantly 
associated with perceived stress, explaining 6.5% of the variance after controlling for group. 
However, none of the adversity variables (sexual victimisation, non-sexual victimisation, 
discrimination and SES) was individually related to perceived stress. However, Bayesian analysis 
selected a model based only on Group + Sexual Victimisation as the winning model. 
For the third hit, multiple linear regression again showed that adversity was significantly 
associated with perceived stress, explaining 6.5% of the variance after controlling for group. 
Fewer years in education and greater other substance use, but not cannabis use, sexual 
victimisation, non-sexual victimisation or discrimination, were individually related to higher 
perceived stress. However, Bayesian analysis selected a model based only on Group as the 
winning model. Sensitivity analyses using G*Power for Windows (Faul et al., 2007) indicated that 
the present regression analyses were powered to associations at effect sizes of f2 = 0.10 to f2 = 





Table 4.5 – Multiple regression models predicting perceived stress by adversity exposure, 
separated by each hit 
Models Predictors B SE B β 
Hit 1     
Step 1*  Constant 4.62 2.49  
F(1,81)  = 32.1 
Adj. R2 = 0.28 
p < 0.001 
Group 
 
8.52 1.50 0.53* 
Step 2* Constant 4.93 2.47  
FC = 4.2 Group 7.51 1.49 0.47*+ 
R2C = 0.35 Family History Psychosis 7.01 2.43 0.27*+ 
p < 0.001 
BFM = 11.5 
Family History Other 
 
1.58 1.95 0.08 
Hit 2     
Step 1* Constant 4.36 2.47  
F(1,89) = 32.7 
Adj. R2 = 0.26 
p < 0.001 
Group 
 
8.42 1.47 0.52* 
Step 2*  Constant 4.61 3.10  
FC = 2.1 Group 8.87 1.48 0.55*+ 
R2C = 0.07 Sexual Victimisation 0.30 0.15 0.18+ 
p < 0.001 Non-Sexual Victimisation 0.04 0.05 0.08+ 
BFM = 7.0 Discrimination 0.40 0.36 0.10 
 Socio-Economic Status 
 
-1.12 0.77 -0.13 
Hit 3     
Step 1*  Constant 4.37 2.39  
F(1,93) = 35.7 
Adj. R2 = 0.27 
p < 0.001 
Group 
 
8.53 1.43 0.53* 
Step 2* Constant 10.46 4.44  
FC = 1.5 Group 7.12 1.62 0.44*+ 
R2C = 0.07 Sexual Victimisation 0.06 0.15 0.04 
p < 0.001 Non-Sexual Victimisation -0.01 0.06 -0.01 
BFM = 18.3 Discrimination 0.09 0.06 0.13 
 Years in Education -0.31 0.18 0.24* 
 Cannabis Use -0.97 0.56 -0.18 
 Other Substance Use 
 
1.92 0.84 0.24* 







The present study is, to our knowledge, the first comparison of healthy and clinical voice-hearers 
on a range of different adversity factors over both childhood and adolescence/adulthood. We 
hypothesised that CVHs and HVHs would differ on their exposure to Hit 3 
(adolescence/adulthood), but not Hit 1 (familial risk) and Hit 2 (childhood). The findings provide 
evidence for differential adversity exposure in CVHs and HVHs in adolescence and adulthood 
(Hit 3), and suggest that exposure to different types of adversity predicts perceived stress, our 
proxy measure for stress-sensitivity, in these populations. Specifically, in Hit 3 we found that 
CVHs had fewer years in education, indicative of a lower SES, and higher levels of cannabis and 
other substance use. Surprisingly, victimisation and discrimination experiences in Hit 3 did not 
differ between CVH and HVHs, suggesting that developmental timing and repeated victimisation 
exposure are less important in need for care than exposure to different types of adversity. 
Indeed, HVHs reported slightly higher exposure to sexual and non-sexual victimisation in 
adulthood, albeit at non-significant trend-level. As predicted, there was no difference between 
the groups in adversity exposure in childhood victimisation. Unlike previous reports (van 
Lutterveld et al., 2014), CVHs were more likely to have family members with a history of 
psychosis, although history of other disorders did not differ between CVHs and HVHs. 
These findings suggest that the emergence of need for care in voice-hearers may ultimately be 
due to exposure to different types of stressors, and potentially their interaction, rather than 
continued exposure to victimisation. Putatively, victimisation and discrimination in childhood 
and adulthood may not only increase the risk for AVH emergence, but create a vulnerability to 
the adverse impact of recreational substances. Neurochemically, dopamine dysregulation due 
to substance misuse may increase the likelihood of maladaptive appraisals of their voices, 
aberrant salience and delusional ideation (Howes and Kapur, 2009; Howes et al., 2012), which 
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would concur with previous findings that HVHs do not present with the upregulated dopamine 
synthesis capacity seen in psychosis (Howes et al., 2013). Alternatively, CVHs may suffer more 
long-term consequences of victimisation and turn to substance misuse as a coping strategy, 
which then becomes maladaptive. Victimisation is frequently associated with substance misuse 
as a coping strategy (Filipas, 2006; Harrison, Fulkerson, and Beebe, 1997), and men are more 
likely to turn to substance misuse after victimisation experiences (Saladin et al., 2003) yet less 
likely to disclose their experiences to others (Ullman and Filipas, 2005). Thus, the gender 
difference in the present sample, which is congruent with the wider HVH literature (see Chapter 
2), may partially relate to maladaptive coping strategies that exacerbate need for care. 
The finding that CVHs were more likely to have a family history of psychosis contradicts our 
hypothesis, and further suggests that a specific genetic vulnerability may be a risk factor for need 
for care in voice-hearers. Nonetheless, it is possible that family history of psychosis may be 
skewed by intrafamilial culture – in some families, where psychotic diagnoses have been 
established amongst family members, psychotic experiences may be interpreted as an indicator 
of mental ill health, and help-seeking is established. In families where they are explained in the 
context of e.g., spiritual experiences, no contact with mental health services may ever be 
established, and in fact social support structures such as membership of spiritual groups may 
emerge.  
The multiple regression models showed that family history of psychosis, fewer years in 
education, and non-cannabis substance use predicted perceived stress after controlling for 
group. However, Bayesian analysis selected slightly different winning models for Hit 2 (Group + 
Sexual Victimisation) and Hit 3 (only Group). It has been proposed that stress exposure 
exacerbates dopaminergic dysregulation, leading to delusional ideation and aberrant salience, 
and increased distress and need for care (Howes et al., 2016).  The present results at least 
partially suggest that several of the specific types of adversity that CVHs are more exposed to 
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are also those driving perceived stress and stress-sensitivity, and may explain the differential 
need for care in voice-hearers both via dopaminergic dysregulation and exacerbated stress-
reactivity. 
4.4.2 Strengths and Limitations 
Strengths included that the assessment of trauma in the present study was highly detailed, 
considering several types of adversity exposure as well as objective (duration; frequency) and 
subjective (impact) indicators of severity. Factor analyses further confirmed validity of the 
employed measure, including the stratification into distinct subscales as well as the severity-
based computation of scores. As demonstrated by Varese et al. (2012), the similar rates of 
reported childhood trauma between prospective and retrospective studies in psychosis suggest 
that recall is accurate, adding confidence in the reliability of our adversity exposure measure. 
Further, the assessment of adversity exposure over lifetime allowed for detailed investigation 
of different developmental periods.  
There were several study limitations. The first was that the study design did not permit a direct 
test of the three-hit model described by Dalskalakis and colleagues (2013); rather, it presents 
findings related to hypotheses and analyses informed by this framework. Larger scale, 
epidemiological studies would be needed to test the model directly and investigate cumulative 
and interaction effects of exposure. A further limitation relates to the validity of several 
exposure variables. Years in education may be cut short by emerging negative symptoms that 
prevent continuing education, and may also reflect lower IQ in clinical participants. Although 
not as heavily biased as adulthood employment as an indicator of SES, this bias may nonetheless 
confound cause and consequence. Second, the cut-off used for puberty onset is based on 
population means, yet puberty may occur significantly earlier or later in individuals, and also 
presents with gender dimorphism (Blakemore, Burnett, and Dahl, 2010). Third, the present 
study did not record onset of cannabis and substance misuse, and timing and frequency of use 
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at different ages may alter the impact of substance use. Fourth, as non-clinical participants were 
selected based on an absence of or low voice-distress, it was not possible to investigate the 
impact of adversity exposure on voice-distress. Fifth, family history of psychosis may be a 
suboptimal measure for genetic risk due to shared environments within families. Finally, 
frequentist and Bayesian analyses were not congruent in the multiple regression models, 
suggesting that these data have to be considered with caution. 
4.4.3 Implications and Future Directions 
Future research should employ more valid measures of genetic risk, such as heritability or 
genome-wide association studies, or assessment of identified risk genes that may also interact 
with stress-function, such as genes coding for the glucocorticoid receptor or the chaperone 
protein FKBP5 (Collip et al., 2013a). Further, the stratification of clinical and non-clinical voice-
hearers undertaken here may exclude individuals who do suffer subclinical distress or who are 
transitioning from psychosis to recovery. Larger, epidemiological population studies are needed 
to explore the role of adversity exposure in more diverse voice-hearing samples, and potential 
additive or interaction effects of adversity types. Whilst the use of a cut-off in adolescence may 
add validity with regards to development of stress physiology, longitudinal research should be 
undertaken to more accurately investigate the role of adversity, including cannabis and 
substance misuse, at different ages.  
Given the substantial gender difference in the present sample, as well as the wider literature 
demonstrating increased psychosis risk associated with male gender (Aleman, Kahn, and Selten, 
2003), future research should investigate whether female gender is protective in the interaction 
with adversity exposure in voice-hearers. It has been hypothesised that the gender imbalance 
in psychosis is due to protective effects of estrogen and its modulation of dopamine (Gogos et 
al., 2015) and HPA signalling (Pruessner et al., 2015). The gender difference may also relate to 
differential use of coping strategies subsequent to adversity exposure, i.e., men may be more 
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likely to use substances (Saladin et al., 2003), whereas women may be more likely to seek social 
support (Hunter, Boyle, and Warden, 2004; Ullman and Filipas, 2005). However, male psychosis 
patients also exhibit more negative symptoms and functional impairments (Chang et al., 2011; 
Morgan, Castle, and Jablensky, 2008; Scott, 2011), and the differential need for care may 
therefore relate to greater comorbid symptom severity. Indeed, evidence from a large cohort 
study suggests that social rank and loneliness mediate the association of social adversity and 
negative symptoms, but not positive symptoms (Jaya, Ascone, and Lincoln, 2016).  
Finally, the present study highlights the importance of adversity types that should be malleable 
to social interventions, including substance misuse and continuing education, a finding that 
should explored further in prodromal psychosis intervention research. 
4.4.4 Conclusions 
The present study provides evidence that clinical and non-clinical voice-hearers differ in some 
types of adversity-, or hit-, exposure in adolescence and adulthood, as well as their family history 
of psychosis.  Exposure to trauma and victimisation across both childhood and adulthood was 
equally high in both groups, suggesting that repeated exposure may be related to the presence 
of voices rather than need for care. Instead, the findings suggest that need for care in voice-
hearers is associated with cannabis and substance misuse in adolescence and adulthood as well 
as lower socio-economic status, in the context of potential greater genetic vulnerability. These 





Chapter 5 – The Effects of Voice Content and Mindfulness on 
Stress Reactivity 
5.1 Introduction 
Auditory verbal hallucinations (AVHs) are typically distressing for clinical voice-hearers and are 
associated with poor outcomes (Upthegrove et al., 2016). However, nascent research, reviewed 
in Chapter 2, has demonstrated that AVHs occur in healthy members of the general public and 
do not necessarily cause distress or imply need for care (Baumeister et al., 2017; Johns et al., 
2014), raising the question as to why distress varies between clinical and non-clinical voice-
hearers. As reviewed in Chapter 3, psychosis is linked to increased subjective reactivity to stress 
(Myin-Germeys and van Os, 2007), altered function of both the hypothalamic-pituitary-adrenal 
axis (Bradley and Dinan, 2010; Pruessner et al., 2017) as well as the autonomous nervous system 
(Montaquila et al., 2015), and it has been argued that early life stress, in particular, contributes 
to the aetiology of psychosis and AVHs (Bentall et al., 2012; Varese et al., 2012). Moreover, stress 
exposure and heightened stress-reactivity in psychosis patients can exacerbate the intensity of 
psychotic experiences (Myin-Germeys and van Os, 2007; Reininghaus et al., 2016), and 
differential distress of voice-hearers may therefore be partially related to stress-reactivity and -
function. 
As reviewed in Chapter 2, a consistent finding in the literature is that clinical voice-hearers 
(CVHs) experience predominantly negative voice content, whereas healthy voice-hearers (HVHs) 
typically report neutral or positive voice content (Baumeister et al., 2017; Johns et al., 2014). 
Several studies have further reported that voice content is associated with negative appraisals 
and mood states, as well as service use and need for care (Beavan and Read, 2010; Daalman et 
al., 2011a; Johns et al., 2014). Within clinical populations, greater negative voice content is 
associated with more voice-distress, depression, and low self-esteem (Smith et al., 2006). It has 
been argued that negative voice content may be crucial in driving the pathological impact of 
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voice-hearing in CVHs relative to HVHs (de Leede-Smith and Barkus, 2013). Thus, negative voice 
content may contribute to the distress experienced by CVHs, and exacerbate the impact of 
stressful situations. 
Cognitive models of psychosis have also highlighted the importance of the appraisal of 
anomalous experiences in determining their impact (Chadwick and Birchwood, 1994; Garety, 
Kuipers, Fowler, Freeman, and Bebbington, 2001). Several studies have provided evidence that 
mindful appraisals of voices, that is, experiencing them with present-moment awareness, a non-
judgmental attitude and ultimately acceptance, is negatively associated with voice-distress and 
mood problems, and positively associated with quality of life (Chadwick et al., 2016; Chadwick, 
Hughes, Russell, Russell, and Dagnan, 2009; López-Navarro et al., 2015; Morris, Garety, and 
Peters, 2014; Shawyer et al., 2007). Reductions in voice-distress and improvements in mood 
have been reported as a result of mindfulness-based intervention studies (Chadwick et al., 2009; 
López-Navarro et al., 2015), and trait mindfulness is higher in non-clinical individuals who report 
psychotic experiences (Peters et al., 2016). Furthermore, mindfulness is associated with lower 
subjective and physiological stress-reactivity (Brown, Weinstein, and Creswell, 2012; Bullis, Bøe, 
Asnaani, and Hofmann, 2014; Daubenmier, Hayden, Chang, and Epel, 2014). Thus, whilst it is 
likely that there is a direct impact of voice content on distress and stress-reactivity, these 
responses may be moderated by ‘mindful’ voice-appraisals. 
In view of this evidence we aimed to test the effect of simulated voices and their content on 
stress-reactivity. We hypothesised that simulated AVHs with negative voice content would 
increase the subjective, cortisol and α-amylase reaction to a psychosocial stress paradigm over 
and above the levels produced by neutral voices or a non-voice ambient control. The latter two 
were hypothesised not to differ. It was further hypothesised that mindful appraisals of voices 
during the paradigm (assessed post-hoc) would be associated with attenuated subjective, 





The sample consisted of 84 healthy participants, with a mean age of 26.1 (SD = 7.2) and 
predominantly female individuals (n = 62, 73.8%). Participants were primarily recruited through 
opportunity sampling via online adverts and the King’s College London research recruitment 
system. Participants were excluded if they: were under the age of 18, were not fluent English 
speakers, had hearing impairments, had previously experienced auditory hallucinations, had 
received secondary care for any mental health issue, or scored 10 or above on the depression 
subscale of the Hospital Anxiety and Depression Scale (HADS). The latter two eligibility criteria 
were decided upon to exclude vulnerable individuals. Ethical approval for the research study 
was granted by the King’s College London Psychiatry, Nursing & Midwifery Research Ethics Sub-
Committee (ref. PNM/14/15-111; Appendix I). 
5.2.2 Measures 
 Montreal Imaging Stress Task 
The Montreal Imaging Stress Task (MIST; Dedovic et al., 2005) is a well-established paradigm 
designed for computerised psychosocial stress induction. In the current study, participants were 
presented with arithmetic exercises on a laptop for a total of 10 minutes. The computer 
algorithm adapts to the individual’s ability to perform maths by making the task always a bit 
harder (both in task difficulty and allotted time) than what the participant is capable of solving 
so that the individual performs poorly, but not so poorly that it becomes obvious that the task 
is impossible. Participants are presented with negative visual feedback on their performance by 
the program (i.e., ‘incorrect’, ‘timeout’, and a comparison of individual performance with (fake) 
average performance), and negative verbal feedback by the experimenter (e.g., “Your 
performance is below of what we normally see, can you please try harder?”). The MIST has been 
utilised in numerous clinical and non-clinical studies and reliably increases subjective, 
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neurological and physiological indicators of stress (Geva, Pruessner, and Defrin, 2014; Hernaus 
et al., 2015; Mizrahi et al., 2014; Voellmin et al., 2015; Zschucke, Renneberg, Dimeo, 
Wüstenberg, and Ströhle, 2015). Participants are fully debriefed after the task is finished and no 
adverse effects have been reported.  
 Voice-simulation  
Three 10 minutes audio materials were developed for the present study: a) negative simulated 
voices (e.g., “What a waste of space”), b) neutral simulated voices (e.g., “Today is the day”), and 
c) non-voice neutral sounds (i.e., the sound of water running). To ensure validity of the voice 
simulation, an initial longlist of negative and neutral voice comments was drawn from a) online 
first-person reports of voice content in service user forums, b) service user literature and c) 
reports from clinicians with expertise in working with psychosis patients. The final shortlist was 
established excluding comments that were performance- and task-specific, or too derogatory 
and/or potentially risky (e.g., commands of self-harm). Voice-tracks were identical in the 
number of statements, the number of first-person statements, as well as the frequency of words 
within the English language (assessed using Subtlex-UK; van Heuven, Mandera, Keuleers, and 
Brysbaert, 2014). The tracks were designed to deliver comments for 10min, with a total of 170 
comments in each. The comments were read out by two male and two female volunteers who 
were instructed to maintain a neutral intonation to avoid confounding content with intonation. 
Time intervals between voices were matched for the negative and neutral tracks, as well as 
which speaker delivered the specific statement. The number of statements delivered by female 
and male voices was even. The non-voice control track consisted of a 10min recording of water 
streams. See Appendix II for a full breakdown of the voice-tracks. 
 Southampton Mindfulness Questionnaire  
The Southampton Mindfulness Questionnaire (SMQ) is a 16-item self-report measure that 
assesses mindful awareness of distressing thoughts, images and voices (Chadwick et al., 2008). 
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For the present study, only mindfulness of voices was assessed.  Items are scored on a 7-point 
Likert scale from 1-7, with total scores ranging from 16 to 112, and higher scores indicating 
greater state mindfulness.  Its validity has been shown in both clinical and healthy samples 
(Chadwick et al., 2008). For the purpose of the present study, the phrasing “Usually when I 
experience distressing voices…” was replaced by “When I heard the voices in the experiment…” 
in order to assess retrospective assessment of mindful appraisals of voices. Cronbach’s α in the 
present study indicated good reliability (0.87). 
  Visual Analogue Stress Scale 
An 8-item visual analogue scale (VAS; Appendix III) was created to assess subjective stress-
reactivity before and after the task, ranging from 0cm to 16.5cm, with total scores ranging from 
0 to 132 and higher scores indicating greater subjective stress levels. Participants were asked 
how stressed, anxious, angry, relaxed (reverse coded), threatened, embarrassed, socially judged 
and expecting of positive vs negative consequences they were, to reflect an array of possible 
stress responses. A Principal Component Analysis was carried out to determine whether the 
scale represented a latent factor indicative of a general subjective stress reaction, using VAS 
scores at post-MIST. The Kaiser-Meyer-Olkin measure was used to verify sampling adequacy 
(KMO =0.84) and Bartlett’s test of sphericity indicated sufficiently large correlations (χ2 (28) = 
259.8, p < 0.001). Only one component had an eigenvalue over Kaiser’s criterion of 1, explaining 
50.49% of the variance. Since no item had a coefficient below 0.5 (Field, 2014), all 8 items were 
included, with the lowest factor loading being 0.61. Cronbach’s α indicated good overall 
reliability (0.86). 
 Biological Control Variables  
To investigate potential confounding variables that may lead to variation in salivary biomarker 
data, a questionnaire (Appendix IV) was created to control for biological factors that may impact 
on physiological stress-function. Items assessed included age (Holochwost et al., 2017; Skoluda 
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et al., 2017), gender (Kirschbaum, Kudielka, Gaab, Schommer, and Hellhammer, 1999), BMI 
(Skoluda et al., 2017), native language (for voice content), current medications, current medical 
diagnoses, time of last meal, time of last drink, time of last cigarette (if applicable; Skoluda et 
al., 2017), first day of last menstrual cycle (if applicable; Kirschbaum et al., 1999), strenuous 
exercise in the preceding 72 hours (h) (Bonato et al., 2017), stress exposure in the preceding 24h 
(Skoluda et al., 2017), and illicit substance use in the preceding 72h (Seibert et al., 2014). A 
composite score for menstrual cycle and oral contraceptives (progesterone) was created using 
stratification by follicular and luteal phase and gender, so that women in luteal phases and men 
were grouped, and women in follicular phases and oral contraceptive users were grouped. This 
is in line with previous research demonstrating the effect of these variables on salivary cortisol 
reactivity to psychosocial stress (Kirschbaum et al., 1999). Participants with substance use in the 
preceding 72h were excluded. 
 Cortisol and α-Amylase Measurements 
Saliva was sampled using Salivettes (Rommelsdorf, Germany). All Salivettes were frozen at -20 
oC in a secure laboratory freezer within 2 hours of collection. Participants were asked to gently 
chew the Salivettes for each collection, and were instructed not to touch samples with their 
hands. All samples were analysed at the StressLab (Trier, Germany) using ELISA-assays for 
cortisol and α-amylase, with an inter-assay variability coefficients of 5.2% and 3.0%, respectively. 
5.2.3 Procedure  
Participants were told that the aim of the study was to test the effects of auditory stimuli on 
cognitive abilities. Figure 5.1 summarises the procedure. Eligible participants completed an 
initial VAS and saliva sample, and were then invited to practice on the MIST (i.e., they completed 
equations without a time limit, and without the audio track) for 10min. All participants were 
instructed to use the keyboard with their non-dominant hand to increase difficulty. During the 
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actual trial, participants wore a headset with the headphone covering their left ear (with the 
experimenter sitting to their right) to present auditory stimuli. Auditory stimuli were block-
randomised (www.sealedenvelope.com) so that there were 28 participants in each group, and 
organised by a collaborator so that the experimenter was blinded to individual conditions. 
Participants were asked not to comment on the content of the auditory stimuli during their 
performance to avoid unblinding the experimenter. Further, they received no instructions on a 
particular response style (e.g., mindfulness) to the auditory stimuli. 
Participants were asked to complete the second VAS and saliva sample, and then started the 
MIST experimental condition for 10min whilst listening to the audio stimuli. Participants in all 
conditions were exposed to criticising negative social feedback by the experimenter, including 
questioning of their arithmetic abilities, their effort in the experiment, as well as warnings that 
they would be excluded if their performance did not improve. The experimenter did not respond 
to any queries made by the participants. Following completion of the MIST, participants were 
immediately asked to complete the third VAS and saliva sample. They were then fully debriefed 
about the true nature of the task, and participants in the two voice conditions completed the 
SMQ. Participants then completed the assessment of control variables, and three more VAS and 









5.2.4 Statistical Analysis 
Frequentist statistical analyses were carried out using SPSS for Windows (IBM Corp., 2015) and 
JASP (JASP Team, 2016) was used for Bayesian analysis to express likelihood of data supporting 
the hypotheses. A repeated-measures mixed 6 (sampling time points) X 3 (condition: negative 
voices; neutral voices; ambient sounds) ANCOVA was carried out on the total VAS scores, cortisol 
and a-amylase. Lower-order repeated-measures ANOVAs were used for post-hoc testing of 
condition-specific effects. To establish normal distribution of cortisol and α-amylase data, 
logarithmic transformations (logn) were undertaken for all analyses. For all cortisol and α-
amylase analyses, associations of dependent variables with potential covariates, including BMI, 
age, gender and menstrual cycle, were assessed and included as covariates if significant. For 
cortisol, bivariate correlations revealed current gender and menstrual cycle as potential 
covariates. For α-amylase, no potential covariates were identified. For tests for associations, the 
area under the curve with respect to the ground (AUCg), i.e., the total amount of biomarker 
secretion across all time points (Pruessner, Kirschbaum, Meinlschmid, and Hellhammer, 2003) 
was calculated as: 
𝐴𝑈𝐶𝑔 = ∑





With ti denoting the time between measurements and mi denoting biomarker values at 
individual measurement time points. Bivariate correlations with AUCg cortisol and α-amylase 
were utilised for associations with SMQ. It was planned to use PROCESS (2.16.3) for SPSS (Hayes, 
2013) for moderation analyses should potential moderators be identified.  
Normal distribution of data was checked by Q-Q plots, and Levene’s test confirmed homogeneity 
of variance between the three conditions. Non-normally distributed data was analysed using 
non-parametric methods. P-values below the two-tailed 0.05 threshold were accepted as 
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statistically significant. False Discovery Rate correction for multiple testing was applied to 
analyses with multiple post-hoc testing, and FDR-adjusted p-values are reported where 
indicated (Benjamini and Hochberg, 1995). Calculated effect sizes were converted to Cohen’s d 
to allow for comparison across effects. Effect size conversions were carried out using formulas 
commonly used in meta-analyses and research synthesis (Borenstein et al., 2009; Cooper et al., 
2009; Fritz et al., 2012; Lipsey et al., 2001; Morris and DeShon, 2002). Bayes factors of 3 and 
above were interpreted as sufficient evidence for the alternative hypothesis, and Bayes factors 
of 1/3 and below as sufficient evidence for the null hypothesis (Kass and Raftery, 1995).  
5.3 Results 
5.3.1 Demographic Descriptives 
One-way ANOVAs showed randomisation was successful, with no significant differences in age 
(F (2, 81) = .03, p = .97, d = 0.05, BF10 = .2), gender (F (2, 81) = 1.16, p = .32, d = 0.34, BF10 = .3), 
BMI (F (2, 81) = 1.4, p = 0.25, d = 0.37, BF10 = 0.3) or number of native English speakers (F (2, 81) 
= .96, p = .39, d = 0.31, BF10 =.2) between conditions. One-way ANOVA also confirmed that VAS 
scores did not differ between conditions at pre-MIST (F (2, 81) = .64, p = .85, d = 0.31, BF10 =.2), 
and neither did cortisol (F (2, 81) = 0.51, p = 0.51, d = 0.22, BF10 = 0.2) or α-amylase (F (2, 81) = 
0.77, p = 0.47, d = 0.28, BF10 = 0.2).  Demographics and questionnaire scores by condition are 
presented in Table 5.1. Two participants in the negative voices condition decided to abort the 
MIST after 8 minutes but nevertheless participated in the rest of the study and were therefore 
included in the analyses. Two participants in the negative voices condition accidentally 





Table 5.1 – Demographics, questionnaire scores and biomarker levels by condition (mean ± SD 
unless specified otherwise) 
 NEG (n = 28) NEU (n = 28) AMB (n = 28) 
Gender (% female) 75.0% 82.1% 64.3% 
Age (y) 25.9 ± 7.6 26.4 ± 8.5 26.0 ± 5.9 
Native Language (% English) 64.3% 71.4% 53.6% 
VAS Overall Delta* 5.5 ± 1.9 3.2 ± 1.7 3.9 ± 2.5 
SMQ* 16.5 ± 3.5 20.5 ± 4.0 - 
Cortisol AUCg (log) 5.5  ± 0.6 5.6  ± 0.6 5.7  ± 0.7 
α-Amylase AUCg (log) 9.3 ± 0.8 9.4  ± 0.6 9.2 ± 0.6 
Note: NEG – negative condition; NEU – neutral condition; AMB – ambient condition; VAS – 
Visual Analogue Scale; SMQ – Southampton Mindfulness Questionnaire; * - statistically 
significant difference between groups 
 
5.3.2 Subjective Effects (VAS scores) 
Sensitivity analyses using G*Power for Windows (Faul et al., 2007) indicated that the repeated-
measures ANOVA analyses were powered to detect within-between group interactions at effect 
sizes of Cohen’s d = 0.26, at β = 0.8. 
Mauchly’s Test of Sphericity was significant; therefore Greenhouse-Geisser statistic is reported. 
Repeated-measures ANOVA confirmed a significant effect of time point on VAS scores (F (2.5, 
198.4) = 234.1, p < .001, d = 3.40, BF10 = 9.5 x 10108), and there was a significant interaction with 
condition (F (4.9, 198.4) = 4.8, p < .001, d = 0.70, BFM = 4308.0). Tests of between-groups effects 
showed no significant effect of group (F (2, 81) = 0.04, p = 0.961, d = 0.006, BF10 = 0.05). As visual 
inspection suggested that the significant interaction arose from pre- to post-MIST, lower-order 
ANOVAs were carried out assessing only pre- to post-MIST VAS scores, using FDR-adjusted p-
values to adjust for multiple comparisons. This showed significant group differences in VAS 
change (F (2, 83) = 9.7, p = .002, d = 0.98, BF10 = 162.7), with significantly greater change in NEG 
compared to NEU (p = .002) and NEG compared to AMB (p = .01), but no differences between 
NEU and AMB (p = 0.41). VAS scores throughout the paradigm are showed in Figure 5.2. Mean 
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deltas from pre- to post-MIST for individual as well as total VAS scores are presented in Figure 
5.3 to show change in stress levels from baseline by condition.  





























Figure 5.3 – Delta scores from pre- to post-MIST for overall and individual VAS item scores by 
individual 
5.3.3 Biomarker Effects 
Mauchly’s Test of Sphericity was significant; therefore Greenhouse-Geisser statistic is reported. 
Repeated-measures ANCOVA controlling for gender and menstrual phase confirmed a 
significant effect of time point on cortisol levels (F (1.9, 150.6) = 5.7, p = .0052, d = 1.87, BF10 = 
2.7 x 1015), but there was no significant interaction with condition (F (3.8, 150.6) = 1.0, p = .41, 
d = 0.55, BFM = 0.03). No significant effect of group was found (F (2, 79) = 0.46, p = 0.63, d = 0.02, 
BF10 = 0.2). Repeated measures ANOVA also confirmed a significant effect of time point on α-
amylase levels (F (2.9, 233.4) = 23.0, p < .001, d = 1.73, BF10 = 3.8 x 1017), but there was no 
significant interaction with condition (F (5.8, 233.4) = 0.1, p = .71, d = 0.42, BFM = 0.01). No 
significant between-groups effect was found (F (2, 80) = 0.32, p = 0.73, d = 0.02, BF10 = 0.3). 





















Figure 5.4 – Cortisol by group by time point (mean ± SE) 
 













































5.3.4 Moderating Effects 
Sensitivity analyses using G*Power for Windows (Faul et al., 2007) indicated that the correlation 
analyses were powered to detect associations at effect sizes of r = 0.30, at β = 0.8. 
Bivariate correlation showed that SMQ scores were negatively associated with total VAS delta 
scores (r = -.39, p = .003, d = 0.85, BF10 = 11.3; Figure 5.6). However, as shown in Table 5.1, 
independent t-test revealed a significant effect of voice condition on SMQ scores (t (54) = 3.92, 
p < .001, d = 1.06, BF10 = 99.8), with significantly lower SMQ scores, indicating lower mindfulness, 
in the negative voice condition (M = 66.18, SD = 14.11) compared with the neutral voice 
condition (M = 81.96, SD = 15.97). Post-hoc analyses further showed that the negative 
association of SMQ scores with VAS deltas was significant in the negative (r = .43, p = .03, d = 
0.95, BF10 = 1.9) but not in the neutral (r = .05, p = .81, d = 0.10, BF10 = 0.24) voice condition, 
although Fisher’s r-to-z suggests the difference in correlations not to be significant (p = .15). Due 
to the lack of independence between SMQ scores and condition it was not possible to carry out 




Figure 5.6 – Scatterplot of Delta VAS scores and SMQ scores with correlation line 
Further bivariate correlations showed no significant association between SMQ scores and either 
logn AUCg cortisol (r = -0.23, p = 0.08, d = 0.47, BF10 = 0.7) or logn AUCg α-amylase (r = 0.03, p = 
0.85, d = 0.06, BF10 = 0.2). Due to the lack of main effect of condition on cortisol or α-amylase it 
was not possible to carry out any moderation analyses. 
5.4 Discussion 
5.4.1 Findings 
Our main finding was that, as predicted, experiencing negative simulated voices exacerbated 
the subjective stress response compared with neutral voices and ambient sounds, with a large 
effect size. The effect of neutral voices and ambient sounds on subjective stress-reactivity did 






























findings thus indicate that there is a large effect of negative voice content on the subjective 
stress response, which in turn may drive differential stress-reactivity in clinical voice-hearers. 
However, this finding was not mirrored in cortisol or α-amylase levels: differences across time 
points indicated that the MIST affected physiological stress response, but there were no 
differences across conditions. A recent study demonstrated that pharmacological suppression 
of both HPA- and ANS-activity via dexamethasone and propranolol does not alter the subjective 
emotional response to psychosocial stress in healthy individuals (Ali, Nitschke, Cooperman, and 
Pruessner, 2017), suggesting that psychological and physiological stress levels can vary 
independently. Thus, it is possible that our findings indicate that voice-content is unrelated to 
potential differences in HPA- and ANS-function of HVHs and CVHs, despite potential subjective 
stress differences. 
We also found that more mindful appraisals of voices were associated with lower subjective 
stress-reactivity. Interestingly, this was only the case in the negative voice condition, but not the 
neutral voice condition. Thus, mindfulness-based coping strategies may be a useful strategy to 
ameliorate distress associated with negative voices; however, negative voice content was also 
associated with lower state mindfulness after stress exposure. This finding adds to evidence 
from trials of mindfulness for clinical voice-hearers, which found evidence of reduced voice 
distress following therapy (Chadwick et al., 2016, 2009; López-Navarro et al., 2015; Shawyer et 
al., 2007). However, the lack of main effect of condition on cortisol or α-amylase made it 
impossible to test for a moderation effect.  
5.4.2 Strengths and Limitations 
We took great care in developing the simulated voices, consulting clinicians and voice-hearers 
on both the content and delivery of the voices in an iterative process. A strength of the present 
study is the development of simulated voices of negative and neutral content for use in research 
that have face validity and evoke differing levels of distress. Whilst previous research has 
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suggested simulated hallucinations are seen as realistic depictions by psychosis patients (Banks 
et al., 2004), to our knowledge this is the first research to show differences in affective reactions 
depending on voice content. Nevertheless, it is important not to assume generalisation of 
findings from research using simulated voices to the experience of clinical voice-hearers. Several 
aspects of AVHs, such as their interactive nature and personalised comments, are difficult to 
simulate, and there were ethical limits on how derogatory the content could be. Also, future 
research is needed to determine the impact of the simulated voices in other contexts, and not 
only under conditions of environmental stress.  
The use of randomisation to control for individual differences in prior stress exposure and stress-
reactivity, and the blinding of the experimenter to condition, further add to the strength of the 
present study. Similarly, Bayesian models were used to successfully confirm frequentist statistics 
in the present study, thereby increasing confidence in the results. A marked limitation of the 
present study is that it remains unclear as to whether the lack of biomarker findings is related 
to an independence of these markers from voice-content (and subjective stress levels) in actual 
voice-hearers as well. Alternatively, HPA- and ANS-parameters may not be sufficiently sensitive 
to reveal subtle differences in stress levels, which are better captured by subjective reports. 
Further, it was not anticipated that voice content conditions would influence mindfulness 
scores, which meant it was not possible to assess moderation effects. Whilst mindfulness 
regarding voices may have been of more relevance to the specific research question, trait 
mindfulness or state assessment before experimental exposure may have been more 
appropriate measures to test the hypothesis. 
5.4.3 Implications and Future Directions 
The present findings suggest that negative voice content may be a driving factor in the subjective 
stress-reactivity and distress of clinical voice-hearers. Future research should investigate the 
predictive value of negative voice content in transition rates of at-risk populations, rather than 
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merely the presence of voices, potentially aiding early identification of at-risk individuals and 
allowing for early intervention. The present subjective stress findings may have further 
implications for understanding the development and maintenance of psychotic disorders. 
According to a recent stress feedback model proposed by Howes and colleagues (2016), stress 
exposure may exacerbate dopaminergic dysregulation, which then leads to greater levels of 
delusional ideation and aberrant salience, increasing need for care and distress and thus 
maintaining this cycle. Increased stress levels due to negative voice content may putatively 
contribute to dopamine dysfunction and the formation of delusional beliefs. In line with this, 
the effect of the present paradigm on delusional ideation, e.g., state paranoia, should be 
assessed in future research. Further, whilst the present study found evidence that mindful 
appraisal of voices is associated with attenuated subjective stress-reactivity, future research 
should address experimentally whether purposefully employed mindful response styles to 
voices also attenuate stress-reactivity, or whether mindful response styles are simply more 
prevalent in individuals with greater stress resilience. 
5.4.4 Conclusions 
Participants exposed to voices with negative content showed an increased subjective stress 
reaction to a psychosocial stressor compared with those who were exposed to voices with 
neutral content or an ambient sounds condition. This effect was moderated by mindful 
appraisals of voices, but negative voice content itself reduced mindful appraisals. No significant 
effect of voice condition on either HPA- or ANS-function were observed. The present study adds 
support to the emergence of mindfulness-based therapies for negative, distressing voices, and 
underscores the importance of addressing both content of voices and appraisals in psychological 




Chapter 6 – Psychophysiological Stress-Function in Clinical and 
Healthy Voice-hearers 
6.1 Introduction 
Several key conclusions can be drawn from the evidence presented in Chapters 2 and 3. First, 
there is considerable evidence to suggest that psychosis is closely linked with stress and stress-
function, and that traumatic stress exposure is directly related to AVHs. Childhood sexual and 
physical abuse are highly prevalent in psychosis patients, and there is evidence to suggest that 
such experiences are particularly linked to auditory verbal hallucinations and other positive 
symptoms (Bentall et al., 2012; Hardy et al., 2016; Read et al., 2005; Shevlin et al., 2007). 
Psychosis patients are more likely to appraise events in daily life as stressful (Myin-Germeys et 
al., 2001), daily life stressors are positively associated with intensity of psychotic experiences 
(Myin-Germeys et al., 2005) and elevated stress-sensitivity to daily events as well as increased 
threat anticipation are associated with greater rates of psychotic experiences (Reininghaus et 
al., 2016). Evidence from self-report, experimental, and neuroimaging studies strongly suggests 
increased threat perception in psychosis and need for care (Reininghaus et al., 2016; Underwood 
et al., 2016). Similarly, physiological stress-function is perturbed in psychosis. In the autonomic 
nervous system (ANS), the sympathetic (SNS) branch is unaltered in psychosis, whereas activity 
of the parasympathetic (PNS) branch is dampened, establishing an imbalance in ANS activity 
(Montaquila et al., 2015). In addition to markers such as heart rate variability and respiratory 
rates, the salivary marker α-amylase has been investigated as a potential measure of ANS 
balance in psychosis, with two reports of increased levels in psychosis (Ieda et al., 2014; Inagaki 
et al., 2010). Further, there is evidence for altered hypothalamic-pituitary-adrenal (HPA) 
function in psychosis. Baseline HPA activity appears to be increased in patients with psychosis 
(Bradley and Dinan, 2010; Pruessner, Cullen, Aas, and Walker, 2017) and there is evidence of a 
blunted response to psychosocial stress (Ciufolini et al., 2014). Further, morning cortisol levels 
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are elevated (Girshkin et al., 2014), and negative feedback in the HPA axis, as measured via 
cortisol response to dexamethasone, a selective agonist of the glucocorticoid receptor (GR), is 
diminished (Bradley and Dinan, 2010). Evidence further suggests that one of the primary 
mechanisms regulating GR-availability, the chaperone protein FKBP5 that binds cytosolic GR, is 
involved in a genetic interaction with childhood trauma in the emergence of psychotic 
symptoms and HPA dysregulation (Collip et al., 2013a). Given the strong link between trauma 
exposure and the emergence of AVHs, it is warranted to also investigate the role that subjective 
and physiological stress-function may play in the impact of voice-hearing. 
Second, the current literature on HVH suggests that their AVHs are closely related to those of 
CVHs, but do not have the same distressing impact. The ability of an individual to respond to 
stress in an adaptive manner and overcome stress exposure may be a key variable when trying 
to understand why some individuals who hear voices suffer distress and present with need for 
care, whilst others do not. To address this question, the present study set out to investigate the 
role of physiological stress-function in leading to need for care in voice-hearers. A cross-sectional 
design was used comparing CVHs, HVHs and healthy controls with no AVHs (HCs). In line with 
recent suggestions of the Research Domain Criteria framework (Insel et al., 2010), recruitment 
of CVHs for the present study was symptom-specific and transdiagnostic, rather than guided by 
diagnostic criteria. That is, for participants to be included as CVHs, they had to a) experience 
AVHs and b) have received mental healthcare specific to psychotic experiences. That means that 
in addition to the classical diagnoses AVHs are usually considered a part of, i.e., schizophrenia 
and schizophreniform disorders, the present study also allowed for the inclusion of research 
participants diagnosed with other disorders, such as depressive disorder, post-traumatic stress 
disorder, and bipolar disorder. Therefore, to our knowledge this is also the first research to 
investigate physiological stress-function specifically in relation to CVHs, rather than in 
schizophrenia populations where AVHs may or may not be present. 
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 Several experimental and natural stress parameters were chosen to allow for a comprehensive 
assessment of stress-function. To investigate baseline HPA and ANS function, salivary cortisol 
and α-amylase were measured three times (Awakening, 3pm and 8pm) over the course of one 
day. To assess GR-function and negative feedback capacity of the HPA axis, the Dexamethasone 
Suppression Test (DST; Cole, Kim, Kalman, and Spencer, 2000) was chosen, with three salivary 
cortisol measurements (Awakening, 3pm and 8pm) over the course of one day following 1mg 
dexamethasone administration. To investigate acute reactivity of the HPA axis and the ANS to a 
psychobiological stress induction, the Socially-Evaluative Cold Pressor Test (SECPT; Schwabe, 
Haddad, and Schachinger, 2008) with salivary assessment of cortisol and α-amylase was chosen, 
as well as subjective reactivity to the stressor and anticipatory stress appraisal. In order to 
characterise the study populations, the study included measures of AVH phenomenology, 
anomalous perceptual experiences, beliefs about voices, drug use, trait mindfulness, symptoms 
of mood disorder as well as perceived life stress. 
6.1.1 Research Questions and Hypotheses 
 Research Questions 
1. Do CVHs, HVHs and HCs differ in their baseline HPA and ANS function, as assessed via 
salivary cortisol and α-amylase levels at three time points (i.e., total diurnal cortisol) 
over one day and at awakening? 
2. Do CVHs, HVHs and HCs differ in their GR-mediated negative feedback, assessed via 
cortisol response to the DST? 
3. Do CVHs, HVHs and HCs differ in their subjective, cortisol and α-amylase response to 
psychobiological stress, induced by the SECPT, as well as their anticipatory stress 
appraisal of the SECPT? 
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 Hypothesis 1 – Baseline Stress Function 
CVHs will have higher cortisol levels at the awakening than both HVHs and HCs. CVHs will show 
elevated overall cortisol and α-amylase levels compared with HVHs and HCs over the total 
(Awakening, 3pm and 8pm) of the day. HVHs will not differ from HCs on either parameter. 
 Hypothesis 2 – Dexamethasone Suppression Test 
CVHs will show less cortisol suppression in response to dexamethasone challenge than HVHs, 
indicative of impaired function of the GR and HPA auto-regulation. HVHs will not differ from 
HCs.  
 Hypothesis 3 – Socially-Evaluative Cold Pressor Test 
CVHs will show an exacerbated salivary α-amylase reaction in the context of a blunted cortisol 
response to the SECPT, compared to HVHs and HCs. Overall cortisol levels will be higher in in 
CVHs compared to HVHs and HCs. CVHs will show increased anticipatory stress appraisal before 
exposure and have higher subjective stress levels throughout the paradigm, including greater 
overall levels and diminished recovery. HVHs will not differ from HCs on any parameters.  
6.2 Methods 
6.2.1 Participants 
 Sample Selection 
Three groups of participants were recruited: 
1. 20 patients with auditory verbal hallucinations (AVH) from two services in the South 
London and Maudsley (SLaM) NHS Foundation Trust Psychosis Clinical Academic 
Group (CAG) (i.e. CVHs) 
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2. 25 voice-hearers with no need for care from community samples and specialist 
organisations (i.e. HVHs) 
3. 23 healthy non-voice-hearing controls from the general population (i.e. HCs). 
 Inclusion and Exclusion Criteria 
All participant groups had to meet the exclusion and inclusion criteria listed in Table 6.1. 
Table 6.1 – Inclusion and exclusion criteria for all groups 
Inclusion Criteria 1. 18 years or above 
Exclusion Criteria 1. Non-fluent speakers of English Language  
2. Lack of capacity to consent 
3. Significant physical illness (particularly sensitivity to 
dexamethasone or other steroids, uncontrolled infection, 
metabolic, endocrine disorders, hepatic disorders, 
cardiovascular disease, or phaechromacytoma) or currently 
taking medications that may interact with dexamethasone (e.g. 
currently taking steroids orally or inhaled steroids, 
immunosuppressants) 
4. Raynaud’s phenomenon (vasospasm in response to cold, 
leading to reduced blood flow) 
5. Allergy to steroids or drug excipients 
6. Pregnancy/ attempting to conceive 
7. Polydipsia (excessive water consumption, assessed via self-
report) 
 
English language abilities were decided to be essential for participation (Exclusion criterion 2). 
Additional selection criteria excluded individuals for whom dexamethasone may be 
contraindicated (Exclusion criteria 3, 5 and 6). In line with findings by Goldman and colleagues 
(2007), individuals with polydipsia (excessive water consumption, assessed by asking about 
excessive thirst or urination) were excluded as this may confound accurate assessment of HPA 
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parameters in psychosis patients (Exclusion criterion 7). Raynaud’s phenomenon, which is 
associated with excessively reduced blood flow in response to cold or stress exposure due to 
vasospasm, was a further exclusion criterion (4) for the SECPT. 
 Clinical Voice-Hearers 
For CVHs to be included in the present study they had to meet the additional following criteria 
in Table 6.2. 
Table 6.2 – Inclusion and exclusion criteria for CVHs 
Inclusion Criteria 1. Current auditory verbal hallucinations (as indicated by a score of 
1 (weekly) or above on the PSYRATS frequency item) in absence of 
drug use and in clear consciousness 
2. They are currently using secondary mental health services in 
relation to psychotic experiences 
Exclusion 
Criteria 
1. Too agitated or distressed to take part (i.e., acutely unwell, as 
informed by care coordinator or assessed to be so by interviewer) 
2. Drug-induced or organic psychosis. 
 
Drug induced or organic psychoses were excluded, as these may have fundamentally different 
aetiologies (Exclusion criterion 2). 
 Healthy Voice-Hearers 
For HVHs to be included in the present study they had to meet the additional following criteria 




Table 6.3 – Inclusion and exclusion criteria for HVHs 
Inclusion Criteria 1. Presence of auditory hallucinations for at least 5 years  
2. Current auditory verbal hallucinations (as indicated by a score of 
1 or above on the PSYRATS frequency item) in absence of drug use 
and in clear consciousness 
Exclusion 
Criteria 
1. They have sought help (either themselves, or someone on their 
behalf) from mental health services in relation to their psychotic 
experiences 
2. They have received secondary care for any mental health issue  
3. A clinical judgement is made that the participant is in need of care 
(e.g., reporting of distress or significant mental health difficulties)  
 
Selection criteria assessing need for care in potential HVHs (Exclusion criteria 1-3) were made in 
line with previous studies on psychotic experiences in healthy individuals (Peters et al., 2016; 
Ward et al., 2014). To further ensure that AVHs were persistent in potential participants and to 
avoid recruiting individuals in a potential prodromal state, AVH had to have been occurring for 
at least 5 years in the absence of need for care (Inclusion criterion 1).  
 Healthy Controls 
For HCs to be included in the present study they had to meet the additional following criteria in 
Table 6.4. 
Table 6.4 – Exclusion criteria for HCs 
Exclusion 
Criteria 
1. Current or past presence of auditory verbal hallucinations 
2. They have sought help (either themselves, or someone on their 
behalf) from mental health services in relation to any psychotic 
experience 
3. They have received secondary care for any mental health issue 
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Healthy controls had to fulfill the same criteria for absence of help-seeking as HVHs, with the 
additional exclusion criterion of previous experience of AVHs. 
 Recruitment 
Recruitment of CVHs was through two primary SLaM sources: a) the PICuP (Psychological 
Interventions Clinic for outpatients with Psychosis) research register, a database of potential 
research volunteers who had been previously assessed and/or treated by the team; and b) 
referrals by the Treatment Review and Assistance Team (TREAT), a specialist service for patients 
with on-going psychotic symptoms (Beck et al., 2014). All recruited CVHs were outpatients. 
Recruitment of HVHs primarily relied on the UNIQUE (‘UNusual experIences enQUiry’) study 
research register, containing contact details for potential volunteers who have reported 
psychotic experiences in previous research studies (Peters et al., 2016; Ward et al., 2014). 
Additionally, the present project utilised opportunity sampling, including research 
advertisement through spiritual groups (e.g., Society for Psychical Research), GumTree 
(www.gumtree.com), as well as direct contacting of individuals advertising themselves as 
‘clairaudient’ mediums or spiritual practitioners, consistent with the approaches used in 
previous studies recruiting this population (Underwood et al, 2016; Peters et al., 2016).  
HCs were recruited through opportunity sampling, including adverts in the KCL internal research 
recruitment newsletters, GumTree (www.gumtree.com), Experimatch (www.experimatch.com; 
a participant recruitment website formerly provided by University College London), and through 





 Experimental Measures 
 Dexamethasone Suppression Test 
The DST uses the synthetic glucocorticoid dexamethasone, a selective agonist for the GR, to 
assess negative feedback capacity in the HPA axis. The present study utilised dexamethasone 
(1mg) in oral pill form, which is a commonly used dose in the DST and recommended by the 
American Endocrine Society (Nieman et al., 2008). The salivary cortisol level was measured at 
three time-points (awakening, 3pm and 8pm) on a baseline day to establish normative HPA 
function. This procedure was carried out by participants at home, using written instructions and 
phone support if needed. Participants then self-administered the 1mg dexamethasone in the 
evening, and salivary cortisol levels were measured again over the following day. Post-DST 
cortisol levels were used to assess whether dexamethasone led to suppression of cortisol release 
and thus whether negative feedback capacity in the HPA axis is normative.  
Further, time of awakening was used for the morning sample, rather than asking participants to 
set an alarm for a specific time. This was decided to allow for individual variation in awakening 
times and diurnal activity patterns. To assess potential differences in awakening between 
groups, participants were asked to record the time of awakening on both days. The 
dexamethasone in the present study was dispensed by the Maudsley Pharmacy and prescribed 
by the study physician. Effects of oral dexamethasone induced cortisol suppression last for 
approximately 2-3 days (Cassidy et al., 2000). 
 Socially Evaluated Cold Pressor Test 
The SECPT is a psychobiological stress task that is designed to elicit an acute stress response. It 
is based on the Cold Pressor Test, where an extremity, typically a hand, is exposed to cold, 
painful stimuli such as ice water or cool packs in order to elicit a stress response. Schwabe and 
145 
 
colleagues (Schwabe, Haddad, and Schachinger, 2008) refined the classic paradigm by including 
a social component to exacerbate the HPA response. In the SECPT participants are additionally 
informed that their facial expressions will be filmed during the task, and they are asked to 
maintain eye contact with a camera set up in front of them, and the experimenter sits adjacent 
to them and pretends to take notes. Implementing these modifications has been shown to 
produce a greater HPA response than the ‘classic’ Cold Pressor Task (Schwabe, Haddad, and 
Schachinger, 2008).  
Conventional freezer ice packs were used to cool down the water, and temperature was 
measured using a digital thermometer to ensure that all participants were exposed to 
temperatures between 0-3oC. Maximum exposure was set at 3min, after which participants 
were asked to remove their hand from the water if they had not already done so. Saliva and 
subjective stress was measured at two time points before exposure (-10min and 0min) and at 5 
time points following exposure (0min, +15min, +30min, +45min and +60min). During the rest 
phase, all participants were presented with a 60-min nature documentary (BBC Natural History 
Unit, 2011) to provide a controlled stimulus. Whilst research studies frequently employ the use 
of magazines for such waiting periods (Birkett, 2011), it was decided that a nature documentary 
would a) not lead to exposure to differential stimuli, i.e., individual articles, b) not pose an 
additional stressor for individuals with impaired reading abilities and c) would be less stressful 
than many news articles. The chosen documentary was age appropriate for children as young as 
six, to ensure that potentially stressful imagery (e.g., animals hunting) was kept to a low level. 
 Saliva Samples 
Salivary cortisol and α-amylase levels were measured using Salivettes (Rommelsdorf, Germany). 
All Salivettes were frozen at -20 oC in a secure laboratory freezer. Freezing occurred within 2 
hours of collection for all SECPT samples, and participants were instructed to freeze samples 
taken at home immediately after taking them. Participants were asked to gently chew the 
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Salivettes for each collection, and were instructed not to touch samples with their hands. All 
samples were analysed at the ViaPath lab at King’s College Hospital, using enzyme linked assay 
by Salimetrics. Inter-assay coefficients of variations were 7.1% for cortisol and 6.3% for α-
amylase. All saliva samples obtained in the SECPT were assessed for cortisol and α-amylase 
content, as were samples taken on the baseline day of the DST. Samples taken following 
dexamethasone administration were assessed for cortisol only. 
 Questionnaire Measures 
 Psychotic Symptoms Rating Scale – AVH 
The Psychotic Symptoms Rating Scale for Auditory Verbal Hallucinations (PSYRATS-AVHs) is a 
scale to assess dimensions of AVHs (Haddock, McCarron, Tarrier, and Faragher, 1999). It is 
administered in a semi-structured interview where 11 items are scored on a 5-point Likert scale 
(0-4). In line with Woodward and colleagues’ (2014) recent cluster analysis, a four-factor 
structure comprising distress (negative content, distress and control), frequency (frequency, 
duration and disruption), attribution (location and beliefs about origin) and loudness was 
utilised. The PSYRATS is a frequently used assessment tool that has repeatedly demonstrated 
validity and reliability in clinical and non-clinical voice-hearer populations (Daalman, et al., 
2011a; Diederen et al., 2012; Haddock et al., 1999; Sommer et al., 2010a; Woodward et al., 
2014). The PSYRATS was administered to voice-hearers only. In the present study, an item was 
included to record age of onset of AVHs. 
 Cardiff Anomalous Perceptions Scale 
The Cardiff Anomalous Perceptions Scale (CAPS) is a self-report scale that measures the 
frequency, intrusiveness and distress of anomalous perceptual experiences that occur in a 
wakeful state, and in the absence of psychotropic medication or intoxication (Bell, Halligan, and 
Ellis, 2006). It contains 32 items, relating to psychotic experiences (e.g., hearing voices), 
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temporal lobe epilepsy symptoms (e.g., altered time perception), and chemosensation (e.g., 
olfactory hallucinations). The present study utilised the overall score (i.e., items endorsed), and 
the subscale totals for frequency, intrusiveness and distress of experiences. Each item is 
endorsed with a binary choice (yes/no), and then the frequency, intrusiveness and distress of 
each item is rated on a 5-point Likert scale from 1-5. This produces 4 scores, firstly the total 
number of items endorsed (total range 0-32), and then total frequency, intrusiveness and 
distress scores (total range for each 0-160), with higher scores reflecting greater endorsement. 
To ensure appropriate weighting, frequency, intrusiveness and distress scores were calculated 
as the sum of item scores divided by the number of items endorsed. It has demonstrated good 
reliability and validity in both clinical and non-clinical samples (Bell et al., 2006; Bell, Halligan, 
and Ellis, 2008; Bell, Halligan, Pugh, and Freeman, 2011). In the present study, the subscales for 
total score (Cronbach’s α = .93), total frequency (Cronbach’s α = .95), total intrusiveness 
(Cronbach’s α = .95) and total distress (Cronbach’s α = .95) all showed excellent reliability. 
 Beliefs About Voices Questionnaire 
The Beliefs About Voices Questionnaire – Revised (BAVQ-R; Chadwick, Lees, and Birchwood, 
2000) is a 30-item scale that measures beliefs about AVHs, as well as reactions to AVHs. Items 
are scored on a 4-point Likert scale (1-4). Beliefs are measured on three subscales each 
consisting of six items with scores ranging from 6-20, including beliefs of malevolence, 
benevolence and omnipotence, and reactions to AVHs (resistance and engagement, both 
emotionally and behaviourally) are measured on two subscales with nine and 8 items with 
scores ranging from 9-36 and 8-32, respectively. Higher scores reflect greater endorsement of 
individual subscales. Validity and reliability of the BAVQ-R has been demonstrated in both 
clinical and non-clinical voice-hearer populations (Andrew et al., 2008; Chadwick et al., 2000). In 
the present study, all subscales were found to be reliable: Malevolence (Cronbach’s α = .94), 
Benevolence (Cronbach’s α = .93), Omnipotence (Cronbach’s α = .76), Resistance (Cronbach’s α 
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= .95), and Engagement (Cronbach’s α = .96). The BAVQ-R was administered to voice-hearers 
only. 
 Voice Power Differential Scale 
The Voice Power Differential Scale (VPDS) is a self-report measure consisting of six items to 
measure perceived power of the voice and voice-hearer (Birchwood et al., 2000). All items are 
bipolar in nature, i.e., they assess whether the voice or the voice-hearer is more powerful in 
relation to the other, rated on seven constructs (i.e., power, knowledge, superiority, strength, 
confidence, respectfulness, and ability to inflict harm). Each item is measured on a 5-point Likert 
scale (1-5; total range 6-30), with higher scores indicating greater voice power. The VPDS has 
demonstrated validity and reliability in CVH populations (Birchwood et al., 2000, 2004, 2014). 
Fifty-six percent of healthy voice-hearers reported being unable to answer the item regarding 
ability to inflict harm.  Thus, the total scale was calculated on the basis of the remaining six items, 
and the harm item is reported separately. Cronbach’s α in the present study indicated good 
reliability for the six-item scale (Cronbach’s α = .83). The VPDS was administered to voice-
hearers only. 
 Depression Anxiety and Stress Scale 
The Depression Anxiety and Stress Scale (DASS) is a 42-item self-report instrument that assesses 
symptoms of depression, anxiety and stress in the preceding week (Lovibond and Lovibond, 
1995). Its validity has been established in clinical as well as healthy samples (Crawford and 
Henry, 2003; Lovibond and Lovibond, 1995). The scale has three subscales covering symptoms 
of depression, anxiety and stress, each containing 14 items. Items are scored on a 4-point Likert 
scale from 0-3, with total subscale scores ranging from 0 to 42 and higher scores indicating 
greater symptoms for each individual subscale. Cronbach’s α in the present study indicated 
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reliability of the total score (Cronbach’s α = .98), as well as the depression (Cronbach’s α = .97), 
anxiety (Cronbach’s α = .91) and stress (Cronbach’s α = .94) subscales. 
 Five Facet Mindfulness Questionnaire 
The Five Facet Mindfulness Questionnaire (FFMQ) is a 39-item self-report measure that assesses 
trait mindfulness (Baer, Smith, Hopkins, Krietemeyer, and Toney, 2006). Items are scored on a 
5-point Likert scale from 1-5, with total scores ranging from 39 to 195, and higher scores 
indicating greater trait mindfulness. Only the total score was used in the present study. Previous 
studies have demonstrated good validity for the questionnaire (Baer et al., 2008; Bohlmeijer, 
ten Klooster, Fledderus, Veehof, and Baer, 2011). The present study found good reliability for 
the total score (Cronbach’s α = .81). 
 Stressful Life Events Questionnaire 
The Stressful Life Events Questionnaire (SLESQ) is a 13-item assessment for lifetime exposure to 
stressful events that is administered as a semi-structured interview (Goodman, Corcoran, 
Turner, Yuan, and Green, 1998; Green, Chung, Daroowalla, Kaltman, and Debenedictis, 2006). 
Items cover life-threatening events and exposure to physical, emotional and sexual abuse, as 
well as witnessing of such events. For each event, age of exposure, as well as specific details 
such as frequency and duration are recorded. For the present study, several scales were 
constructed, including total number of items endorsed (range 0-13), total number of sexual 
trauma exposure and total number of physical trauma exposure (each based on frequency item; 
both range 0-8).  
 Stress Appraisal Measure 
To measure subjective anticipatory stress appraisal several subscales (Threat; Centrality; 
Uncontrollability) of the Stress Appraisal Measure (SAM; Peacock and Wong, 1990) were used, 
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combining how threatening, central (i.e., perceived as important to oneself) and uncontrollable 
the task was anticipated to be. The 12 selected items were scored on a 5-point Likert scale from 
1-5, with total scores ranging from 5 to 60, and higher scores indicating greater anticipatory 
stress appraisal. The subscales have shown good validity (Peacock and Wong, 1990). The 12-
item scale utilised here was found to be reliable in the present study (Cronbach’s α = .90).  
 Visual Analogue Scales 
A 9-item visual analogue scale (VAS; Appendix VI) was created to assess subjective stress-
reactivity, ranging from 0cm to 16.5cm (due to size of the scales on printed paper), with total 
scores ranging from 0 to 16 (one point for each centimetre interval) and higher scores indicating 
greater subjective stress levels. Participants were asked how stressed, in pain, anxious, angry, 
relaxed (reverse coded), threatened, embarrassed, socially judged and expecting of positive vs 
negative consequences they were, to reflect an array of possible stress responses to the SECPT. 
A Principal Component Analysis was carried out to determine whether the scale represented a 
latent factor indicative of a general subjective stress reaction, using VAS scores at baseline. The 
Kaiser-Meyer-Olkin measure was used to verify sampling adequacy. This showed KMO = .82 and 
Bartlett’s test of sphericity was significant (χ2 (36) = 289.2, p < 001). Three components had an 
eigenvalue over Kaiser’s criterion of 1, explaining 72.5% of the variance. A one factor structure 
was most appropriate (Eigenvalue = 4.44). It was decided to suppress items with coefficients 
below 0.5 (Field, 2014), leading to exclusion of one item (expecting positive vs negative 
consequences), with the lowest factor loading being .53. Cronbach’s α indicated the scale to be 
reliable (.85). 
 Drug Use 
To assess use of recreational substances, a questionnaire was created to assess lifetime and 
current use of alcohol, tobacco, cannabis and amphetamines (including cocaine, crack-cocaine 
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methamphetamine, and 3,4-methylenedioxy-methamphetamine (MDMA)). For each class of 
drugs, frequency of use was recorded (if not current, then average at the time), current use and 
age of first exposure was assessed. 
 Demographics 
A demographics questionnaire was created to assess age, gender, ethnicity, living status, 
relationship status, employment status, level of achieved education and native language of 
participants. 
 Biological Control Variables 
To investigate potential confounding variables that may lead to variation in salivary biomarker 
data, a questionnaire was created to control for biological factors that may impact on 
physiological stress-function. Items assessed included age (Holochwost et al., 2017; Skoluda et 
al., 2017), gender (Kirschbaum et al., 1999), BMI (Skoluda et al., 2017), current medications, 
current medical diagnoses, time of last meal, time of last drink, time of last cigarette (if 
applicable; Skoluda et al., 2017), first day of last menstrual cycle (if applicable; Kirschbaum et 
al., 1999), strenuous exercise in the preceding 72h (Bonato et al., 2017), stress exposure in the 
preceding 24h (Skoluda et al., 2017), and illicit substance use in the preceding 72h (Seibert et 
al., 2014). A composite score for menstrual cycle and oral contraceptives (progesterone) was 
created using stratification by follicular and luteal phase and gender, so that women in luteal 
phases and men were grouped, and women in follicular phases and oral contraceptive users 
were grouped. This is in line with previous research demonstrating the effect of these variables 





The study was carried out between November 2015 and February 2017. Potential participants 
were identified through research registers, opportunity or through care coordinators/nurses 
who asked potential participants if they would be happy to be contacted by the research team. 
All screenings were carried out by the research student. Once identified for potential eligibility 
for the project, participants were given an information sheet (see Appendix VII), informed about 
aims, methods and risks of the study and possible concerns, their rights as participants and what 
their participation entailed was discussed. Depending on the participants’ preference this was 
possible on the phone or face to face. Participants had at least 2 days to consider their 
participation before consenting.  
If participants expressed their interest to participate, capacity to consent was assessed following 
standard procedures to determine capacity (Owen et al., 2013), consent was obtained and 
eligibility was assessed using inclusion/exclusion criteria. Again, this was possible on the phone 
or face to face depending on the participants’ preference. A study doctor was available for 
consultation on those issues if appropriate; in the case of uncertainty about previous, relevant 
medical diagnoses of e.g. endocrine disorders, participants were excluded. If the research 
student believed capacity was lacking or that understanding of the study and the procedures 
was not sufficient, participants were not included in the study. Participants were considered 
enrolled in the study once consented and verified eligible for inclusion. A record was held of 
those eligibility checks on a Clinical Research Form, which also documented completion of 
procedures by individual participants and any adverse events. Study procedures are presented 
in Figure 6.1. 
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 Day 1 Assessment 
At the first assessment, the study doctor screened all participants and, if necessary, carried out 
pregnancy testing. Participants then completed the questionnaire battery (in order: 
demographics; drug use; PSYRATS; CAPS; BAVQ-R; VPDS; SLESQ; DASS; FFMQ) with the research 
student. The procedures for the dexamethasone test were discussed in detail, and the research 
student ensured that participants understood those procedures by asking them to explain the 
procedure back to him. Participants further received a comprehensive flowchart (see Appendix 
VIII) detailing their participation and the procedures, as well as an information sheet about the 
dexamethasone suppression test and saliva sampling procedures (see Appendix V). Participants 
received 1mg of dexamethasone and 6 oral sorbettes, as well as full instructions for the sampling 
procedure. These instructions detailed the dexamethasone self-administration (Appendix V), 
saliva sampling and storage, as well as subsequent transportation, for which a padded envelope 
and sealable bags were provided. 
 Dexamethasone Administration and Saliva Sampling 
Participants followed the saliva sampling procedures over two days at their home. All 
participants were offered reminder phone calls for the preceding day and the two sampling days 
to ensure compliance, acceptability and understanding and, if necessary, the procedure was 
explained again in more detail. On the first day, participants obtained one saliva sample upon 
awakening, another sample at 3pm, and a final sample in the evening at 8pm. Participants then 
took the 1mg dose of dexamethasone at 11pm, and repeated the collection of saliva samples 
upon awakening, 3pm and at 8pm of the following day. They were asked to store saliva samples 
in a provided bag in their fridge or freezer, and were scheduled for the second assessment at 
least 7 days following dexamethasone administration to avoid any carry-over effects (effects of 
oral dexamethasone induced cortisol suppression may last for approximately 2-3 days). 
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Participants who did not wish to receive reminder phone calls were contacted following the 
dexamethasone administration to ensure no adverse side-effects occurred. 
 Day 2 Assessment 
On Day 2, participants brought their saliva samples and were again asked about any difficulties 
or subjective effects of dexamethasone. Participants then completed the Socially Evaluated Cold 
Pressor Task (SECPT). The protocol for the SECPT in the present study was as follows: at baseline, 
a saliva sample, subjective stress (VAS) as well as threat appraisal (SAM) measures (e.g., how 
stressful they anticipate the task to be; how well they think they will cope with the task) were 
taken. Then, 10min after the baseline time point, participants completed a second VAS and 
saliva sample, and were asked to immerse their hand up to and including the wrist in ice water, 
and keep their hand submersed for as long as possible. Participants were instructed to maintain 
eye contact with a camera placed in front of them, under the pretence that this was to analyse 
facial expressions. Additionally, participants were observed by the experimenter the whole time, 
who also took notes. Participants who still had their hand submersed after 3min were asked to 
remove it at that point. A record of the time their hand was submersed was taken for each 
participant. Upon completion, the third saliva sample and VAS score were obtained. Over the 
remaining 60min, during which participants had the opportunity to rest whilst watch a nature 
documentary, saliva and subjective stress (VAS) were measured every 15min.  
 Following their participation, participants were debriefed about the sham camera, and asked to 
complete a feedback questionnaire to assess acceptability of the research study. Participants 
were reimbursed for travel, and reimbursed with £10 for each research session. For non-clinical 
individuals who were unable to attend two separate sessions (e.g., due to long travel), sessions 
1 and 2 were joined into one longer session. All assessments for the joined sessions were 
completed in the same order as in assessments on separate days. 
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 Premature Withdrawal 
If participants decided to withdraw prematurely they were free to do so, without the need to 
justify their decision. Any data collected until that point was retained unless requested 
otherwise by the participant. As with all other participants, they were offered a follow-up phone 
call to discuss any issues raised from the research.  
 




6.2.4 Ethical Considerations 
 Ethical Approval  
The present study was assessed and approved by several committees.  The Research Committee 
of the SLaM Psychosis CAG approved the study proposal on February 12th 2015 (CAG Reference: 
PSYR&D14/009; Appendix IX). The Risk Assessment Committee of King’s College London 
approved the study protocol as within an acceptable level of risk on March 24th 2015 (Appendix 
X). Full approval by the NHS Research Ethics Sub-Committee (NRES) London-Dulwich was 
granted on August 6th 2015 (REC Reference: 15/LO/0880; Appendices XI - XIV).  
 Assessment of Safety  
No serious adverse events, i.e. situations that pose a serious threat to the physical and/or 
psychological wellbeing to participants and require medical or otherwise professional 
intervention, were expected to occur during this study. The dexamethasone suppression test 
has been found to have a very low side effect profile and is considered safe to use in psychiatric 
samples. Similarly, both the assessment of stressful life events and psychotic symptoms, as well 
as the exposure to psychosocial stress paradigms such as the Cold Pressor Test, have been 
extensively practiced in mental health research and participant groups such as the ones in the 
present study. A study doctor was available to consult/advice if appropriate during the eligibility 
screening, conduct an assessment and arrange any further care should any participant report 
adverse effects. Should a serious adverse event have occurred, this would have been 
immediately reported to both the REC and the sponsor, the protocol would have been adapted 
in order to minimise the risk of reoccurrence and feasibility of the study would have been 
reconsidered if necessary. Additionally, a Research Interview and Distress Protocol (Appendix 
XV) was put in place in line with existing guidelines (Draucker, Martsolf, and Poole, 2009), to 
ensure a systematic approach to managing any potential participant distress. 
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Preventive measures were taken to reduce the risk of adverse events and ensure optimal 
participant experience. Service user and participant representatives reviewed the methodology 
and judged it to be tolerable. Adverse events, such as distress in participants, would have been 
immediately reported and discussed within the research team, led to changes in our research 
procedures, and, if considered significant, the REC and sponsor would have been informed.  
6.2.5 Statistical Analyses 
 Questionnaire Measures 
All statistical analyses were carried out using SPSS for Windows (IBM Corp., 2015), and 
additionally JASP (JASP Team, 2016) was used for Bayesian analysis to express likelihood of data 
supporting the hypotheses. P-values below the 0.05 two-tailed threshold were accepted as 
statistically significant. In instances of multiple post-hoc testing, False Discovery Rate (FDR)-
adjusted p-values are reported (Benjamini and Hochberg, 1995). Bayes factors of 3 and above 
were interpreted as sufficient evidence for the alternative hypothesis, and Bayes factors of 1/3 
and below as sufficient evidence for the null hypothesis (Kass and Raftery, 1995). Bayesian 
statistics were carried out to provide an additional metric to evaluate findings with greater 
confidence. Additionally, effect sizes were calculated and converted to Cohen’s d to allow for 
comparison across effects. For three-way chi-square analyses, Cramer’s v is reported, which has 
similar effect size scaling to Cohen’s d. Effect size conversions were carried out using formulas 
commonly used in meta-analyses and research synthesis (Borenstein et al., 2009; Cooper et al., 
2009; Fritz et al., 2012; Lipsey et al., 2001; Morris and DeShon, 2002). Normal distribution of 
data was checked by Q-Q plots and Kolmogorov-Smirnov tests, and Levene’s test was used to 
assess homogeneity of variance. Cronbach’s α was assessed for all questionnaire measure to 
ensure reliability.  
For group comparisons of sociodemographic and questionnaire data, separate analyses were 
carried out for each questionnaire variable (dependent variables); with group (i.e., CVH vs HVH 
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vs HC) as the independent variable. Chi-square analyses were carried out for binary dependent 
variables. Normality of continuous variables was examined by visual inspection of Q-Q plots, as 
well as the Kolmogorov-Smirnov test. For 3-way comparisons, homogeneity of variance was 
additionally confirmed using Levene’s test. For normally distributed data, independent samples 
t-tests (CVH vs HVH) and ANOVA (CVH v HVH vs HC) were used for group comparisons on 
continuous variables. For post-hoc group comparisons, Tukey’s HSD was chosen. In group 
comparisons for non-normally distributed continuous variables, non-parametric Mann-Whitney 
U (CVH vs HVH) and Kruskall-Wallis (CVH vs HVH vs HC) tests were used. When total group 
comparisons showed significance, lower-order post-hoc comparisons were carried out.  
For analysis of subjective stress levels during the SECPT, a repeated-measures mixed ANOVA was 
carried out on total VAS scores (DV) (within-participant independent variable) and group as the 
between-participants independent variable. For recovery of subjective stress-levels, paired-
samples t-tests within groups were carried out on VAS scores from post-SECPT to 15min. 
 Saliva Data 
For all cortisol and α-amylase analyses, associations of dependent variables with potential 
covariates, including BMI, age, gender and menstrual cycle/contraceptive pill, were assessed 
and included as covariates if significant. To establish normal distribution of cortisol and α-
amylase data, logarithmic transformations (logn) were undertaken for all analyses. 
For assessment of baseline stress-function, repeated-measures ANCOVA using group as the 
independent variable and cortisol at 3pm and 8pm and α-amylase values at all three time points 
as the dependent variables was carried out. For assessment of morning cortisol, one-way 
ANCOVA was carried out. For cortisol, bivariate correlation analyses showed no significant 
covariates. For α-amylase, progesterone treatment was identified as a potential covariate.  
Further, outlier analyses were undertaken via assessment of interquartile ranges and extreme 
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values (i.e., those outside Q1 – 3 * IQR and Q3 + 3 * IQR) were excluded.  This procedure was 
carried out due to the risk of faulty saliva sample self-administration or non-compliance with 
sampling instructions (e.g., participants may have had something to drink, thereby decreasing 
biomarker level concentrations artificially). Non-compliance rates in cortisol home sampling 
procedures may go as high as 30% (Broderick, Arnold, Kudielka, and Kirschbaum, 2004), and thus 
outlier exclusion at the cost of statistical power was decided upon as the most prudent 
approach.  
To assess outcome of the dexamethasone suppression test, participants were classified as 
suppressors or non-suppressors, in line with the literature (Bradley and Dinan, 2010). As 
suggested by Cassidy et al. (2000), a cut-off value was assigned to all three sampling time points 
on the day following dexamethasone administration. In line with recent research on GR function 
(Castro, Elias, Quidute, Halah, and Moreira, 1999; Chriguer et al., 2005) as well as comparison of 
plasma and salivary cortisol response to dexamethasone (Ansseau et al., 1984), a cut-off cortisol 
value of 2.6nmol/L was decided upon. Thus, participants who had a cortisol value above 
2.6nmol/L for any of their three samples were classified as non-suppressors. Likelihood chi-
square analysis was carried out to investigate significant differences between groups, with 
lower-order post-hoc analyses for individual group differences. 
For assessment of salivary cortisol and α-amylase response to the SECPT, repeated-measures 
ANCOVAs were carried out with group as the between-participants IV, time point as the within 
participants IV and log-transformed cortisol and α-amylase as the DV. For cortisol, bivariate 
correlations revealed current oral contraceptives (progesterone) as a potential covariate. For α-
amylase, menstrual phase was identified as a potential covariate. Post-hoc testing of group-
specific outcomes was carried out via pairwise comparisons as well as lower order ANOVAs for 
specific time points. For assessments of peak cortisol and α-amylase responses between groups, 
repeated-measures ANCOVAs for cortisol and α-amylase (with the covariates identified above) 
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were carried out from post-SECPT to 15min for cortisol, and pre-SECPT to post-SECPT for α-
amylase.  
6.3 Results 
6.3.1 Sample Characteristics 
The present study recruited 23 CVHs, 27 HVHs, and 23 HCs. Three CVH participants withdrew 
after their first assessment and did not provide any saliva data, and two HVHs could not be 
assessed on saliva data due to significant physical illness deemed likely to skew results (one 
participant with a pituitary gland tumour, one participant on high dose steroid treatments). 
Their questionnaire data were therefore excluded from the present analyses. Thus, the final 
sample reported on here comprised 20 CVHs, 25 HVHs and 23 HCs.  
Sample sizes per measure are shown in Table 6.5. Two CVHs and seven HVHs did not consent to 
taking the dexamethasone. Three HCs did not return their home saliva sampling packs. Two 
HVHs were not available to attend the SECPT session. For awakening cortisol, two outliers (i.e., 
values outside Q1 – 3 * IQR and Q3 + 3 * IQR; 1 CVH, 1 HC) were removed. For saliva samples on 
the baseline day, eleven samples did not contain sufficient amounts of saliva to be analysed for 
cortisol (1 CVH, 6 HVH, 4 HC), and one could not be analysed for α-amylase (1 CVH). For diurnal 
cortisol, two outliers were identified and removed (1 CVH, 1 HVH), and for diurnal a-amylase, 
two outliers were removed (1 CVH, 1 HVH).  
No adverse events occurred during any of the study procedures. Participant groups did not differ 
significantly on age, ethnicity, and first language. However, group differences were found for 
gender, employment status, living status, relationship status, education level and body-mass 
index. Group specific differences are presented in Table 6.6. Clinical characteristics of CVHs are 
presented in Table 6.7. 
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Table 6.5 – Sample sizes per measure 
Measure CVHs HVHs HCs 
Questionnaires 20 25 23 
Awakening Cortisol 19 20 19 
Diurnal Cortisol/ a-Amylase* 20 24 20 
DST 18 18 20 
SECPT 20 23 23 




Table 6.6 – Sample demographics (Mean ± SD, [% Exposed])    
 CVHs (n = 20) HVHs (n = 25) HCs (n = 23) Statistics CVH vs HVH CVH vs HC HVH vs HC 
Age 47.7 ± 8.5 45.24 ± 14.4 45.2 ± 10.4 F (67) = 0.3, p = 0.7,  
d = 0.2, BF10 = 0.1 
- -  
Gender (% Female) 35.0% 64.0% 30.4% χ2 = 6.5, p = 0.04,  
v = 0.31, BF10 = 2.4 
χ2 = 3.7, p = 0.05,  
d = 0.60, BF10 = 2.2 
χ2 = 0.1, p = 0.75, d = 
0.10, BF10 = 0.4 
χ2 = 5.4, p = 0.02,  
d = 0.71, BF10 = 4.9 
Ethnicity (% White British) 65.0% 52.0% 60.9% χ2 = 0.8, p = 0.7, 
 v = 0.11, BF10 = 0.2 
- - - 
First Language (% English) 75.0% 80.0% 87.0% χ2 = 1.0, p = 0.6,  
v = 0.12, BF10 = 0.1 
- - - 
Employment (% 
Unemployed) 
100.0% 16% 8.7% χ2 = 46.0, p < 0.001, 
v = 0.82, BF10 = 7.2 x 109 
χ2 = 31.5, p < 0.001,  
d = 3.06, BF10 = 2.5 x 
107 
χ2 = 35.7, p < 0.001,  
d = 4.42, BF10 = 3.6 x 108 
χ2 = 0.6, p = 0.4,  
d = 0.23, BF10 = 0.3 
Living Status (% Alone) 57.1% 16.0% 17.4% χ2 = 12.8, p = 0.002,  
v = 0.43, BF10 = 30.6 
χ2 = 9.4, p = 0.002,  
d = 1.03, BF10 = 34.2 
χ2 = 8.3, p = 0.004,  
d = 0.98, BF10 = 22.0 
χ2 = 0.1, p = 0.9,  
d = 0.09, BF10 = 0.3 
Relationship Status (% 
Single) 
60.0% 24.0% 43.5% χ2 = 6.0, p = 0.049,  
v = 0.30, BF10 = 2.1 
χ2 = 6.0, p = 0.01,  
d = 1.03, BF10 = 6.5 
χ2 = 1.2, p = 0.28,  
d = 0.34, BF10 = 0.6 
χ2 = 2.0, p = 0.2, 

























χ2 = 19.4, p = 0.01,  
v = 0.38, BF10 = 13.8 
χ2 = 12.3, p = 0.02,  
d = 1.23, BF10 = 23.4 
χ2 = 12.3, p = 0.02,  
d = 1.27, BF10 = 20.8 
χ2 = 5.8, p = 0.2, 
d = 0.74, BF10 = 0.2 
Body-Mass Index 31.1 ± 7.6 26.9 ± 6.7 24.5 ± 4.4 F (62) = 5.7, p = 0.006,  
d = 0.84, BF10 = 4.9 
Tukey HSD p = 0.10 Tukey HSD p = 0.004 Tukey HSD p = 0.40 
Water Temperature (°C) 0.4 ± 0.5 0.5 ± 0.7 0.3 ± 0.3 F (63) = 0.8, p = 0.46,  
d = 0.31, BF10 = 0.2 
- - - 
SECPT Time in water 
(mm:ss) 
02:18 ± 00:57 02:26 ± 01:01 02:41 ± 00:36 F (63) = 1.1, p = 0.35,  
d = 0.37* 
- - - 
Day 1 Awakening (hh:mm) 7:56 ± 1:22 7:15 ± 1:31 7:05 ± 1:15 F (48) = 1.5, p = 0.23,  
d = 0.51* 
   
Day 2 Awakening (hh:mm: 7:52 ± 1:40 7:46 ± 1:39 7:31 ± 1:02 F (55) = 0.3, p = 0.77,  
d = 0.20* 
   

































6.3.2 Questionnaire Results 
Sensitivity analyses using G*Power for Windows (Faul et al., 2007) indicated that the present 
analyses were powered to detect group difference effect sizes of Cohen’s d = 0.77, at β = 0.8. 
Assessment of substance use between groups using Kruskal-Wallis H tests revealed no 
significant differences in lifetime use, age of first use, current use or frequency of use for alcohol, 









Table 6.8 – Substance use between groups (Means ± SD unless specified otherwise) 
 CVHs 
(n = 20) 
HVHs 
(n = 25) 
HCs 
(n = 23) 
Group Statistics (chi-squares 
for frequency data; Kruskal-
































2.8 ± 0.8 
 
Χ2 = 1.1, p = 0.58,  
v = 0.13, BF10 = 0.2 
Χ2 = 0.51, p = 0.79,  
d = 0.29, BF10 = 0.2 
Χ2 = 2.8, p = 0.25,  
v = 0.21, BF10 = 0.5 
Χ2 = 4.6, p = 0.10,  
































3.2 ± 2.0 
 
Χ2 = 2.3, p = 0.32,  
v = 0.18, BF10 = 0.7 
Χ2 = 1.0, p = 0.60,  
d = 0.24, BF10 = 0.2 
Χ2 = 4.1, p = 0.13,  
v = 0.28, BF10 = 1.7 
Χ2 = 0.8, p = 0.68,  
































2.6 ± 1.7 
 
Χ2 = 2.9, p = 0.24,  
v = 0.21, BF10 = 0.9 
Χ2 = 0.3, p = 0.87,  
d = 0.31, BF10 = 0.2 
Χ2 = 0.3, p = 0.85,  
v = 0.08, BF10 = 0.2 
Χ2 = 0.4, p = 0.83,  
































3.8 ± 4.5 
 
Χ2 = 0.7, p = 0.69,  
v = 0.11, BF10 = 0.4 
Χ2 = 0.6, p = 0.74,  
d = 0.29, BF10 = 0.3 
Χ2 = 0.8, p = 0.67,  
v = 0.17, BF10 = 0.5 
Χ2 = 0.03, p = 0.99,  
d = 0.34, BF10 = 0.3 
 





Kruskal-Wallis H analyses showed significant differences for total DASS scores across groups, as 
well as for Depression, Anxiety and Stress subscales. Specifically, CVHs showed higher levels on 
total DASS scores as well as all subscales compared to both HVHs and HCs, who did not differ 
from each other. Kruskal-Wallis H analysis also showed significantly lower FFMQ scores in CVHs 
compared to both HVHs and HCs, who again did not differ from each other (see Table 6.9).  
Kruskal-Wallis H analyses further identified significant group differences for total endorsed CAPS 
scores. Specifically, CVHs and HVHs endorsed significantly more items than HCs, but did not 
differ from each other. Similarly, the Intrusiveness subscale scores showed significantly lower 
scores for HCs, with no differences between CVHs and HVHs. For Distress and Frequency 
subscales, CVHs had significantly higher scores than HVHs and HCs, and HVHs had significantly 
higher scores than HCs. Groups differed significantly on total and physical abuse scores of the 
SLESQ, but not sexual abuse scores. Paired comparisons showed that CVHs had significantly 
higher scores on total scores compared to HCs, whilst HVHs differed from neither CVHs nor HCs. 
For physical abuse, CVHs had significantly higher scores than both HCs and HVHs, who did not 
significantly differ from each other. Questionnaire results are presented in Table 6.9.  
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Table 6.9 – Questionnaire results (Mean ± SD)    
 CVHs 
(n = 20) 
HVHs 
(n = 25) 
HCs 
(n = 23) 










15.9 ± 6.8 
 
3.1 ± 0.8 
 
3.1 ± 1.0 
 
3.4 ± 0.8 
 
13.4 ± 6.7 
 
2.6 ± 0.9 
 
1.6 ± 0.6 
 
1.7 ± 0.7 
 
2.0 ± 2.8 
 
1.3 ± 0.5 
 
1.3 ± 0.6 
 
1.3 ± 0.6 
 
χ2 = 39.9, p < 0.001,  
d = 2.38, BF10 = 5.8 x 108 
χ2 = 38.4, p < 0.001,  
d = 2.28, BF10 = 3.8 x 107 
χ2 = 36.5, p < 0.001, 
 d = 2.15, BF10 = 4.8 x 108 
χ2 = 40.2, p < 0.001,  
d = 2.41, BF10 = 3.1 x 1011 
 
U = 202, Z = 1.1, p = 0.27,  
d = 0.21, BF10 = 0.5 
U = 180, Z = 1.6, p = 0.11, 
 d = 0.38, BF10 = 0.7 
U = 41, Z = 4.8, p < 0.001,  
d = 1.97, BF10 = 91880.2 
U = 24, Z = 1.6, p < 0.001,  
d = 2.38, BF10 = 5.2 x 106 
 
U = 8, Z = 5.5, p < 0.001,  
d = 2.91, BF10 = 2.3 x 108 
U = 14, Z = 5.4, p < 0.001, 
 d = 2.70, BF10 = 5.4 x 107 
U = 20, Z = 5.3, p < 0.001,  
d = 2.52, BF10 = 1.9 x 106 
U = 11, Z = 5.4, p < 0.001,  
d = 2.80, BF10 = 1.0 x 109 
 
U = 29, Z = 5.4, p < 0.001,  
d = 2.41, BF10 = 7.1 x 106 
U = 37, Z = 5.2, p < 0.001, 
 d = 2.24, BF10 = 92968.7 
U = 180, Z = 2.4, p = 0.02, 
 d = 0.68, BF10 = 0.8 
U = 167, Z = 2.6, p = 0.01, 










53.0 ± 27.3 
 
20.4 ± 12.6 
 
14.7 ± 8.3 
 
18.0 ± 10.3 
 
14.6 ± 16.1 
 
3.1 ± 4.9 
 
3.2 ± 4.7 
 
8.3 ± 7.3 
 
11.8 ± 10.8 
 
3.5 ± 4.2 
 
1.9 ± 2.4 
 
6.3 ± 6.1 
 
χ2 = 29.9, p < 0.001,  
d = 1.77, BF10 = 3.2 x 107 
χ2 = 28.7, p < 0.001,  
d = 1.71, BF10 = 7.8 x 107 
χ2 = 34.7, p < 0.001,  
d = 2.04, BF10 = 1.2 x 108 
χ2 = 17.2, p < 0.001,  
d = 1.04, BF10 = 1014.8 
 
U = 47, Z = 4.6, p < 0.001,  
d = 1.85, BF10 = 21408.7 
U = 45, Z = 4.7, p < 0.001,  
d = 1.89, BF10 = 76829.3 
U = 39, Z = 4.9, p < 0.001,  
d = 2.01, BF10 = 18834.4 
U = 104, Z = 3.4, p = 0.001, 
d = 1.06, BF10 = 45.7 
 
U = 29, Z = 4.9, p < 0.001,  
d = 2.29, BF10 = 202346.0 
U = 43, Z = 4.6, p < 0.001,  
d = 1.99, BF10 = 31163.4 
U = 12, Z = 5.4, p < 0.001,  
d = 2.77, BF10 = 661078.0 
U = 77, Z = 3.8, p < 0.001,  
d = 1.46, BF10 = 436.2 
 
U = 258, Z = 0.4, p = 0.66,  
d = 0.18, BF10 = 0.4 
U = 258, Z = 0.6, p = 0.53,  
d = 0.18, BF10 = 0.3 
U = 260, Z = 0.6, p = 0.56,  
d = 0.16, BF10 = 0.5 
U = 237, Z = 1.1, p = 0.29,  




107.3 ± 17.2 
 
139.3 ± 14.1 
 
135 ± 19.3 
 
χ2 = 26.9, p < 0.001,  
d = 1.16, BF10 = 299171.1 
 
U = 34, Z = 4.9, p < 0.001,  
d = 2.12, BF10 = 430225.2 
 
U = 66, Z = 4.0, p < 0.001,  
d = 1.61, BF10 = 1246.7 
 
U = 254, Z = 0.7, p = 0.48,  









(n = 20) 
HVHs 
(n = 25) 
HCs 
(n = 23) 
Group Statistics CVH vs HVH CVH vs HC HVH vs HC 








5.6 ± 2.2, 100% 
 
1.5 ± 2.2, 55.0% 
 
4.3 ± 2.2, 85.0% 
 
4.7 ± 2.7, 92.0% 
 
0.9 ± 1.7, 36.0% 
 
2.2 ± 2.2, 64.0% 
 
3.2 ± 2.9, 95.7% 
 
0.7 ± 1.3, 34.8% 
 
1.9 ± 2.6, 43.5% 
 
χ2 = 9.0, p = 0.01, 
 d = 0.78, BF10 = 3.1 
χ2 = 2.7, p = 0.26,  
d = 0.41, BF10 = 0.3 
χ2 = 10.7, p = 0.01,  
d = 0.86, BF10 = 8.4 
 
U = 209, Z = 1.0, p = 0.34,  
d = 0.16, BF10 = 0.5 
- 
 
U = 138, Z = 2.6, p = 0.01,  
d = 0.73, BF10 = 6.5 
 
U = 102, Z = 3.1, p = 0.002, 
d = 1.17, BF10 = 10.3 
- 
 
U = 114, Z = 2.9, p = 0.004, 
d = 1.05, BF10 = 9.0 
 
U = 203, Z = 1.8, p = 0.076, 
d = 0.52, BF10 = 1.0 
- 
 
U = 242, Z = 1.0, p = 0.32,  
d = 0.27, BF10 = 0.3 
Note: CAPS = Cardiff Anomalous Perceptions Scale; DASS = Depression Anxiety Stress Scale; FFMQ = Five Facet Mindfulness Questionnaire; SLESQ = Stressful Life Events Screening Questionnaire; bold + 
italics = significant p-value; χ2 = Kruskal-Wallis H test;  d = Cohen’s d; BF = Bayes Factor 
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Comparing AVH parameters between CVHs and HVHs, CVHs had significantly higher scores on 
Frequency, Loudness and Distress subscales of the PSYRATS, but did not differ on the attribution 
subscale. HVHs had a significantly earlier age of onset of AVHs. On the BAVQ-R, CVHs scored 
significantly higher on the Malevolence, Omnipotence and Resistance subscales, and 
significantly lower on the Benevolence and Engagement subscales. On the VPDS, total scores 
(excluding the Harm item) did not differ significantly between the groups. Scores on the Harm 
item (for those participants who endorsed it) were significantly higher for CVHs. AVH-specific 
questionnaire results are showed in Table 6.10. 
Table 6.10 – AVH results (Mean ± SD unless specified otherwise) 
 CVHs 
(n = 20) 
HVHs 











Age of Onset: 
 
7.0 ± 2.0 
 
2.1 ± 0.9 
 
5.3 ± 1.4 
 
16.2 ± 3.8 
 
27.3 ± 11.4 
 
3.3 ± 1.1 
 
1.4 ± 0.8 
 
5.7 ± 1.1 
 
1.5 ± 2.0 
 
15.3 ± 11.2 
 
U = 15, Z = 5.5, p < 0.001,  
d = 2.67, BF10 = 4.0 x 107 
U = 138, Z = 2.8, p = 0.005,  
d = 0.83, BF10 = 4.4 
U = 407, Z = 1.4, p = 0.20,  
d = 1.27, BF10 = 0.5 
U = 1, Z = 5.7, p < 0.001, d = 
3.20, BF10 = 7.3 x 1016 
t (43) = 3.5, p = 0.001,  












16.9 ± 5.3 
 
9.3 ± 3.7 
 
17.2 ± 4.4 
 
28.1 ± 5.7 
 
10.0 ± 2.4 
 
6.2 ± 0.8 
 
19.7 ± 4.9 
 
12.0 ± 3.1 
 
10.4 ± 2.5 
 
25.8 ± 6.0 
 
U = 2, Z = 6.1, p < 0.001,  
d = 3.15, BF10 = 4.7 x 109 
U = 31, Z = 5.0, p < 0.001,  
d = 2.24, BF10 = 1.0 x 107 
t (33) = 4.4, p < 0.001, 
d = 1.32, BF10 = 494.9 
t (25) = 13.9, p < 0.001,  
d = 4.17, BF10 = 1.9 x 1014 
U = 16.5, Z = 5.4, p < 0.001, 




20.2 ± 5.9 
 
19.2 ± 3.5 
 
U = 212, Z = 0.9, p = 0.38,  
d = 0.26, BF10 = 0.4 
Harm Item: 
(% answered) 
100%, 4.1 ± 1.1 44.0%, 2.7 ± 1.1 U = 48, Z = -2.7, p = 0.008,  
d = 1.90, BF10 = 9.9 




6.3.3 Baseline Stress Function 
Hypothesis: CVHs will show significantly higher morning cortisol levels compared to HVHs and 
HCs, who will not differ from each other. 
Sensitivity analyses using G*Power for Windows (Faul et al., 2007) indicated that the present 
analyses were powered to detect group difference effect sizes of Cohen’s d = 0.82, at β = 0.8. 
One-way ANOVA showed that there were no significant differences in awakening time on Day 1 
(F (2, 48) = 1.5, p = 0.23, d = 0.51), or Day 2 (F (2, 55) = 0.3, p = 0.77, d = 0.20), confirming equal 
awakening times across groups (see Table 6.6). However, only 49 out of 64 participants provided 
these data for Day 1, and 56 did so for Day 2. 
One-way ANOVA showed a significant effect of group on morning cortisol levels (F (2, 55) = 4.5, 
p = 0.015, d = 0.81, BF10 = 3.6). Contrary to predictions, pairwise comparisons with FDR-adjusted 
p-values showed that cortisol levels were significantly lower (rather than higher) for CVHs (Mlogn 
= 1.5, SD = 0.2) than for HVHs (Mlogn = 2.4, SD = 0.2; p = 0.02, d = 4.5, BF10 = 4.3), and HCs (Mlogn 
= 2.1, SD = 0.2; p = 0.03, d = 3.0, BF10  = 1.7), who did not differ from each other (p = 0.66, d = 





Figure 6.2 – Logn cortisol levels at awakening by group (mean ± SE) 
Hypothesis: CVHs will show significantly higher diurnal cortisol and α-amylase levels compared 
to HVHs and HCs, who will not differ from each other. 
Sensitivity analyses using G*Power for Windows (Faul et al., 2007) indicated that the present 
analyses were powered to detect effect sizes of Cohen’s d = 0.38 for cortisol and d = 0.36 for α-
amylase, at β = 0.8. 
Repeated-measures ANOVA showed a significant effect of time on cortisol (F (1, 53) = 19.3, p < 
0.001, d = 0.53, BF10 = 231.8), with overall higher scores at the 3pm timepoint compared to the 
8pm timepoint. Contrary to predictions, there was no significant group effect (F (2, 53) = 0.01, p 
= 0.99, d = 0.00, BF10 = 0.17), and no interaction effect with group (F (2, 53) = 2.5, p = 0.09, d = 




























For α-amylase levels over all three time-points, repeated-measures ANCOVA controlling for 
progesterone treatment found a significant effect of timepoint (F (1.5, 85.8) = 4.0, p = 0.03, d = 
0.42, BF10 = 5.1 x 1014), with a general increase over the day (see Figure 6.3). Contrary to 
predictions, there was no significant group effect (F (2, 55) = 0.78, p = 0.46, d = 0.34, BF10 = 0.28), 




Figure 6.3 – Diurnal α-amylase levels (mean ± SE) by group 
 
6.3.4 Dexamethasone Suppression Test 
Hypothesis: CVHs will show significantly less cortisol suppression following dexamethasone 

























Sensitivity analyses using G*Power for Windows (Faul et al., 2007) indicated that the present 
analyses were powered to detect group difference effect sizes of Cramer’s v = 0.41, at β = 0.8.  
Classification of participants into suppressors or non-suppressors showed that a total of 33.9% 
of participants did not respond to the dexamethasone. Specifically, 55.6% of CVHs (n = 10), 
33.3% of HVHs (n = 6), and 15% of HCs (n = 3), were non-suppressors. Likelihood ratio chi-square 
analysis showed this difference to be statistically significant (χ2 = 7.2, p = .03, v = 0.35, BF10 = 
3.5). As predicted, post-hoc analyses using FDR-adjusted p-values revealed that CVHs were 
significantly more likely to be non-suppressors than HCs (χ2 = 7.2, p = .03, d = 0.97, BF10 = 10.6), 
whilst HVHs differed from neither CVHs (χ2 = 1.8, p = .18, d = 0.45, BF10 = 0.9) nor HCs (χ2 = 1.8, 
p = .18, d = 0.45, BF10 = 0.75). Results are presented in Figure 6.3.  
 
























*= CVHs significantly differ from HCs 
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6.3.5 Socially Evaluative Cold Pressor Test 
Sensitivity analyses using G*Power for Windows (Faul et al., 2007) indicated that the present 
analyses were powered to within-between interactions at effect sizes of Cohen’s d = 0.28, at β 
= 0.8. One-way ANOVA showed that there were no significant differences in water temperature 
between groups (F (2, 63) = 0.8, p = 0.46, d = 0.31, BF10 = 0.2), nor did participant groups differ in 
how long they kept their hand in the ice water (F (2, 63) = 1.1, p = 0.35, d = 0.37), confirming 
equal exposure across groups (see Table 6.6). 
 Subjective Response 
Hypothesis: CVHs will show increased anticipatory stress appraisal before exposure and have 
higher subjective stress levels throughout the paradigm, including greater overall levels and 
diminished recovery (measured from Post-SECPT to 15min) compared to HVHs and HCs, who will 
not differ from each other. 
One-way ANOVA showed significant group differences in anticipatory SAM scores prior to the 
task across groups (F (2, 63) = 7.6, p = 0.001, d = 0.39, BF10 = 29.4). As predicted, post-hoc 
comparison with FDR-adjusted p-values showed that this was due to significantly higher SAM 
scores in CVHs (M = 23.2, SD = 1.6) compared to both HVHs (M = 17.1, SD = 1.5, p = 0.009) and 
HCs (M = 15.1, SD = 1.5, p = 0.003), who did not differ from each other (p = 0.35).  
Repeated measures ANOVA suggested a violation of Mauchly’s test of sphericity for VAS scores, 
and therefore the Greenhouse-Geisser statistic was used. This revealed a significant effect of 
timepoint on VAS scores (F (1.9, 118.1) = 4.8, p = 0.01, d = 0.14, BF10 = 292.4), but no significant 
interaction with group (F (3.8, 118.1) = 0.62, p = 0.64, d = 0.04, BFM = 0.03). However, there was 
a significant effect of group on VAS scores (F (2, 63) = 31.7, p < 0.001, d = 1.00, BF10 = 3.2 x 107), 
with post-hoc group comparison with FDR-adjusted p-values showing significantly higher VAS 
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scores in CVHs compared to both HVHs (p = 0.002) and HCs (p = 0.002), but no differences 
between HVHs and HCs (p = 0.66), as predicted.  
In terms of recovery post-SECPT, HVHs (t (24) = 2.5, p = 0.03, d = 0.59, BF10 = 2.3) and HCs (t (22) 
= 3.0, p = 0.02, d = 0.46, BF10 = 7.1) showed a significant decrease in VAS scores from Post-SECPT 
to 15min, which was not observed in CVHs (t (19) = 0.2, p = 0.86, d = 0.06, BF10 = 0.2). FDR-
adjusted p-values are reported. Subjective stress results are presented in Figure 6.5. 
 
 



































*= CVHs significantly differ from HVHs & HCs; **= Significant change within HVHs & HCs
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 Cortisol Response 
Hypothesis: CVHs will show overall higher cortisol levels, coupled with a blunted cortisol response 
(indicated by blunted increase from post-SECPT to 15min) to the SECPT compared to HVHs and 
HCs, who will not differ from each other. 
Repeated measures ANCOVA, controlling for oral contraceptives (progesterone), also suggested 
a violation of Mauchly’s test of sphericity for cortisol, and therefore the Greenhouse-Geisser 
statistic was used. This revealed a significant effect of timepoint on cortisol levels (F (3.1, 191.8) 
= 15.9, p < 0.001, d = 0.41, BF10 = 4.0 x 1012), as well as a significant interaction with group (F 
(6.3, 191.8) = 2.8, p = 0.01, d = 0.17, BFM = 8.4). Test of between-participants effects showed 
trend-level significance (F (2, 61) = 2.88, p = 0.064, d = 0.61, BF10 = 1.6). Pairwise comparison 
showed that, as predicted, CVHs had trend-level higher cortisol levels than HVHs (p = 0.07), 
however, contrary to predictions they did not differ from HCs (p = 0.97). Unexpectedly, HVHs 
also showed trend-level lower cortisol levels than HCs (p = 0.07). Lower order ANOVAs with FDR-
adjusted post-hoc comparison revealed significant group differences at Baseline (F(2, 63) = 5.0, 
p = 0.02, d = 0.28, BF10 = 5.2; CVH vs HVH: p= 0.01, CVHs vs HC: p= 0.50, HVH vs HC: p= 0.04); 
Pre-SECPT (F(2, 63) = 5.1, p = 0.02, d = 0.28, BF10 = 5.3;  CVH vs HVH: p= 0.01, CVHs vs HC: p= 
0.50, HVH vs HC: p = 0.04), and 0min Post-SECPT (F(2, 63) = 5.1, p = 0.02, d = 0.28, BF10 = 5.5; 
CVH vs HVH: p= 0.01, CVHs vs HC: p = 0.51, HVH vs HC: p = 0.04), with lower cortisol in HVHs 
compared to both CVHs and HCs, who did not differ from each other.  
To assess blunting of the peak cortisol response, repeated measures ANCOVA controlling for 
progesterone revealed a significant effect for time point on cortisol levels (F (1, 62) = 19.0, p < 
0.001, d = 1.11, BF10 = 343.1), with a trend-effect effect of group on cortisol (F (2, 62) = 2.7, p = 
0.08, d = 0.59, BF10 = 1.4), and a significant interaction effect of group and time point on cortisol 
(F (2, 62) = 4.2, p = 0.02, d = 0.74, BFM = 5.2). Post-hoc paired-samples t-test within groups with 
FDR-adjusted p-values were carried out from pre-SECPT to 15min post-SECPT (i.e., peak cortisol 
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response), revealing that, as predicted, there was no significant change in cortisol levels in CVHs 
(t (19) = 0.5, p = 0.61, d = 0.03, BF10 = 0.2), whilst cortisol levels increased significantly in HVHs (t 
(22) = 3.0, p = 0.009, d = 0.48, BF10 = 9.0) and HCs (t(22) = 3.6, p = 0.006, d = 0.63, BF10 = 29.5).  
Although no specific hypothesises were made regarding recovery rates, visual inspection further 
suggested differential recovery rates between time points 15min and 45min between HVHs and 
HCs. Paired-samples t-test within groups were carried out from 15min and 30min, and 30min 
and 45min post-SECPT within HVHs and HCs. HVHs showed no significant change in cortisol 
levels at 15min-30min (t (22) = 0.9, p = 0.37, d = 0.07, BF10 = 0.3), whilst their cortisol levels 
decreased significantly at 30min-45min (t (22) = 3.4, p = 0.008, d = 0.33, BF10 = 19.5). HCs showed 
a significant decrease in cortisol levels at 15min-30min (t (22) = 2.6, p = 0.04, d = 0.46, BF10 = 
3.4), whilst cortisol levels did not change at 30min-45min (t (22) = 1.3, p = 0.29, d = 0.16, BF10 = 
0.4). FDR-adjusted p-values are reported. Cortisol levels during the SECPT are presented in 
Figure 6.6.  
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Figure 6.6 – Logn cortisol values by group by timepoint (mean ± SE) 
 
 α-Amylase Response 
Hypothesis: CVHs will show an exacerbated α-amylase response to the SECPT (from pre-
SECPT to post-SECPT) compared to HVHs and HCs, who will not differ from each other. 
Repeated measures ANCOVA, controlling for menstrual cycle, also suggested a violation 
of Mauchly’s test of sphericity for α-amylase, and therefore the Greenhouse-Geisser statistic 
was used. This revealed no significant effects for timepoint on α-amylase levels (F (4.0, 244.4) = 
0.7, p = 0.60, d = 0.24, BF10 = 0.02), nor was there an interaction with group (F (8.0, 244.4) = 0.8, 
p = 0.63, d = 0.19, BFM = 4.0 x 10-4). Test of between-participants effects showed no significant 
effect of group on α-amylase level (F (2, 61) = 0.1, p = 0.87, d = 0.01, BF10 = 0.4).  Similarly, 
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effect for time point on α-amylase levels (F (1, 61) = 1.2, p = 0.27, d = 1.00, BF10 = 0.5), no effect 
of group on α-amylase (F (2, 61) = 0.2, p = 0.79, d = 0.18, BF10 = 0.6), and no interaction effect of 
group and time point on α-amylase (F (2, 61) = 0.97, p = 0.38, d = 0.36, BFM = 0.1). α-Amylase 
levels during the SECPT are presented in Figure 6.7. 
Figure 6.7 – Logn α-amylase values by group by timepoint (mean ± SE) 
 
6.4 Discussion 
6.4.1 Findings  
The present study is, to our knowledge, the first to report several alterations of 
psychophysiological stress-functions specific to AVHs and need for care. The overall hypotheses 
were partially supported: there were significant differences on some, but not all, parameters 
between CVHs, and HVHs and HCs, although the differences found were not always in the 
































results emerged, including increased rates of dexamethasone non-response in HVHs, and lower 
cortisol levels during the SECPT.  
 Contrary to the hypothesis, CVHs showed lower, rather than higher, awakening cortisol levels 
than both HVHs and HCs, who did not differ from each other. This finding contradicts the meta-
analysis finding of exacerbated awakening cortisol levels in schizophrenia (Girshkin et al., 2014). 
However, that meta-analysis also found lower effect sizes in medicated compared to 
unmedicated patients, and in outpatients compared to inpatients; in addition, several other 
studies have reported a blunted cortisol awakening response in psychosis patients (Braehler et 
al., 2005; Mondelli et al., 2010, 2015; Monteleone et al., 2014;Pruessner, Cullen, Aasand Walker, 
2017). Similarly, contrary to our hypotheses, no significant group differences for diurnal cortisol 
and α-amylase were found. The increased diurnal cortisol levels reported in schizophrenia 
(Pruessner et al., 2017), as well as increased α-amylase levels reported in other studies (Ieda et 
al., 2014; Inagaki et al., 2010), were not observed in the present clinical population. The 
seemingly normative baseline cortisol levels in CVHs may be a consequence of antipsychotic 
medications (Pruessner et al., 2017), as increased baseline cortisol is primarily observed in 
medication-naïve psychosis populations (Gunduz-Bruce et al., 2007; Mondelli et al., 2010). 
Indeed, this may explain why overall cortisol levels in CVHs did not differ compared to HCs, whilst 
functional GR impairments, discussed below, were much more prevalent. Further, the fact that 
the clinical population consisted of voice-hearers across diagnostic boundaries may be another 
reason for differences to studies with samples conducted in schizophrenia patients. The α-
amylase levels in CVHs were somewhat surprising, and may partially suggest that stress 
physiology alterations in CVHs are specific to the HPA axis, but not the ANS.  
As hypothesised, CVHs showed greater rates of dexamethasone non-suppression than HCs, at 
rates congruent with the evidence from systematic reviews (Bradley and Dinan, 2010; Yeragani, 
1990). Unexpectedly, however, the findings on dexamethasone non-suppression rates suggest 
that HVHs may form a middle point between CVHs and HCs in terms on their GR-function. This 
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pattern is similar to that of the prevalence of stressful life events in the present study, where 
CVHs showed significantly higher rates than HCs, but HVHs did not differ from either group, and 
previous studies have implicated adversity exposure in DST non-response (Carpenter et al., 
2009). Thus, the partial evidence for impaired GR-function in HVHs may also be related to 
adversity exposure in this population.  
As hypothesised, subjective stress response to the SECPT differed significantly between groups, 
with higher anticipatory stress appraisals and subjective stress levels in CVHs throughout. 
Furthermore, they appeared to show no subjective reaction to the SECPT, whereas subjective 
stress levels in HVHs and HCs decreased following exposure. CVHs also showed similar overall 
cortisol levels to HCs during the SECPT, yet failed to show the increase in cortisol secretion in 
response to the stressor, as was observed in HVHs and HCs. This blunted stress response is in 
line with our hypotheses, as well as with previous meta-analytic evidence in psychosis 
populations (Ciufolini et al., 2014) and mirrors the one existing study applying the SECPT to a 
psychosis population (Rubio et al., 2015). However, the hypothesis of exacerbated α-amylase 
response in CVHs was not supported, with no significant group differences observed. These 
findings suggest that most HPA-alterations observed in psychosis are also specifically observed 
in CVHs, whereas the ANS marker utilised here showed no such effects.  
An intriguing finding was that HVHs showed lower total cortisol levels during the SECPT than 
both HCs and CVHs, especially during the initial phases of the SECPT paradigm. Whilst this was 
not mirrored in their diurnal cortisol levels, this finding nonetheless requires future 
investigation. There are several studies reporting that childhood (Carpenter et al., 2007; 
Carpenter, Shattuck, Tyrka, Geracioti, and Price, 2011; Voellmin et al., 2015) as well as lifetime 
adverse events in healthy individuals (Elzinga et al., 2008; Lovallo, Farag, Sorocco, Cohoon, and 
Vincent, 2012) are associated with similar HPA stress-reactivity patterns (i.e., reduced cortisol 
levels in stress paradigms) as those observed in the HVHs in this study. Interestingly, these 
differences in HPA-activity are independent of subjective stress levels (Voellmin et al., 2015). As 
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reviewed in Chapters 2 and 4, HVHs have been found to report greater levels of trauma exposure 
than HCs, and although this difference failed to reach significance in the present study, it may 
be the most likely explanation for the present finding. It remains unclear whether these HPA 
alterations (i.e., lower cortisol levels in stress paradigms) constitute a risk factor for the future 
development of stress-related pathology, or if the decreased HPA activity of trauma-exposed 
individuals in psychosocial stress paradigms is in fact indicative of resilience (Voellmin et al., 
2015). Supporting the resilience hypothesis, the adversity-exposed individuals in these studies, 
as well as the present study, have no mental health disorders despite trauma exposure. 
Conversely, Chapter 2 presented evidence of greater risk for mental disorders in HVHs, and the 
observed HPA-reactivity pattern, as well as the finding on potentially decreased GR function, 
may partially underlie this vulnerability. Perhaps higher rates of DST non-suppression are also 
mirrored by the SECPT results, where HVHs showed a slower recovery than HCs, suggesting 
slower negative feedback in HVHs compared to HCs. Like HCs however, and unlike CVHs, they 
showed a normative cortisol increase in response to the stress exposure.  
As would be expected, group comparisons on questionnaires showed significantly greater 
depression, anxiety and stress scores in CVHs compared with HVHs and HCs, who did not differ 
from each other. CVHs also scored lower on trait mindfulness than both HVHs and HCs, in line 
with previous findings on less mindful voice appraisals in CVH (Peters et al., 2016). CVHs were 
significantly more likely to have a low SES (indicated by current employment and educational 
attainments), and were more likely to be socially isolated (as indicated by cohabitation and 
relationship status).  CVHs reported significantly higher rates of total stressful life events than 
HCs, whereas HVHs did not differ from either HCs or CVHs.  For physical abuse CVHs reported 
significantly higher rates than both HVHs and HCs, who did not differ from each other. 
Surprisingly, the three sample populations did not differ on any parameters related to substance 
use, and all showed high rates of exposures to cannabis and amphetamines. Potentially, the 
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recruitment of participant groups from the urban South London environment, where illicit 
substances may be more readily available than e.g., rural areas, may explain these high rates. 
CVHs and HVHs did not differ in the total anomalous experiences they endorsed on the CAPS, or 
their intrusiveness, with higher scores in both CVHs and HVHs than in HCs. However, for 
frequency and distressing impact of anomalous experiences, CVHs scored significantly higher 
than HVHs, who in turn scored significantly higher than HCs. AVH-specific parameters also 
differed between CVHs and HVHs, with CVHs showing greater loudness, frequency and distress 
on the PSYRATS, and later age of onset than HVHs, yet no differences in attribution. CVHs also 
reported more maladaptive beliefs about and responses to their voices, as indicated by higher 
malevolence, omnipotence and resistance BAVQ-R scores, and lower benevolence and 
engagement scores. Furthermore, whilst overall VPDS scores did not differ, CVHs were more 
likely to perceive their voice as being able to harm them. These findings are broadly in line with 
the systematic review presented in Chapter 2. 
6.4.2 Strengths and Limitations 
There are several key strengths to the present study. To the best of the author’s knowledge, this 
is the first study to characterise HPA-alterations specifically in voice-hearers with and without a 
need for care. Further, this is the first study to characterise the stress-function of HVHs in 
relation to HCs and CVHs, thus allowing for specific evaluation of the role of stress-function in 
need for care. Further, very detailed assessments of psychophysiological stress-function were 
undertaken, and the study employed a symptom-focused design, in line with recent suggestions 
that this leads to more precise, valid and transferable research findings (Insel et al., 2010).  
Moreover, several efforts were also undertaken to ensure validity of findings and pre-empt 
confounds. There is well documented evidence for lower pain sensitivity in schizophrenia 
patients (Stubbs et al., 2015), which could potentially impact the stress response during the 
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SECPT. However, the inclusion of a social stress component in the present paradigm meant that 
the stressor was not exclusively pain-dependent. Furthermore, study analyses showed no 
significant differences in the time CVHs could endure the ice water, suggesting that differential 
pain sensitivity did not affect the results. Finally, in addition to classical frequentist statistical 
methods, sensitivity analyses and reporting of effect sizes as well as Bayesian statistics were 
carried out. Thus, it is possible to assess the power of the present design, and evaluate the 
magnitude of effects and reliability of statistical results with more detail and confidence. 
However, there were also several limitations. It was not possible to measure dexamethasone 
levels following administration. Nevertheless, Cassidy et al. (2000) showed that the use of a 
wider time window including several sampling time points over the day minimised confounding 
risk and meant it was not necessary to measure variance in dexamethasone levels directly. Prior 
studies have similarly not measured dexamethasone levels (Coryell, Fiedorowicz, Zimmerman, 
and Young, 2008; Fries et al., 2014; Thompson et al., 2007), giving confidence that the present 
design was able to detect differences accurately. Similarly, it was attempted to assess for 
potential effects of different awakening times across groups. Whilst the data indicated no such 
differences, the self-report at home was nonetheless patchy and not all participants recorded 
their awakening time. 
Sample characteristics suggest at least partial matching, including for age and ethnicity, but not 
for gender, the confounding effect of which cannot be ruled out. Sample sizes further slightly 
differed between groups and stress measures, potentially leading to some statistical noise in the 
present findings. All CVHs in the present study were medicated, with second generation 
antipsychotic and clozapine treatment in 85% of CVHs. As noted in the literature on psychosis 
and HPA-function (Pruessner et al., 2017), antipsychotic medications, particularly atypical 
antipsychotics, impact on cortisol levels. Thus, it is possible that some of the findings on HPA-
function in CVHs in the present study, particularly those concerning overall cortisol levels and 
SECPT reaction, were skewed by antipsychotic treatment, and may not be specific to AVHs or 
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need for care. Due to the small sample size of this study, it was not possible to covary for the 
effect of medication use, or other potential confounders such as gender or BMI. 
Whilst efforts were made to characterise the study samples on several relevant variables 
identified by Chapter 3, Chapter 4 and Chapter 5, such as substance misuse, beliefs about voices 
and life events, the potential moderating and/or mediating effects of these variables could not 
be explored. Due to the limited sample size, it was not possible to apply more complex statistical 
procedures that could reveal structural relationships between such variables and the stress 
parameters assessed. Such analyses may have clarified some of present findings, most notably 
the reasons behind the lower overall cortisol levels in HVHs during the SECPT, which can 
presently only be speculated about. Further, the small sample sizes limit the interpretability of 
study findings and their relation to the extant literature. For example, the role of trauma 
exposure is likely to affect the relationship between need for care, AVHs and stress measures in 
the present study, however it was not possible to test for such an effect with adequate power. 
The lack of plasma biomarker data in the present study meant it was not impossible to assess 
the association of cortisol in blood and saliva to determine a study-specific cut-off value for 
classifying dexamethasone non-suppressors. In relation to this, the home sampling procedures 
utilised in the present project may be suboptimal in ensuring compliance with saliva sampling 
procedures, which has been shown to impact sample quality in previous research (Broderick et 
al., 2004). However, several steps were undertaken to maximise compliance, including reminder 
phone calls, careful and repeated instructions, the use of a time window the DST as well as 
exclusion of outliers in the statistical analyses.  
By only considering the salivary markers cortisol, for the HPA axis, and a-amylase, for the 
autonomic nervous system, the assessment of stress-function in the present study was limited. 
Especially a-amylase, a somewhat novel marker that has not yet been fully characterised yet 
(Nater et al., 2006; Rohleder et al., 2004), may not be sufficient to investigate ANS function 
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comprehensively. Rather, heart rate variability, respiratory rate and/or plasma adrenaline 
measurements would be necessary to get a more complete picture of ANS function specific to 
AVHs and need for care. Similarly, whilst great care was undertaken do assess different aspects 
of HPA activity, including morning and baseline activity, stimulated activity and negative 
feedback capacity, all of these measures have their limitations. Previous studies have used 
higher numbers of samples to assess diurnal cortisol patterns, and often sampled for several 
days to decrease the impact of outlier data. Some studies have further utilised 24h-urine 
measurements of cortisol, or hair cortisol, for more accurate assessments of short- and long-
term cortisol secretion. Similarly, the cortisol awakening response is often characterised using 
several sampling time points over the first hour post-awakening. Further, whilst the 
dexamethasone suppression test is suggestive of impaired GR feedback, the molecular 
mechanisms remain unclear unless other assessments, such as genetic and epigenetic 
investigations, are also undertaken. 
6.4.3 Implications and Future Directions 
Several important clinical and research implications can be drawn from the present study. First, 
the present data suggest that stress-function differs depending on the need for care of voice-
hearers. Future longitudinal research is needed to assess whether the stress response is a 
marker of resilience in HVHs. The lower cortisol levels of HVHs during the SECPT could be related 
to wider stress resilience of the HPA axis, which could explain the non-clinical status. Further, it 
should be evaluated to which degree a change in need for care, i.e., therapeutic response to 
psychological or pharmacological treatments, is also associated with normalisation of stress-
function. In depression, there is evidence that GR function is normalised through antidepressant 
treatments (Anacker et al., 2011), and early evidence in PTSD suggests normalisation of FKBP5 
mRNA expression is associated with treatment response to CBT (Levy-Gigi, Szabó, Kelemen, and 
Kéri, 2013).  Potentially, treatment approaches that alleviate voice-distress subjectively may 
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partially do so through physiological adaptations. The present evidence suggests that 
antipsychotic medication alone is not sufficient to restore GR function.  
Second, there is some evidence to suggest the DST could be valuable as a risk assessment tool 
in populations presenting with AVHs. To explore this potential, future longitudinal research 
should assess GR-function in at-risk populations as well as adolescent samples presenting with 
AVHs, and determine whether impaired GR-function is a predictor of later need for care. 
Notably, previous research in depression has suggested that the presence of childhood 
traumatic experiences may skew Dex/CRH test specificity and diminish its potential as a 
biomarker to identify depressed endophenotypes, despite being initially hailed as such 
(Carpenter, Ross, et al., 2009). Given that the gradients of adversity exposure (CVH > HVH > HC) 
are similar to that of dexamethasone non-response (CVH > HVH > HC), a similar effect could 
apply here. To assess this, future research should obtain larger sample sizes as well as more 
comprehensive HPA and adversity exposure assessments. Similarly, the confounding effects of 
antipsychotic treatment on HPA-function, particularly baseline cortisol and acute reactivity, can 
only be controlled for through the recruitment of medication-naïve or at least currently 
unmedicated CVH participants. 
Third, a more comprehensive HPA assessment in CVHs and HVHs is needed to outline the 
functional and aetiological implications of the present research. Genetic risk alleles related to 
HPA function, and their interactions with and modulation by early life adversity, e.g., through 
epigenetic adaptations, are implicated in aberrant HPA activity as well as schizophrenia 
(Daskalakis and Binder, 2015; Palma-Gudiel, Córdova-Palomera, Leza, and Fañanás, 2015; 
Sinclair, Fullerton, Webster, and Weickert, 2012). Several genes related to GR function, including 
N3RC1, the glucocorticoid receptor gene, and its promoter regions, as well as FKBP5, the 
chaperone protein that binds cytosolic GR and modulates transportation to the nucleus, are 
valuable markers to understand both GR function as well as patterns of HPA-reactivity 
(Daskalakis and Binder, 2015; Palma-Gudiel et al., 2015; Sinclair et al., 2012). Given the strong 
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association of AVHs with adversity exposure, as well as the evidence of HPA dysregulation 
presented here, these molecular markers should be investigated further in relation to AVHs and 
need for care. Similarly, more detailed analyses of functional HPA and ANS alterations should be 
undertaken to further increase a) the confidence in the present findings and b) the knowledge 
about functional relationships between individual assessments, e.g. GR function and acute 
reactivity. This could include: a) more detailed assessment of subjective and physiological stress-
reactivity through the use of more psychosocial (e.g., Montreal Imaging Stress Test; Dedovic et 
al., 2005) or more physiological (e.g., CO2 challenge; van Duinen, Schruers, Maes, and Griez, 
2005) stressors, b) the use of more sampling time points and days to decrease statistical noise, 
c) the assessment of more long-term HPA-function including hair and 24h-urine cortisol, and d) 
more detailed assessment of ANS function including respiratory rate, heart rate variability and 
plasma adrenaline. The collection of such data in large samples could, in combination with 
psychosocial interview assessments as those carried out here, lead to the ability to use more 
complex statistical methods, e.g., structural equation models, that can help inform about the 
precise interrelationships of psychological and physiological stress-function.  
Fourth, the association of specific HPA-activity patterns with other biomarkers implicated in 
need for care need to be investigated. The dopamine hypothesis proposes that elevated 
dopaminergic activity in the striatum underlies aberrant salience of unwarranted stimuli and 
associations between such stimuli, which then causes the formation of delusional explanations 
and beliefs (Howes and Kapur, 2009; Kambeitz, Abi-Dargham, Kapur, and Howes, 2014). As 
demonstrated by Howes et al. (2013), HVHs do not present with the upregulated dopamine 
synthesis capacity seen in psychosis patients. The mesolimbic dopamine system is highly 
responsive to glucocorticoid secretion (Marinelli and Piazza, 2002), and several studies have 
demonstrated that acute psychosocial stress leads to increased regional dopamine signalling 
(Hernaus et al., 2015; Mizrahi et al., 2014; Nagano-Saito et al., 2013; Pruessner, Champagne, 
Meaney, and Dagher, 2004; Vaessen, Hernaus, Myin-Germeys, and van Amelsvoort, 2015). 
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Interestingly, Mizrahi et al. (2012) have reported that medication-naïve schizophrenia patients 
and individuals at clinical high-risk have significantly greater dopaminergic responses to 
psychosocial stress than healthy controls. Investigating the stress-dopamine link in CVHs and 
HVHs may further explain pathophysiological adaptations associated with need for care, the link 
between AVHs and delusional ideation, as well as the impact such a link may have on 
psychological sequelae, such as beliefs about voices. Indeed, perhaps the most difficult task for 
future research will be to integrate psychological and physiological findings. For some ANS 
markers, such as HRV, a clear link to emotion regulation has been demonstrated (Holzman and 
Bridgett, 2017). Future research should assess to which degree psychological differences in CVHs 
and HVHs, such as cognitive responses to and appraisals of voices are related to stress 
physiology. For example, CVHs undergoing cognitive behavioural therapy could be assessed on 
stress biomarkers as well as key psychological variables, to then investigate whether markers 
correlate in their treatment response.  
6.4.4 Conclusions  
The present study demonstrates significant alterations to the stress physiology of clinical and 
healthy voice-hearers, with significant differences depending on need for care. Specifically, our 
research is the first to demonstrate that HPA-function is specifically implicated in the 
pathophysiology of CVHs. However, against our expectations, HVHs showed HPA-patterns 
divergent from HCs, raising the interesting possibility of specific resilience markers. Activity of 
the ANS has not been implicated in the present study. Future research needs to be undertaken 
to explore the functional, psychological, aetiological and predictive implications of these findings 




Chapter 7 – Discussion 
7.1 Findings 
The present doctoral project revealed several key findings to add to the extant literature on 
auditory verbal hallucinations (AVHs), psychosis and stress, presented in Table 7.1. 
In Chapter 4, the potential developmental impact of adversity exposure on need for care was 
evaluated in the context of a 3-Hit conceptualisation (Daskalakis et al., 2013). The findings 
provided evidence for differential adversity exposure in CVHs and HVHs in adolescence and 
adulthood (Hit 3), as well as greater familial risk (Hit 1). In line with the hypotheses, HVHs and 
CVHs did not differ in adversity exposure in childhood (Hit 2). However, CVHs were more likely 
than HVHs to have fewer years in education, and more exposure to cannabis and other 
substance use. Contrary to expectations, victimisation and discrimination experiences in Hit 3 
did not differ between the groups, suggesting that developmental timing and repeated 
victimisation exposure may be less important in leading to a need for care than exposure to 
different, or specific, types of adversity. Unlike previous findings (van Lutterveld et al., 2014), 
CVHs were more likely to have family members with a history of psychosis, although history of 
other disorders did not differ between CVHs and HVHs. Family history of psychosis, fewer years 
in education, and non-cannabis substance use predicted perceived stress after controlling for 
group, suggesting that several of the specific types of adversity that CVHs are more exposed to 
are also those driving perceived stress. Thus, this study extended the existing evidence on 
familial risk and adversity exposure in CVHs and HVHs detailed in Chapter 2, identified key 
variables that differentiate CVHs and HVHs, and therefore AVHs and need for care, and may 
contribute to the stress-sensitivity of CVHs.  
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Table 7.1 – Key findings of each experimental study 
Chapter Key Findings 
Chapter 4 - Need for care, adversity 
exposure and perceived stress in clinical and 
healthy voice-hearers 
• The 3-Hit model is a useful framework within which to assess the impact of adversity on need for 
care in voice-hearers  
• Victimisation and discrimination exposure do not differ significantly in CVHs and HVHs, in 
childhood (Hit 2) or adolescence/adulthood (Hit 3), neither do childhood socio-economic status 
or family history of non-psychotic mental disorders 
• Substance misuse and years in education, as well as family history of psychosis, differ significantly 
between CVHs and HVHs  
• These variables are predictive of perceived stress after controlling for group 
 
Chapter 5 - The effects of voice content and 
mindful appraisals on stress-reactivity in a 
voice analogue study 
• Voice content may be a crucial driver of differential, subjective stress-reactivity in CVHs and HVHs 
• Voice content does not seem to impact on salivary stress markers 
• Mindful appraisals of voices are associated with a lessened stress response, although negative 
content also decreased mindful appraisals 
 
Chapter 6 - Psychophysiological Stress-
Function in Clinical and Healthy Voice-
hearers 
• CVHs have a diminished, rather than an increased, awakening cortisol response compared to 
both HVHs and HCs, who do not differ from each other 
• Basal cortisol levels do not differ between groups 
• CVHs show a significantly blunted dexamethasone response compared to HCs, whereas HVHs 
seem to form a middle point between the groups 
• CVHs show greater subjective stress levels throughout the SECPT, greater anticipatory stress 
appraisals, and greater perceived stress levels in the previous week, than HVHs and HCs, who do 
not differ from each other 
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Chapter Key Findings 
• CVHs have a blunted cortisol response to the SECPT, while HVHs showed the same response as 
HCs 
• HVHs have a normative HPA response, but lower cortisol throughout the SECPT, than both CVHs 
and HVs 
• CVHs, HVHs and HCs do not differ on diurnal or SECPT-stimulated α-amylase levels 
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Chapter 5 investigated whether negative voice content between CVHs and HVHs exacerbate 
stress-reactivity in an analogue study using simulated voices in healthy individuals with no AVHs. 
For this purpose, a novel voice simulation paradigm was developed, utilising the reports of 
clinicians and voice-hearers to establish valid and reliable stimuli, as well as precise matching of 
word frequencies, narrators and timing of voices across conditions with different voice content. 
Negative simulated voices exacerbated the subjective stress response to the Montreal Imaging 
Stress Task compared to neutral voices and ambient sounds, which did not differ from each 
other. However, there was no effect of voice-content on cortisol or α-amylase levels. There are 
two potential reasons for these discrepant findings. First, it is feasible that voice-content is 
unrelated to potential differences in HPA- and ANS-function of HVHs and CVHs. Alternatively, it 
is possible that the subjective stress response has subtler and more sensitive gradings than the 
physiological response. Nonetheless, the large effect of negative voice content on the subjective 
stress response may drive differential stress-reactivity in CVHs, compared to HVHs. Consistent 
with evidence from trials of mindfulness for clinical voice-hearers, which showed reduced voice 
distress following therapy (Chadwick et al., 2016, 2009; López-Navarro et al., 2015; Shawyer et 
al., 2007), a mindful stance towards the voices during the paradigm was associated with lower 
subjective stress levels. However, exposure to negative voice content was in turn related to 
lower mindfulness, suggesting that the capacity for mindful voice-appraisals may be diminished 
by negative voice content. Building on the evidence identified in Chapter 2, this study provides 
experimental evidence to show that voice-hearing in itself may not be problematic; rather it is 
the negative voice content that leads to pathological outcomes, such as increased subjective 
stress and reduced capacity for mindful voice-appraisals, and may therefore drive need for care. 
Finally, Chapter 6 investigated the role of psychophysiological stress-function in the impact of 
AVHs on need for care. As reviewed in Chapter 3, there is substantial evidence to suggest that 
psychosis is closely linked with stress-exposure, -reactivity and -physiology. Childhood trauma 
193 
 
elevates psychosis risk and sensitises to stress exposure in later life.  Both major branches of the 
physiological stress system appear altered in psychosis patients (Montaquila et al., 2015; 
Pruessner et al., 2017), suggesting that subjective changes in stress-function are accompanied 
by allostatic load. However, despite the evidence on childhood trauma and AVHs, as well as 
childhood trauma and dysregulated stress-function, stress-function has not been investigated in 
voice-hearers specifically.  
To address this gap, CVHs, HVHs and HCs were compared on key measures identified by the 
psychosis stress literature reviewed in Chapter 3. This comprehensive assessment of 
psychophysiological stress-function included basal and stimulated hypothalamic-pituitary-
adrenal (HPA) and autonomic nervous system (ANS; assessed via α-amylase) activity, and 
subjective stress levels. Further, key variables identified in Chapter 2 and Chapter 3 were 
assessed, including voice phenomenology, beliefs about voices, mood disturbance, trait 
mindfulness, substance use, and exposure to stressful life events. Group differences on voice 
phenomenology, mood disturbances, trait mindfulness, anomalous experiences and exposure 
to stressful life events were broadly in line with the literature reviewed in Chapter 2 and findings 
from Chapter 4, although substance use did not differ between groups.  
Compared to both HVHs and healthy controls (HCs), CVHs showed diminished awakening 
cortisol levels as well as impaired negative HPA feedback capacity, as assessed by the 
Dexamethasone Suppression Test. Furthermore, they reported significantly greater subjective 
stress levels throughout the Socially Evaluative Cold Pressor Test (SECPT), greater anticipatory 
stress appraisals, and greater perceived stress levels in the week before assessment than the 
other two groups, who did not differ from each other. Unlike HVHs and HCs, the CVHs also 
showed a blunted cortisol response to the SECPT. Unexpectedly, HVHs showed significantly 
lower cortisol levels than both CVHs and HCs throughout the task, while they were in between 
the other two groups in terms of their negative HPA feedback capacity. No significant group 
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differences were found for basal diurnal cortisol or α-amylase, or SECPT α-amylase response. 
Thus, study indices of HPA-function but not ANS-function in CVHs is congruent with findings 
reported in the wider stress and psychosis literature presented in Chapter 3, and may contribute 
to differential need for care of CVHs and HVHs. Indeed, it may be possible that the lower cortisol 
levels in HVHs during the SECPT hint towards a resilience mechanism in this population. 
7.2 Strengths and Limitations 
The present project had several key strengths. First, the individual studies presented here are 
novel in their contribution to the field of stress research in the psychosis continuum. Second, 
the thesis employed a symptom-focussed approach, thereby ensuring that findings apply 
specifically to AVHs and help understand this particular symptom, as opposed to previous 
research that relied on the diagnostic schizophrenia classification combining different symptoms 
and experiences. Third, the research utilised HVHs as a comparison population; they are unique 
in the potential to help research determine whether findings in CVHs relate to the experience 
of AVHs, or need for care. Fourth, a range of methodological approaches were undertaken, 
including cross-sectional and experimental paradigms, as well as self-report and physiological 
measures. Whilst the studies comparing HVHs and CVHs thus allowed for direct testing in target 
populations, the use of an experimental paradigm provides a way to test the theoretical 
implications voice content may have in stress-reactivity, which cannot be tested otherwise. 
Similarly, the use of biological and psychological measures, as well as measures of social 
adversity, provides a way to integrate and compare the stress research data in the context of a 
biopsychosocial framework. Last, for all data chapters sensitivity analyses and reporting of effect 
sizes as well as Bayesian statistics were carried out, in addition to classical frequentist statistical 
methods. This strategy made it possible to assess the power of the studies, and evaluate the 




However, there are also several limitations to the studies reported in this thesis. Notably, due 
to the time and budgetary restraints of a doctoral thesis, few of the studies presented here were 
carried out with designs that allow for inference of causal relationships. All studies consist 
entirely of cross-sectional research. Whilst some of the literature presented in Chapter 3, most 
notably that on childhood trauma, suggests that adversity exposure increases psychosis risk, it 
remains impossible to assess whether the identified factors, such as voice content, differential 
adversity exposure or altered stress physiology, are simply epiphenomena of pathology. 
Similarly, small sample sizes may have contributed to some of the inconsistent findings between 
individual chapters, most notably the divergent findings on substance misuse in Chapter 4 and 
Chapter 6, as well as the findings of increased familial risk in HVHs reported on in Chapter 2 and 
not replicated in Chapter 4. This smaller sample size may have further confounded the ability of 
the present study to generalise the findings to wider, more divergent voice-hearer populations 
(e.g., medication-naïve CVHs), and likely decreased the power to adequately covary for 
confounding variables. 
Further limitations are related to the validity of several measures and experimental methods. In 
Chapter 4, several variables, including substance misuse and socioeconomic status, as well as 
genetic loading, lacked the detail of the adversity exposure assessment. Specifically, the validity 
of the proxies for socioeconomic status and genetic loading may have suboptimal measurement 
validity, whilst age ranges were not available for substance use. The voice simulation utilised in 
Chapter 5 necessarily only approximates the experience voice-hearers may have, but is unlikely 
to lead to the same impact or appraisals as in actual voice-hearers. Similarly, the stress tasks in 
both Chapters 5 and 6 are laboratory stressors, which, whilst effective in eliciting 
psychophysiological responses, are unlikely to reflect stressful experiences commonly 
experienced in daily life of psychosis patients. Particularly interpretation of SECPT findings is 
affected by this ecological limitation. Further, whilst dexamethasone response does reflect GR-
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responsiveness, HPA activity also involves activity of the mineralocorticoid receptor (MR), which 
is activated by cortisol but not dexamethasone. There is some evidence for negative feedback 
mechanisms involving the MR (Atkinson et al., 2008), and thus dexamethasone potentially 
represents a quite artificial induction of negative feedback in the HPA axis. Some of the 
measures employed in HVHs and CVHs may also be impacted by factors variables relating to 
clinical status, such as the potential effect of illness onset on years in education in Chapter 4, 
and the effects of antipsychotic on stress physiology in Chapter 6. 
7.3 Implications and Future Directions 
Several implications for clinical treatment and future research can be drawn from the present 
project. 
Whilst some gaps identified in Chapter 2 were addressed in the present thesis, several others 
remain to be taken up by future research. For more precise assessments of AVH 
phenomenology, mental health risk, social support structures as well as developmental 
pathways, large epidemiological and longitudinal research designs are necessary. To assess the 
long-term impact of voice-hearing on mental health risk, a cohort of young adolescents should 
be assessed for presence of voices as well as phenomenology of voices and then followed over 
several decades to identify variables that can determine mental health risk and aid early 
intervention. Putatively, presence of social support may also shape more benevolent outcomes 
as opposed to circumstances where such social structures are lacking. Particularly the fact that 
these individuals are frequently recruited from spiritualist groups suggests that voice-hearing in 
a context where such experiences are encouraged and shared may be associated with less risk 
of mental health difficulties, and this should be investigated further. The inclusion of less 
dichotomised samples, such as voice-hearing populations that have transitioned from or to need 
for care, would also be helpful in determining variables specific to need for care, and variables 
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specific to AVHs. Specifically, factors like voice content, relationship to voices or stress-function 
could potentially change over time for better or worse, and it would be useful to know whether 
a) such changes precede onset of or recovery from clinical status and b) can be modulated to 
facilitate recovery. Further, this would provide more detail on the psychosis continuum 
framework. 
The evidence in Chapter 4 should be built upon in epidemiological population studies to explore 
the role of adversity exposure in more diverse voice-hearing samples, and assess potential 
additive or interaction effects of adversity types. Evidence from a 10-year prospective cohort 
study showed that early exposure to adversity increased the risk of adversity exposure in 
adolescence, which in case of recent severe adversity, interacted additively to increase the risk 
of psychosis (Lataster et al., 2012). Similar relationships could be present in determining 
outcome of AVHs and should be investigated using similar designs as that of Lataster and 
colleagues (2012). More valid measures of genetic risk, such as heritability, genome-wide 
association or molecular genetic studies, socioeconomic status, and more detailed assessment 
of substance misuse should also be carried out. The timing of substance misuse differentially 
affects psychosis risk, with a greater risk effect of adolescent as opposed to adult use (Arseneault 
et al., 2002). Similarly, early cannabis use has a greater effect of HPA dysregulation that later 
onset (Huizink et al., 2006), and future research should take such effect into account. Similarly, 
the present study, and all existing literature on HVH familial risk, used family incidence of mental 
illness as a marker of genetic loading. However, evidence suggests an interaction of FKBP5 
polymorphisms and childhood trauma in increasing risk for psychotic symptoms and HPA 
dysregulation (Collip et al., 2013a). Such interaction effects can only be sensibly investigated 
using specific genetic markers.  Further, the chapter highlights the importance of adversity types 
that could be malleable to social interventions, including substance misuse and continuing 
education, which should be explored further in prodromal psychosis intervention research. 
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Whilst Chapter 5 suggested no effect of voice-content on stress physiology, the potential 
association of voice-content with stress physiology in HVHs and CVHs should nonetheless be 
investigated. Future research should also investigate the predictive value of negative voice 
content in transition rates of at-risk populations. In line with the hypothesised effect of stress 
exposure on dopaminergic dysregulation, and subsequent delusional ideation, the effect of 
simulated voices on state paranoia should also be assessed in future research. Putatively, 
negative voice content may drive maladaptive appraisals and foster paranoid ideation. Finally, 
future research should address experimentally whether purposefully employed mindful 
response styles to voices also attenuate stress-reactivity, whether mindful response styles are 
simply more prevalent in individuals with greater stress resilience, or both. 
Several important clinical and research implications can be drawn Chapter 6. First, it 
should be evaluated to which degree a change in need for care, i.e., therapeutic response, is also 
associated with normalisation of stress-function. To investigate whether normalisation of stress-
function mediates clinical improvements, psychophysiological stress-measures should be 
included in trials of psychological interventions shown effect in psychosis and AVHs such as 
cognitive-behavioural therapy (Burns, Erickson, and Brenner, 2014; Turner, van der Gaag, 
Karyotaki, and Cuijpers, 2014) or mindfulness interventions (Chadwick et al., 2016; Strauss, 
Thomas, and Hayward, 2015). Similarly, the identification and assessment of therapeutic 
methods that could aid normalisation of dysregulated stress-function, such as heart rate 
variability training for the autonomic nervous system, should be addressed in future clinical 
research. Second, future longitudinal research should assess GR-function in at-risk populations 
as well as adolescent samples presenting with AVHs, to determine whether impaired GR-
function is a predictor of later need for care. Third, the confounding effects of antipsychotic 
treatment on HPA-function can only truly be controlled for through research in medication-
naïve CVH participants. Fourth, a more comprehensive HPA and ANS assessment in CVHs and 
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HVHs, including more detailed and varied sampling methods (e.g., hair cortisol or heart rate 
variability), assessment of risk alleles and gene environment interactions, is needed to specify 
the functional and aetiological implications of altered stress-function in CVHs and HVHs. Fifth, 
the collection of such data in large samples could aid more complex statistical methods in 
highlighting the precise interrelationships of psychological and physiological stress-function, and 
help understand the finding of lower SECPT cortisol in HVHs.  
Finally, the association of specific HPA-activity patterns with dopaminergic activity need 
to be investigated in the context of AVHs. The mesolimbic dopamine system is highly responsive 
to glucocorticoid secretion (Marinelli and Piazza, 2002), and several studies have demonstrated 
that acute psychosocial stress leads to increased regional dopamine signalling as measured by 
positon emission photography (Hernaus et al., 2015; Mizrahi et al., 2014; Nagano-Saito et al., 
2013; Pruessner, Champagne, Meaney, and Dagher, 2004; Vaessen, Hernaus, Myin-Germeys, 
and van Amelsvoort, 2015). Interestingly, Mizrahi et al. (2012) have reported that medication-
naïve schizophrenia patients and individuals at clinical high-risk have significantly greater striatal 
dopaminergic responses to psychosocial stress than healthy controls. In line with these findings, 
Howes and colleagues (2016) have recently proposed a stress feedback model whereby stress 
contributes to dopaminergic dysregulation, which in turns leads to increased formation of 
delusions and aberrant salience, which then leads to increased distress and need for care. 
Assessing the effects of psychosocial stress on HPA-reactivity and dopamine signalling in CVHs 
and HVHs may further elaborate whether the link of HPA and dopamine activity explains the 
differential need for care. 
7.4 Conclusion 
The present PhD project contributed to current knowledge of the relationships between stress-
function, distress and adversity in the experience of voice-hearing individuals with and without 
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need for care.  CVHs demonstrate several alterations in their stress physiology, including blunted 
reactivity to stress and impaired negative feedback, which appear uniquely linked to need for 
care, rather than AVHs in general. The inclusion of HVHs in this research project has allowed us 
to identify several developmental (e.g., substance misuse), experiential (i.e., voice content), 
psychological (e.g., voice appraisals) as well as physiological (i.e., HPA-reactivity) variables that 
may explain the resilience of HVHs, as well as need for care of CVHs. Future research will need 
to further explore whether and how these differences are related to the aetiology and 
maintenance of need for care, and whether their modulation through therapeutic strategies can 
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Appendix II – Voice Simulation Scripts 
Time (m:s) Voice NEG NEU 
0.04 F1 Can't do anything right Come and see us 
0.11 M1 Don't do that Make me proud 
0.12 M2 What a waste of space They do it now 
0.17 F1 Hey idiot Same thing 
0.18 F2 Coward Morning 
0.19 F1 Stupid Later 
0.2 F2 Stupid Later 
0.23 M2 Shame on you You will return 
0.29 M1 They all know They do it now 
0.3 M1 See how they look at 
you 
They take the medicine 
0.31 F2 Repulsive Maybe 
0.32 M1 They are laughing at 
you 
They do what they're told 
0.33 F1 Repulsive Maybe 
0.34 M2 Worthless Alright 
0.42 M2 You're losing it You are coming 
0.43 M1 Crazy Spring 
0.44 F2 You're really a mess You look like them 
0.53 F1 Wrong Right 
0.54 M2 No good Same thing 
0.55 F2 Wrong Right 
0.55 M1 Mistake Spring 
1.02 F2 Give up Be careful 
1.08 M1 Should be ashamed Wait and see 
1.09 F1 Shame on you You will return 
1.09 F2 Shame on you You will return 
1.15 M1 Hey idiot Hello 
1.18 M1 Hey idiot Hello 
1.19 M1 Hey idiot Hello 
1.2 M2 Hey idiot Hello 
1.21 F2 Hey idiot Hello 
1.28 F1 Look how ugly you are Now you're going out of the 
door 
1.34 M2 Not good enough The right thing 
1.41 F1 Everyone hates you You look like them 
1.42 F1 Go away Be careful 
1.43 F2 Go away Be careful 
1.44 F1 Give up Give it to us 
1.45 F2 Better disappear Wait and see 
1.46 M2 Go away Be careful 
1.47 M1 Give up Wait and see 
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Time (m:s) Voice NEG NEU 
1.48 M1 Don't do that Give it to us 
2.03 M1 Can't do anything right Come and see us 
2.14 F2 Coward Morning 
2.15 F2 Can't do anything right Come and see us 
2.23 M2 Loser Alright 
2.24 M1 Loser Alright 
2.25 M2 Loser Alright 
2.26 M1 Loser Alright 
2.27 M2 Loser Alright 
2.39 M2 Everyone hates you You remain silent 
2.46 M1 Not good enough The right thing 
3.05 M1 Fraud Spring 
3.06 F2 They all know They do it now 
3.11 M2 They are laughing at 
you 
You look like them 
3.22 M2 Worthless Maybe 
3.24 M1 Worthless Maybe 
3.25 F2 Stupid Later 
3.26 F1 Worthless Maybe 
3.37 M1 Go away Be careful 
3.38 M2 Give up That's yours 
3.45 F2 Look how ugly you are Now you're going out of the 
door 
3.46 M2 Should be ashamed Come and see us 
4.02 M1 Coward Morning 
4.03 F2 Loser Alright 
4.04 M1 What a waste of space They do it now 
4.05 F2 Repulsive Maybe 
4.07 F1 Not good enough The right thing 
4.08 F2 No good Same thing 
4.19 F2 Look how ugly you are Now you're going out of the 
door 
4.21 F2 Everyone hates you You remain silent 
4.33 F1 Hey idiot Hello 
4.35 F1 Can't get rid of me I send them 
4.42 F2 Don't do that Make me proud 
4.48 M1 Can't get rid of me I send them 
4.55 F2 Wrong Right 
4.56 M1 Wrong Right 
4.58 F1 Mistake Spring 
4.59 F2 Stupid Later 
5 M2 No good Same thing 
5.01 M1 You're losing it You're solid 
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Time (m:s) Voice NEG NEU 
5.02 F2 Loser Alright 
5.03 F1 What a waste of space They do it now 
5.17 F1 Don't do that Make me proud 
5.18 F2 Hey idiot Hello 
5.3 F2 Stupid Later 
5.43 M2 Everyone hates you You remain silent 
5.48 M1 Worthless Maybe 
5.5 M2 They are laughing at 
you 
You look like them 
5.51 M1 Can't do anything right Come and see us 
5.52 F1 Repulsive Alright 
6.01 F1 Hey idiot Hello 
6.03 F1 Fraud Spring 
6.04 F2 Coward Morning 
6.06 F2 Look how ugly you are Now you're going out of the 
door 
6.08 M1 See how they look at 
you 
You look like them 
6.09 F1 Repulsive Time to go to sleep 
6.11 M1 They are laughing at 
you 
You are laughing 
6.12 F2 Repulsive That's yours 
6.13 M2 You're really a mess You're solid 
6.15 M2 You're losing it You will return 
6.2 M1 Can't do anything right Today is the day 
6.21 F1 Not good enough The right thing 
6.23 M1 Mistake Spring 
6.24 F2 Not good enough The right thing 
6.25 F1 Mistake Spring 
6.26 M1 Bad Alright 
6.27 M2 Loser Later 
6.38 M2 Go away Be careful 
6.39 M1 Stupid Maybe 
6.41 F2 Worthless Morning 
6.51 F2 They are laughing at 
you 
It seems like a commercial 
6.56 F1 Not good enough The right thing 
6.57 F2 Mistake Spring 
6.58 F1 You're losing it Wait and see 
6.59 M1 Can't do anything right Time to go to sleep 
7.01 M2 Don't do that Make it really good 
7.03 M1 Repulsive Later 
7.04 F2 They are laughing at 
you 
You are laughing 
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Time (m:s) Voice NEG NEU 
7.05 F2 Stupid Right 
7.06 F1 Can't do anything right Today is the day 
7.08 M1 Hey idiot Hello 
7.09 M2 They all know They do it now 
7.1 F2 Mistake Spring 
7.11 F1 Bad Right 
7.12 M1 Crazy Later 
7.14 F2 Don't do that Make me proud 
7.15 F1 Crazy Later 
7.16 M2 Should be ashamed Come and see us 
7.17 M1 Go away Be careful 
7.19 F2 What a waste of space They do it now 
7.2 F1 Stupid Right 
7.24 M2 Hey idiot Hello 
7.25 M1 Stupid Right 
7.26 F1 You're really a mess You're solid 
7.27 F2 Everyone hates you You remain silent 
7.39 F2 Can't do anything right Today is the day 
7.45 M1 Hey idiot Hello 
7.46 F2 Loser Morning 
7.47 M1 Go away Come and see us 
8.01 F1 Stupid Later 
8.03 M1 Wrong Right 
8.04 F1 Can't do anything right Time to go to sleep 
8.05 M2 Loser Spring 
8.06 M2 Loser Spring 
8.07 F1 Hey idiot Hello 
8.08 F2 Stupid Alright 
8.11 M2 You're really a mess You are coming 
8.25 F2 Not good enough Time to go to sleep 
8.32 F1 What a waste of space It's just the way it is 
8.44 F2 Shame on you You remain silent 
8.5 M1 Look how ugly you are You look like them 
8.59 M2 Should be ashamed Wait and see 
9.09 M1 Worthless Morning 
9.15 F2 Stupid Spring 
9.17 F1 Worthless Morning 
9.18 F2 Wrong Right 
9.19 M1 No good Alright 
9.2 M2 Coward Maybe 
9.21 F1 Mistake Morning 
9.22 M1 Bad Later 
9.23 M1 Stupid Alright 
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9.23 F1 Stupid Alright 
9.25 M2 Not good enough Make me proud 
9.29 M1 Hey idiot Hello 
9.31 F2 Should be ashamed Wait and see 
9.38 M2 Loser Later 
9.39 M1 Stupid Spring 
9.48 F2 Can't do anything right Time to go to sleep 
9.49 M1 Give up Come and see us 
9.51 M2 Coward Morning 
9.52 F2 What a waste of space Today is the day     
 
F1 - Female Voice-Actor 1 
 
 
F2 - Female Voice-Actor 2 
 
 
M1 - Male Voice-Actor 1 
 
 




















Appendix III – VAS Simulation Study 
 
VAS 
Participant ID:                                                                                                      Date:  
Time Point: ______                                                                                 Exact Time:  
 
Please put a mark on the line below to indicate you how feel  RIGHT NOW  from not at all stressed 
to very stressed. 
 
Not at all stressed Very stressed 
 
Please put a mark on the line below to indicate you how feel  RIGHT NOW  from not at all anxious 
to very anxious. 
 
Very anxious Not at all anxious 
 
Please put a mark on the line below to indicate you how feel  RIGHT NOW  from not at all angry to 
very angry. 
 
Not very angry Very angry 
 
Please put a mark on the line below to indicate you how feel  RIGHT NOW  from not at all relaxed 
to very relaxed. 
 
Very relaxed Not at all relaxed 
 
Please put a mark on the line below to indicate you how feel  RIGHT NOW  from not at all 
threatened to very threatened. 
 
Not at all threatened Very threatened 
 
Please put a mark on the line below to indicate you how feel  RIGHT NOW  from not at all 
embarrassed to very embarrassed. 
 
Not at all embarrassed Very embarrassed 
 
Please put a mark on the line below to indicate you how feel  RIGHT NOW  from expecting positive 
consequences to expecting negative consequences. 
 
Expecting positive consequences Expecting negative consequences 
 
Please put a mark on the line below to indicate you how feel  RIGHT NOW  from socially judged to 
not socially judged at all. 
 
Socially judged Not socially judged at all 
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Appendix IV – Control Data 
 
 
Participant ID: _____________ 
   
Date: ________________ 
 
   
Control data 
    
   
Anthropometric: 
 






Do you suffer from any medical conditions?  Y / N 






Time of last meal?: _____________ Was it a (circle) -  light breakfast / full breakfast / light 
meal / full meal  
Description: 
________________________________________________________________________________________________________ 
And in 4hrs prior to collection… please give description and approximate time consumed 
 
Snacks?  Y / N   
____________________________________________________________________________________________________________ 
 
Drinks?  Y / N   
____________________________________________________________________________________________________________ 
 
Cigarettes?  Y / N   
______________________________________________________________________________________________________ 
 
If female: When was the first day of your last cycle? (dd/mm) - 
________________________________________________ 
 
When did you last perform strenuous exercise (e.g. weightlifting)? 
__________________________________________ 
 
Are you currently taking any medication?  Y / N  
If yes, please provide details (continue on reverse if required) 
    



















Did you encounter any particularly stressful situations in the last 24 hours? Y / N   If 
yes, please provide details: 
____________________________________________________________________________________________________________ 
 













Appendix V – Cortisol Instructions 
Measuring your biological levels of Stress:  
A step by step guide for the saliva collection  
Participant ID:_______________                                          Date: _____________  
 
For this test, we need you to take several saliva samples over the course of two consecutive 
days. Please carefully read the instructions on how to take the saliva samples. During the first 
day, you will take one sample IMMEDIATELY after waking up, before having brushed your teeth 
or having drunk or eaten anything. Then, you will take another sample at 3pm in the afternoon, 
and one at 8pm in the evening, again without having eaten or drunk in the preceding 30min. In 
the evening at 11pm you will take the pill of 1mg dexamethasone, and then repeat the same 
procedure for saliva sampling on the second day. Please store all tubes away from heat and 
direct sunlight and put them into a fridge as soon as possible. Please use this instruction sheet 
and fill out the boxes as you go along. If you have any questions about any of these instructions 
please call David Baumeister on 020 7848 5718 or 079 4479 8105. If agreed upon this before, 
you will receive a reminder phone call on the evening before the first day, and on the evening 




Wake up (before 10 a.m.)  
Immediately after waking up collect your saliva by chewing on the cotton wool pad for 2 
minutes, then put it back in the tube with an orange dot marked 1. You should not eat or drink 
anything, or smoke or brush your teeth before. 










At 3 pm - collect your saliva using the tube with an orange dot marked 2. You should not eat or 
drink anything, or smoke or brush your teeth in the 30 minutes before 3pm. 
• What time is it now? 
________________________________________________________ 
• What were you doing before giving the sample? 
___________________________________  
• Did you accidentally have anything to eat or drink before taking the sample? If yes, 
please describe it here: 
________________________________________________________________ 
• Did you have any difficult or tense situation, unpleasant thoughts or any kind of pain 












At 8 pm - collect your saliva using the tube with an orange dot marked 3. You should not eat or 
drink anything, or smoke or brush your teeth in the 30 minutes before 8pm. 
 
• What time is it now? 
________________________________________________________ 




• Did you accidentally have anything to eat or drink before taking the sample? If yes, 
please describe it here: 
________________________________________________________________ 
• Did you have any difficult or tense situation, unpleasant thoughts or any kind of pain 




Store the tubes away from the heat and direct sunlight and put them into the fridge as soon 
as possible.  




Instructions: Please swallow the pill of 1mg dexamethasone we gave you at 11:00pm (please note the 
exact time below). You do not need to fast before taking the pill, and you are allowed to drive after 
having taken it. You can also take any medication as usual, unless these are steroid creams or inhalers. 
You will not be able to eat or drink anything, or brush your teeth before your saliva sample is taken 
between the next morning. If you are unsure about any of the procedure, please let the research team 
know and they will give you a call to guide you through the procedure.  
 





Day 2 – following dexamethasone 
 
Wake up (before 10 a.m.)  
Immediately after waking up collect your saliva by chewing on the cotton wool pad for 2 
minutes, then put it back in the tube with a blue dot marked 1. You should not eat or drink 
anything, or smoke or brush your teeth before. 













At 3 pm - collect your saliva using the tube with a blue dot marked 2. You should not eat or 
drink anything, or smoke or brush your teeth in the 30 minutes before 3pm. 
• What time is it now? 
________________________________________________________ 




• Did you accidentally have anything to eat or drink before taking the sample? If yes, 
please describe it here: 
________________________________________________________________ 
• Did you have any difficult or tense situation, unpleasant thoughts or any kind of pain 






At 8 pm - before dinner collect your saliva using the tube with a blue dot marked 3. You should 
not eat or drink anything, or smoke or brush your teeth in the 30 minutes before 8pm. 
 
• What time is it now? 
________________________________________________________ 




• Did you accidentally have anything to eat or drink before taking the sample? If yes, 
please describe it here: 
________________________________________________________________ 
• Did you have any difficult or tense situation, unpleasant thoughts or any kind of pain 




Store the tubes away from the heat and direct sunlight and put them into the fridge as soon 
as possible.  
Please note name and time of any medication taken today (including the contraceptive pill): 
_____________________________________________________________________________ 
If you are female: Please indicate the age of your first menstrual cycle: 
______________________  














Appendix VI – VAS Clinical Study 
 
VAS 
Participant ID:                                                                                                      Date:  
Time Point: ______                                                                                 Exact Time:  
 
 
Please put a mark on the line below to indicate how you feel RIGHT NOW from not at all stressed 
to very stressed. 
 
Not at all stressed Very stressed 
 
Please put a mark on the line below to indicate how you feel RIGHT NOW from not at all in pain to 
very much in pain. 
 
Not at all in pain  Very much in pain  
 
Please put a mark on the line below to indicate how you feel RIGHT NOW from not at all anxious 
to very anxious. 
 
Very anxious Not at all anxious 
 
Please put a mark on the line below to indicate how you feel RIGHT NOW from not at all relaxed 
to very relaxed. 
 
Very relaxed Not at all relaxed 
 
 
Please put a mark on the line below to indicate how you feel RIGHT NOW from not at all in control 
to not at all in control. 
 
 
Very in control Not at all in control 
 
Please put a mark on the line below to indicate how you feel RIGHT NOW from not at all 
threatened to very threatened. 
 






Please put a mark on the line below to indicate how you feel RIGHT NOW from not at all 
embarrassed to very embarrassed. 
 




Please put a mark on the line below to indicate how you feel RIGHT NOW from expecting positive 
consequences to expecting negative consequences. 
 
Expecting positive consequences Expecting negative consequences 
 
Please put a mark on the line below to indicate how you feel RIGHT NOW from socially judged to 
not socially judged at all. 
 














Participant Information Sheet 
Stress-reactivity in clinical and non-clinical voice hearers 
Ethics Reference Number: 15/LO/0880 
 
The department of Psychology of the Institute of Psychiatry, Psychology & Neuroscience 
at King’s College London would like to invite you to take part in a research study. Before 
you decide to participate it is important for you to understand why the research is being 
done and what it would involve for you. Please take time to read the following 
information carefully and ask us if there is anything that is not clear or if you would like 
more information. 
 
What is the purpose of the study? 
We are interested in speaking to people who report hearing voices, people or spirits 
talking to them that other people are not able to hear. We know that such experiences are 
more common than is often assumed, and are not necessarily related to mental illness. 
We are interested in gaining a fuller understanding of the different ways in which people 
respond and adapt to hearing voices or spirits. For some people these experiences have a 
positive impact and can be life-enriching. For others these experiences have a negative 
impact on their life and result in input from mental health services. This research will 
attempt to identify what distinguishes people whose voices are positive from those whose 
experiences become distressing. We are hoping that this understanding will help us in the 
future to find the best way to help people who have distressing voices. 
 
Specifically, we are interested in understanding how the body’s stress system may be 
involved in the distress suffered by some voice-hearers. To do this we would like to 
compare the stress hormones, present  in saliva, of three groups: individuals who hear 
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voices or spirits but are not troubled by them, individuals who find them distressing and 
have received some input from mental health services, and individuals who do not hear 
any voices and spirits. 
 
Why are we asking for your help?  
During the course of this study, which is conducted as part of a PhD project at King’s 
College London, approximately 70 people who are hearing voices or spirits will be asked 
to take part, as well as 35 people who do not hear voices or spirits. You have been invited 
to participate because you or an organisation you belong to has identified that you might 
be interested in helping with this research.  
 
Do you have to take a part? 
No, it is entirely up to you. We will describe the study to you and go through this 
information sheet, which you can keep. We will then ask you to sign a consent form to 
show that you have agreed to take part in the study, and will then ask a few questions to 
make sure you are able to take part.  
 
You may choose to ask for independent information or advice about your rights as a 
research participant or about being involved in this particular research study by contacting 
the Research Governance Officer at King’s College London (please see below for contact 
details). 
 
What will happen if I start but then don’t want to carry on with the study? 
Participants can withdraw from the study at any time without having to justify their 
decision. If you decide to withdraw from the study you can tell us whether you are happy 
for us to use the information obtained up to that point. If you are not, any information that 
you have given will be destroyed and you will not be contacted by us again.   
 
What will we ask of you if you take part in the study? 
The whole process will require an initial meeting to ensure that this research is right for 
you, and then two further separate appointments on two different days. Our initial chat 
should only take a few minutes and involves a brief consultation with a medical doctor to 
assess whether you can be included in the study. This is to make sure you are not currently 
taking any medication or suffer from medical conditions (such as diabetes, cardiovascular 
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disease and steroid allergies) that may make the study unsuitable for you, and, if you are 
female, this screening will include a pregnancy test. 
Then the day 1 appointment should take no more than 45 minutes, whereas the other 
appointments on day 2 and 3 should take no more than 1-1.5 hours, and will be carried 
out at the Institute of Psychiatry, Psychology & Neuroscience in Denmark Hill, London 
SE5.  
 
For this project we will ask you to do several tasks that will allow us to measure your 
body’s stress system, which will help us understand how you respond to stress. First, we 
will ask you to take three saliva samples over the course of one day (when you first wake 
up, in the afternoon, and early evening). Then that evening you will take a pill called 
‘Dexamethasone’ or ‘Dex’, which is a commonly used, very mild medication that 
interacts with your stress system. Then the next day you will take three more saliva 
samples, same as the first day.  
 
This medication tells us how efficient your body is at recovering from stress and 
regulating itself. This is a procedure that has been carried out safely in many patients. The 
dose of medication is very small and will not affect your health, and it is very unlikely 
that it will change how you feel. At most, you may experience some headache or 
dizziness.  
 
After you have completed this part of the procedure, we will invite you for your first 
appointment, where you will need to bring your saliva samples with you, and we will go 
through some questionnaires and interviews together (13 in total, each taking 
approximately 5-10 minutes). These questionnaires will ask about your current well-
being, drug and alcohol use, mood and quality of life, as well as experience of hearing 
voices or spirits, and any previous stressful events in your life. This appointment should 
take no more than 1 hour. Some of the questionnaires will ask questions of a personal 
nature, but you don’t have to answer any question you feel uncomfortable with, and you 
can just move on to the following questions.  
 
 
On the second appointment you will be asked to provide more saliva samples, before and 
after holding your hand in a container with very cold water for a short while. This will 
allow us to measure your body’s stress response to mild physical discomfort. During this 
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procedure, your facial expressions will be filmed for later analysis. You won’t be 
expected to have your hand in the cold water for very long, and in any case you will be 
free to remove your hand at any time if it becomes too uncomfortable. After you have 
finished we will then take several saliva samples over a 1 hour period, during which time 
you can just relax reading magazines. Overall the whole appointment should take no 
longer than 1.5 hours.  
 
What are the possible disadvantages and risk of taking part?  
Some of the questionnaires may cover issues that are sensitive, such as questions asking 
about previous stressful life events and drug/ alcohol use. These questions are chosen to 
help us understand why some people become distressed by their voices and to find ways 
to help. You can choose not to answer any questions that you feel are too distressing or 
are uncomfortable to answer, and just move on to the following questions, or you can stop 
the interview at any stage. 
 
Both the ‘Dex’ test and the cold water task have been carried out in previous research 
studies without adverse events and have been approved by an independent NHS ethics 
committee. If ‘Dex’ medication is taken on a long-term basis (eg at high doses over a 
period of years) it can be associated with side-effects such as headache, dizziness, 
restlessness, irritability and anxiety, however a single low dose, as used in this study, 
typically do not produce any noticeable side-effects, and if any occurred they would be 
mild and transient. At the end of the study you will have a chance to tell us what your 
experience of participating in the research was like, and we will take this into 
consideration for this and future studies. 
 
What are possible benefits of taking part?  
There are no specific benefits to you in taking part in this study. However, you may find 
participating in our research interesting, and you will be remunerated for your time. The 
results of the study will hopefully help us to better understand how the body’s stress 
system is involved in why some people find voice-hearing distressing and others do not. 
It may also help to further develop interventions that specifically target these factors, such 
as mindfulness-based stress reduction.  
 
Will I be compensated for my time? 
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We will reimburse any travel expenses that you incur and offer you £10 per appointment 
for your time. Reimbursement payment may need to be declared for tax or benefit 
purposes. If you think this may apply for you, please ask the researcher for more 




Will my taking part in the study be kept confidential?  
All of the information you give for the study is treated confidentially. In the unlikely 
event that you were to tell us something that suggested that there would be a reason for 
us to be worried about harm to yourself, or to someone else we would have to breach this 
confidentiality. In these circumstances it would be important for us to share this 
information appropriately.   
 
All the information and saliva samples you provide will be anonymised (ie your name 
will be removed) and you will not be identifiable in any research outcome. Only 
researchers belonging to the study team will be able to know which sample belongs to 
whom. The data will be handled and kept securely in line with the Data Protection Act 
and will be accessed only by the research team. Personal data will be stored securely at 
the Institute of Psychiatry, Psychology & Neuroscience for a maximum of 12 months 
after completion of the study and then destroyed. Data generated by the research will be 
destroyed after a maximum of 5 years after completion of the study. Should you wish to 
have your data destroyed after your participation, the deadline for any data withdrawal is 
1 month following our meeting. 
 
What will happen with the results of the research study?  
We anticipate the study to be finished in early 2016, at the very latest in mid 2017. We 
will prepare a report of the results to share with colleagues in local, national and 
international meetings. The study will also be written up for publication in a scientific 
journal. We can send you a newspaper style article informing you about the results of the 
study, if you wish. Your questionnaires/interviews and samples will be coded and there 





Any complaint about the way you have been dealt with during the study or any possible 
harm you might suffer will be addressed. If you have a concern about any aspect of this 
study, you can speak with the researcher in the first instance, or the researcher’s 
supervisor, Dr Emmanuelle Peters, who will do their best to answer your questions. If 
you remain unhappy and wish to complain formally, you can do this through the Director 
of Research Quality (see below).   
 
Harm 
Compensation for harm arising from an accidental injury and occurring as a 
consequence of your participation in the study will be covered by King’s College 
London. If you are harmed and this is due to someone’s negligence then you may 
have grounds for legal action for compensation against King’s College London 
(with respect of any harm arising out of the participation in the research study). 
 
Who has reviewed the study?  
All research in the NHS is looked at by an independent group of people, called a Research 
Ethics Committee, to protect your safety, rights, well-being and dignity. This study has 
been approved by the London Dulwich Research Ethics Committee (reference 
15/LO/0880). In addition this study has been reviewed and approved by the South London 
and Maudsley Foundation NHS Trust (SLaM) Risk Assessment Committee, and KCL 
Research & Development office. Thank you very much for your time and once again 
please ask for more information on the project if it is still unclear.  
 




Institute of Psychiatry, Psychology & Neuroscience 
Tel: 0207 848 5718  
 
Dr Emmanuelle Peters 
Reader in Clinical Psychology / Supervisor 
Institute of Psychiatry, psychology & Neuroscience 
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Tel: 0207 848 0347 
 
If you would like to speak to someone to get some independent advice about your rights 
as a research participant, you can contact the local R&D office:  
 
Research Governance Officer  
King’s College London 
Box  P005 
De Crespigny Park  
London, SE5 8AF  
Tel: 020 7848 0251 
 
If you wish to make a complaint about the conduct of this study, you can do this through 
the Director of Research Quality: 
 
Dr Gill Dale 
Director of Research Quality 
Joint R&D Office of South London and Maudsley NHS Foundation Trust and Institute 
of Psychiatry, P005, Institute of Psychiatry (King's College London), De Crespigny 
Park, London SE5 8AF  





We wish to thank you for taking the time to read this sheet and considering taking 



















Appendix IX – CAG Approval 
First chat
•Chance for both of us to ask questions and decide together if 
this study is appropriate for you 
•Fully explain what study consists of




•We will ring/text you the evening before to remind you what 
to do
•First day: Do one sample when you wake up, one at 3pm and 
one at 10pm
•Take the pill (ie dexamethasone) at 11pm, repeat saliva 
sampling the next day exactly like on the first day
Day 1 
Assessment
•We fill out questionnaires together
•We discuss the procedure for the saliva sampling
Day 2 
Assessment
•At least 5 days after Day 1 Assessment
•You need to come to the meeting with your saliva samples
•Carry out cold pressor test (i.e. holding your hand in ice water)




From: McKenzie, Sandra <Sandra.McKenzie@slam.nhs.uk> 
Sent: 12 February 2015 15:19 
To: Baumeister, David 
Cc: CAG - Psychosis R and D; Liebscher, Jennifer 






Following today’s Psychosis Research Committee meeting we are pleased to advise that your  
proposal for project title “Stress Reactivity in Clinical & Non-Clinical Voice Hearers” has been  
agreed in principle. 
 
Please note the above Psychosis CAG reference number that has been allocated to the project  
which should be quoted in future correspondence with us. 
 
Please note that you must not start your study until you have received formal written R&D  
approval from the SLaM/IoP R&D office. 
 
In terms of the practical implementation of the project, your proposal has been forwarded to  
the following research leads who will be in touch with you to discuss the application in relation  
to staff capacity :  
 
Acute Pathway :  
Ijaz Rehman (Associate Clinical Director)  
 
Complex Care Pathway : 
Melinda Sweeting (Associate Clinical Director)  
 
Recovery Pathway : 
Suzanne Jolley (Consultant Clinical Psychologist for Lambeth Only) 
Ros Ramsay (Associate Clinical Director)  
 


















From: Liebscher, Jennifer 
Sent: 24 March 2015 12:51 
To: Baumeister, David; Fanigliulo, Adriana 





Re RAA2014-013 Stress-reactivity in clinical and non-clinical voice hearers– CI David 
Baumeister 
 
I am pleased to advise that the risk assessment committee has now classified your study as 
within an  
acceptable level of risk and has approved the protocol.  The risk assessment is now completed. 
 
Adriana will now undertake the sponsorship review for your study. Could you please email 
Adriana the  
IRAS full project dataset and final protocol.  If anything else is needed Adriana will be in 







Jenny Liebscher  
R&D Governance Manager 
Joint R&D Office of South London and Maudsley NHS Foundation Trust and Institute of 
Psychiatry, Psychology &  
Neuroscience (IoPPN) 
 
PO05, Institute of Psychiatry, Psychology & Neuroscience (IoPPN) 
  
020 7848 0251  
jennifer.liebscher@kcl.ac.uk 
Visit the R&D Office web pages at Research and Development Office 
 







































NRES Committee London - Dulwich  
Health Research Authority 
Skipton House  




Tel: 0207 972 2463 
 
 
07 September 2015 
 
Mr David Baumeister  
PhD Student, Psychology 
King's College London 
Room B4.04, Addiction Sciences Building  




Dear Mr Baumeister 
 
Study title: Stress-reactivity in clinical and non-clinical voice 
hearers  
REC reference: 15/LO/0880 
Amendment number: AM01 
Amendment date: 14 August 2015  
IRAS project ID: 149736 
 




The members of the Committee taking part in the review gave a favourable 
ethical opinion of the amendment on the basis described in the notice of 




The documents reviewed and approved at the meeting were: 
 
Document Version Date 
Notice of Substantial Amendment (non-CTIMP) AM01 14 August 2015 
    
Other [Flowchart CVH] V2 14 August 2015 
    
Other [Flowchart HVH & HC] V2 14 August 2015 
    
Other [Recruitment Poster] V2 14 August 2015 
   
Participant information sheet (PIS) [Information sheet CVH] Tracked v4 03 September 2015 
   
Participant information sheet (PIS) [Information sheet HC] Tracked v4 03 September 2015 
   
Participant information sheet (PIS) [Information sheet HVH] Tracked v4 03 September 2015 
   
Research protocol or project proposal V2 14 August 2015 
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Membership of the Committee 
 





All investigators and research collaborators in the NHS should notify the R&D office 
for the relevant NHS care organisation of this amendment and check whether it 
affects R&D approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 














Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to: Ms Jennifer Liebscher, 
Mr Keith Brennan 
259 
 
NRES Committee London - Dulwich 
 














     
         
Dr Martin Keech  Clinical Project Manager  Yes    
        
Dr Michael Philpot  Consultant Psychiatrist  Yes    
         
 





Position (or reason for attending) 
 
   
     
Mr Ali Hussain  REC Assistant  









London - Dulwich Research Ethics 
Committee  
Health Research Authority 
Skipton House 








02 October 2015 
 
Mr David Baumeister 
PhD Student, Psychology 
King's College London  
Room B4.04, Addiction Sciences Building 




Dear Mr Baumeister 
 
Study title: Stress-reactivity in clinical and non-clinical voice 
hearers 
REC reference: 15/LO/0880 
Amendment number: Minor Amendment 30th September 2015 
 
IRAS project ID: 149736 
 
Thank you for your email of 30th September 2015 notifying the Committee of the 
above amendment. It is noted that the Five Facet Mindfulness Questionnaire 
(FFMQ), a fully validated questionnaire was submitted with the initial IRAS 
submission and explicitly mentioned in the approved protocol and A13 and A58 
of the IRAS form. Due to a technical error with the system the FFMQ was not 
included in the original review. 
 
The Committee does not consider this to be a “substantial amendment“ as defined in 
the  
Standard Operating Procedures for Research Ethics Committees. The 
amendment does not therefore require an ethical opinion from the Committee 
and may be implemented immediately, provided that it does not affect the 





The documents received were as follows: 
 
Five Facet Mindfulness Questionnaire 
 




The Committee is constituted in accordance with the Governance Arrangements 
for Research Ethics Committees and complies fully with the Standard Operating 
Procedures for 
Research Ethics Committees in the UK. 
 















Copy to: Ms Jennifer Liebscher, 












London - Dulwich Research Ethics 
Committee  
Health Research Authority 
Skipton House 







20 October 2015 
 
Mr David Baumeister 
PhD Student, Psychology 
King's College London  
Room B4.04, Addiction Sciences Building 




Dear Mr Baumeister 
 
Study title: Stress-reactivity in clinical and non-clinical voice 
hearers 
REC reference: 15/LO/0880  
Amendment number: 3 
Amendment date: 09 October 2015 
IRAS project ID: 149736 
 




The members of the Committee taking part in the review gave a favourable 
ethical opinion of the amendment on the basis described in the notice of 










Notice of Substantial Amendment (non-CTIMP)   09 October 2015 
    
Participant consent form [CVH] 2  09 October 2015 




Participant consent form [HC & HVH] 2  09 October 2015 
    
Participant information sheet (PIS) [CVH] 3  09 October 2015 
    
Participant information sheet (PIS) [HVH] 3  09 October 2015 
    
Participant information sheet (PIS) [HC] 3  09 October 2015 
    
 
Membership of the Committee 
 





All investigators and research collaborators in the NHS should notify the R&D office 
for the relevant NHS care organisation of this amendment and check whether it 
affects R&D approval of the research. 
 
Statement of compliance 
 
The Committee is constituted in accordance with the Governance Arrangements for 
Research Ethics Committees and complies fully with the Standard Operating 
Procedures for Research Ethics Committees in the UK. 
 
We are pleased to welcome researchers and R & D staff at our NRES committee 
members’ training days – see details at http://www.hra.nhs.uk/hra-training/ 
 













Enclosures: List of names and professions of members who took part in the 
review 
 
Copy to: Ms Jennifer Liebscher, 
Mr Keith Brennan 
 
London - Dulwich Research Ethics Committee 

















     
         
Dr Urmi Bapat  Pharmaceutical  Yes    
   Physician      
        
Dr Michael Philpot  Consultant Psychiatrist  Yes    









                 Appendix I - Research Interview and Distress Protocol 
 
Indications of Distress During 
Interview 






Indicate verbally that they are 
experiencing a high level of 
stress or emotional distress, 
AND/OR make facial 
expressions denoting 
emotional distress (eg 
anxiety/pain/anger etc) 
AND/OR exhibit behaviours 
suggestive that the interview 
is too stressful, such as crying, 
incoherent speech, etc. 
1. Stop the interview. 
2. Apologise, offer support and validation of distress. 
Allow participant time to regroup. 
3. Determine if participant is experiencing acute 
emotional distress beyond what would be normally 
expected in an interview about a sensitive topic. 
 Y / N Y / N Y / N 
Indicate that they are thinking 
of hurting themselves 
1. Stop the interview. 
2. Express concern, and conduct safety assessment in 
sensitive manner: 
a) Do you intend to harm yourself? 
b) How do you intend to harm yourself? 
c) When do you intend to harm yourself? 
e) Do you have the means to harm yourself? 
3. Determine whether participant is imminent danger to 
self. 




1. If a participant’s distress reflects an emotional response reflective of what would be expected in an interview about a sensitive topic, offer support and extent the opportunity 
to: a) stop the interview; b) regroup; c) continue. 
2. If a person’s distress reflects acute emotional distress or a safety concern beyond what would be expected in an interview about a sensitive topic, but NOT imminent danger, take 
the following actions: 
a. Encourage participant to contact his/her mental health provider or a significant other/friend/relative for follow-up and provide with follow-up contacts list. 
b. Provide the participant with emergency contacts and encourage the participant to call if they experience significant distress in the hours/days following the interview. 
c. Indicate that, with the participant’s permission, the researcher will contact them the next day to see if they are okay. 
d. Notify academic supervisors of the situation and recommendations given to participant. 
3. If a participant’s distress reflects imminent danger, take the following actions: 
a. Contact local authorities unless arrangements can be made for the participant to be transported to the emergency room by researcher or a caregiver. Also contact the patient’s 
clinical team. 
b. Indicate that, with the participant’s permission, the researcher will contact him/her the next day to see if they are okay. 
c. Immediately notify academic supervisors of action taken and, if the adverse event is considered significant, inform REC and sponsor. 
 
 
Indicate that they are thinking 
of hurting others 
1. Stop the interview. 
2. Express concern, conduct safety assessment in 
sensitive manner: 
a) Do you intend to harm someone else? Who? 
b) How do you intend to harm them? 
c) When do you intend to harm them? 
e) Do you have the means to harm them? 
3. Determine whether participant is imminent danger to 
others. 
 Y / N Y / N Y / N 
